# National Institute for Health and Care Excellence

Final

## **Perioperative care in adults**

### [H] Evidence review for pre-operative fasting

NICE guideline NG180

Evidence reviews underpinning recommendations 1.4.1 and 1.4.2 and research recommendation in the NICE guideline

August 2020

Final

This evidence review was developed by the National Guideline Centre



Perioperative care: FINAL

#### Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

#### Copyright

© NICE 2020. All rights reserved. Subject to Notice of rights.

ISBN: 978-1-4731-3827-8

### Contents

| 1  | Preo   | perativ  | e fasting strategy  | 6   |
|----|--------|----------|---|-----|
|    | 1.1    |          | w question: What is the most clinically and cost effective preoperative | •   |
|    |        | -        | strategy for adults?  |     |
|    | 1.2    |          | uction  |     |
|    | 1.3    |          | table   |     |
|    | 1.4    |          | al evidence   |     |
|    |        | 1.4.1    | Included studies  |     |
|    |        | 1.4.2    | Excluded studies  |     |
|    |        | 1.4.3    | Summary of clinical studies included in the evidence review             | 8   |
|    |        | 1.4.4    | Quality assessment of clinical studies included in the evidence review  | 19  |
|    | 1.5    | Econo    | mic evidence  | 34  |
|    |        | 1.5.1    | Included studies  | 34  |
|    |        | 1.5.2    | Excluded studies  | 34  |
|    |        | 1.5.3    | Unit costs  | 34  |
|    | 1.6    | Evider   | nce statements  | 34  |
|    |        | 1.6.1    | Clinical evidence statements  | 34  |
|    |        | 1.6.2    | Health economic evidence statements                                     | 37  |
|    | 1.7    | The co   | ommittee's discussion of the evidence                                   | 37  |
|    |        | 1.7.1    | Interpreting the evidence   | 38  |
|    |        | 1.7.2    | Cost effectiveness and resource use                                     | 39  |
|    |        | 1.7.3    | Other factors the committee took into account                           | 39  |
| Ap | pendi  | ces      |   | 50  |
| •  | -      |          | Review protocols  |     |
|    | ••     | endix B: | •   |     |
|    |        |          | linical search literature search strategy                               |     |
|    |        |          | ealth Economics literature search strategy                              |     |
|    | Appe   |          | Clinical evidence selection   |     |
|    | • •    |          | Clinical evidence tables  |     |
|    | •••    |          | Forest plots  |     |
|    |        |          | arbohydrate drinks versus placebo drinks                                |     |
|    |        |          | /ater versus Fasting  |     |
|    | Appe   |          | GRADE tables  |     |
|    | •••    |          | Health economic evidence selection                                      |     |
|    | •••    | endix H: |   |     |
|    | ••     | endix I: | Excluded studies  |     |
|    | , .ppc |          | xcluded clinical studies  |     |
|    |        |          | cluded health economic studies  |     |
|    | Anne   | endix J: | Research recommendation   |     |
|    | whhe   | JIUIN J. | research recommendation   | 107 |

 $\circledcirc$  NICE 2020. All rights reserved. Subject to Notice of rights.

## **1** Preoperative fasting strategy

## 1.1 Review question: What is the most clinically and cost effective preoperative fasting strategy for adults?

#### 1.2 Introduction

Patients are expect to be 'nil by mouth', or have a period of starvation, prior to undergoing a surgical procedure that requires a general anaesthetic. While some may not fully understand the mechanism of risk (aspiration of stomach contents), all are aware that eating and drinking prior to your operation can be very bad for you.

While we have consensus guidance from the royal colleges of Anaesthetists and Nursing promoting the liberal, or relaxed, fasting guidance we still see variance in our local practice. Unsurprisingly this causes confusion, not only for the patient, but also the clinical staff, who often opt for a 'better safe than sorry' strategy. This in turn leads to prolonged periods of starvation and the negative consequences being without fluid and sustenance.

Over the past 10 years we have seen perioperative care evolve. One such advancement is the use of high energy, carbohydrate rich, drinks to aid recovery. These are given before and after surgery with the assumption that they provide the patient with a metabolic boost to overcome the negative effects, and reduce the complications, of surgery. Again, as with fasting, the timing and impact of these drinks appears varied, with no clear guide on appropriate timing or dosing of these drinks.

This review will include an analysis of evidence to hopefully clarify these issues and provide clinicians the detail needed to develop standardised and safe fasting protocols.

#### 1.3 PICO table

For full details see the review protocol in appendix A.

|                               | indidiciensities of review question   |
|-------------------------------|---|
| Population                    | Adults 18 years and over having surgery.  |
| Interventions/<br>Comparisons | <ul> <li>no food for &lt;4 hours</li> <li>no food for 4-6 hours</li> <li>no food for &gt;6 hours</li> <li>no fluids for &lt;2 hours</li> <li>no fluids for 2-4 hours</li> <li>no fluids for 4-6 hours</li> <li>no fluids for &gt;6 hours</li> <li>no fluids for &gt;6 hours</li> <li>maintaining clear fluids (non-milk, non-particulate drinks) before surgery</li> <li>combinations of food and fluid restriction strategies</li> </ul> |
| Outcomes                      | Critical outcomes:<br>• health-related quality of life<br>• mortality<br>• patient, family and carer experience of care<br>• adverse events and complications (Clavien-Dindo, postoperative morbidity<br>score (POMS), aspiration – pulmonary complications, acute kidney injury)<br>Important outcomes:<br>• length of hospital stay<br>• unplanned ICU admission  |

Table 1: PICO characteristics of review question

|              | <ul><li> thirst</li><li> headache</li><li> cancellation of surgery</li></ul>  |
|--------------|---|
| Study design | Randomised controlled trials (RCTs), systematic reviews of RCTs.<br>Observational studies if no relevant RCTs are identified. |

#### 1.4 Clinical evidence

#### 1.4.1 Included studies

One Cochrane review including twenty seven RCTs and a further nineteen randomised controlled trials were included in the review;<sup>3, 7, 17, 19, 20, 30 31, 37, 41, 43, 44, 58, 73, 84, 96-98, 102, 110, 115</sup> these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3).

See also the study selection flow chart in appendix C, study evidence tables in appendix D, forest plots in appendix E and GRADE tables in appendix F.

#### 1.4.2 Excluded studies

See the excluded studies list in appendix I.

#### 4.3 Summary of clinical studies included in the evidence review

#### Table 2: Summary of studies included in the evidence review

| Study                       | Intervention and comparison  | Population             | Outcomes  | Comments   |
|-----------------------------|--|------------------------|---|--|
| Smith 2014 <sup>102</sup>   | Cochrane Reviews of twenty one randomized trials which have<br>compared carbohydrate drinks to a placebo drink or traditional<br>fasting. The population of patients were adults undergoing<br>elective surgery. The intervention protocols for the two groups<br>are summarized below:<br>Clear fluids (carbohydrate):<br>The intervention group included all participants who were given<br>at least 45 g of carbohydrate by oral beverage or by the<br>intravenous route. To be included, studies must have planned<br>to administer the carbohydrates within four hours of surgery<br>start time, or induction of anaesthesia. Co-intervention with<br>other oral substances in the four hours before surgery was<br>permitted so long as the dose of carbohydrate was at least 45g.<br>Control:<br>The intervention group was compared with a control group<br>consisting of participants who received less than 45 g of<br>carbohydrate in the four hours before anaesthesia. Control<br>participants may have received a placebo drink containing less<br>than 45 g of carbohydrate, clear liquids or nothing by mouth<br>during this time. The control group may have received<br>intravenous fluid therapy during the four hours before surgery<br>start time, so long as the total combined dose of carbohydrates<br>given by oral and intravenous routes remained less than 45g.<br>Clear fluids (carbohydrate<br>drink): |                        | <ul> <li>Length of hospital stay</li> <li>Postoperative<br/>complication rate</li> <li>Aspiration</li> <li>Fatigue</li> <li>Nausea and vomiting</li> <li>General wellbeing</li> </ul> | Six studies from this Cochrane<br>review were not included for<br>analysis as they included<br>populations or interventions not<br>suitable for this review (cardiac<br>surgery or a comparison with only<br>water). |
| Ajuzieogu 2016 <sup>3</sup> | drink):<br>800 mL of oral carbohydrate   | I and II scheduled for | <ul><li>Patient satisfaction</li><li>Nausea and vomiting</li></ul>  |  |

| Study                     | Intervention and comparison   | Population  | Outcomes  | Comments  |
|---------------------------|---|---|---|---|
|                           | (Nutricia preop®; Nutricia,<br>Zoetermeer, The Netherlands)<br>the night before surgery and an<br>additional 400 mL 2 h before<br>induction of anaesthesia (n=30)<br>Control (fasting):<br>Fasting from midnight until the<br>surgery (n=30)  | 18-42 years<br>Nigeria  |   |   |
| Asakura 2015 <sup>7</sup> | Clear fluids (carbohydrate<br>drink):<br>Received 250ml of<br>preoperative CHO (Arginaid<br>Water™, 18% carbohydrates,<br>Nestle Health Science, Tokyo,<br>Japan) between 6.00–6:30 a.m.<br>on the morning of surgery. This<br>is because 250ml of Arginaid<br>Water are approved as a meal<br>(n=46)<br>Control (fasting):<br>Control group, did not receive<br>any preoperative CHO and<br>were fasted starting at midnight<br>on the day of surgical<br>procedure (N=45) | Patients ASA physical status<br>1 and 2 adults, age 20 to 79<br>years, who were scheduled<br>to undergo a surgical<br>procedure of body surface<br>Mean age (SD):<br>CHO: $63.4 \pm 13.6$ ; Fasting:<br>$64.5 \pm 10.4$ ; | <ul> <li>Patient reported quality<br/>of recovery</li> <li>Length of stay</li> </ul>              | The QoR-40 is a global measure<br>of quality of recovery. It<br>incorporates five dimensions of<br>health: patient support, comfort,<br>emotions, physical independence,<br>and pain; each item is graded on<br>a five-point Likert scale. QoR-40<br>scores range from 40 (extremely<br>poor quality of recovery) to 200<br>(excellent quality of recovery) is<br>given as a median |
| Cakar 2017 <sup>17</sup>  | Clear fluids (carbohydrate<br>drink):<br>These patients were given an<br>oral carbohydrate solution<br>(PreOp-Nutricia-12.5%<br>carbohydrate, 50 kcal 100<br>mL21, 290 mOsm kg21,pH:  | Adult patients undergoing an elective thyroid operation and ASA physical status I or II.<br>Mean age (SD):  | <ul> <li>Thirst</li> <li>Tiredness</li> <li>Headache</li> <li>Nausea</li> <li>Vomiting</li> </ul> | Results reported as an Incidence<br>Rate Ratio  |

| Study                         | Intervention and comparison  | Population   | Outcomes  | Comments  |
|-------------------------------|--|--|---|---|
|                               | <ul> <li>5.0); 800 mL at 12:00 a.m. and 400 mL 2 hours before surgery (n=30)</li> <li>Control (fasting):<br/>The routine fasting procedure was implemented, in which patients were instructed not to take any fluid or food by mouth after midnight (12:00 a.m.) preoperatively and were not given an intravenous (IV) injection (n=33)</li> </ul> | CHO: 48.17 (9.81)<br>Glucose infusion: 55.53<br>(19.20)<br>Fasting: 50.07 (9.95)<br>Turkey   |   |   |
| Canbay 2014 <sup>19</sup>     | Clear fluids (carbohydrate<br>drink):<br>received 800 ml oral glucose<br>solution containing 12.5 %<br>glucose (Nutricia preop) at<br>24:00 h before surgery and 400<br>ml at 04:00 h, 2 h prior to<br>the surgery (n=25)<br>Control (fasting):<br>oral intake was<br>restricted starting from 24:00 h<br>(n=25)                                   | Adult patients who were in<br>ASA I–II group and would<br>undergo open radical<br>retropubic prostatectomy<br>surgery under elective<br>conditions<br>Mean age (SD):<br>CHO: 60.00 ± 10.37<br>Fasting: 58.36 ± 11.19<br>Turkey | • Thirst  |   |
| Celiksular 2016 <sup>20</sup> | Clear fluids (carbohydrate<br>drink):<br>The patients were given 800<br>mL and 400 mL (12.5%) of<br>oral carbohydrate solution<br>(PreopQ, Nutricia, Holland) 8 h<br>and 2 h before their elective<br>surgery, respectively (n=40)   | Patients ASA I-II patients<br>undergoing total hip<br>replacement surgery due to<br>coxarthrosis<br>Mean age (SD): 52.9 (16.47)  | <ul> <li>Nausea and vomiting<br/>(postoperative)</li> </ul> | Patients in either group<br>underwent surgery with general<br>anaesthesia OR epidural |

| Study                    | Intervention and comparison  | Population  | Outcomes  | Comments   |
|--------------------------|--|---|---|--|
|                          | Control (Fasting):<br>This group of patients<br>underwent surgery under<br>general anaesthesia or epidural<br>after an 8-h preoperative<br>fasting period (n=40)   | Turkey  |   |  |
| Doo 2018 <sup>30</sup>   | Clear fluids (carbohydrate):<br>Subjects in the carbohydrate<br>group also fasted,<br>but received 400 ml of<br>carbohydrate-rich drink (12.8%<br>carbohydrates, 50 kcal/100 ml;<br>Nucare NONPO(®, Daesang<br>Wellife, Korea) 2 hours before<br>induction of anaesthesia.<br>(n=25)<br>Control (fasting):<br>Subjects in the control group<br>were requested to obey<br>traditional preoperative fasting<br>after midnight prior to the day<br>of surgery. (n=25) | Patients aged<br>20–65 years with ASA I or II,<br>who were scheduled to<br>undergo open thyroidectomy<br>under general anaesthesia<br>Mean age (SD):<br>CHO: $49.8 \pm 7.1$<br>Fasting: $51.0 \pm 7.5$<br>Korea | <ul> <li>Thirst</li> <li>Fatigue</li> <li>Nausea and vomiting</li> <li>Anxiety</li> <li>Patient satisfaction</li> </ul> | All outcomes reported as a<br>median from a 0-10 scale for<br>thirst, fatigue, nausea, vomiting<br>and anxiety, and a five point scale<br>for patient satisfaction |
| Faria 2009 <sup>31</sup> | Clear fluids (carbohydrate<br>drink):<br>Received 200 ml of a<br>carbohydrate beverage<br>containing 12.5% (25 g,<br>50 kcal per 100 ml and<br>approximately 285 mOsm) of<br>maltodextrine (Nidex, Nestle,<br>Brazil) 2 h before operation<br>(n = 12)   | Adult women scheduled to<br>undergo elective<br>laparoscopic<br>cholecystectomy<br>Median age (range):<br>CHO: 47 (19–65); Fasting:<br>48 (29–65)<br>Brazil   | Vomiting  |  |

| Study                      | Intervention and comparison   | Population   | Outcomes   | Comments |
|----------------------------|---|--|--|----------|
|                            | Control (fasting):<br>conventional preoperative<br>fasting of 8 h (n = 13)  |  |  |          |
| Gilbert 1995 <sup>37</sup> | Clear fluids (water):<br>Patients in group A (water)<br>were asked to drink 500 ml- 1L<br>of water over 2 h, before a 3 h<br>pre-operative fast (n=46)<br>Control (fasting):<br>Group B (fasting) followed the<br>standard regimen of fasting<br>from midnight for the morning<br>list or 'tea and toast' before<br>08.00 h for the afternoon<br>session (n=49)   | Patients scheduled for minor<br>operations who were ASA I<br>or II<br>Water: 45.6 (15.6); Fasting:<br>48.3 (16.6)<br>UK  | <ul> <li>Thirst</li> <li>Nausea</li> <li>Vomiting</li> <li>Drowsiness</li> <li>Headache</li> </ul> |          |
| Hausel 2001 <sup>41</sup>  | Clear fluids (carbohydrate):<br>During the evening before<br>surgery, the CHO group<br>consumed 800 mL of an iso-<br>osmolar carbohydrate-rich drink<br>(12.5% carbohydrates, 50<br>kcal/100 mL, 290 mOsm/kg, pH<br>5.0, Nutricia Preop®; Numico,<br>Zoetermeer, the Netherlands).<br>After midnight, nothing by<br>mouth was allowed, except a<br>single morning dose of 400 mL<br>of the CHO drink (n=80)<br>Control:<br>patients were fasted from<br>midnight (n=86) | Patients scheduled for<br>elective laparoscopic<br>cholecystectomy or<br>elective major colorectal<br>surgery<br>Median age (IQR):<br>Laparoscopic<br>cholecystectomy –<br>Fasted: 48 (37–59);<br>Placebo: 52 (34–58);<br>CHO: 49 (36–58);<br>Colorectal surgery:<br>Fasted 52 (34–66);<br>Placebo 56 (46–69); | <ul> <li>Malaise</li> <li>Nausea</li> </ul>  |          |

| Study                       | Intervention and comparison  | Population  | Outcomes   | Comments |
|-----------------------------|--|---|--|----------|
|                             |  | CHO 56 (50–67)  |  |          |
| Helminen 2009 <sup>44</sup> | Clear fluids (carbohydrate):<br>Patients in the CHO group<br>were given nothing after<br>midnight and a 12.5% CHO<br>(Nutricia Preop; Numici, The<br>Netherlands), that is 400ml<br>(=200 kcal), between 6 and 7<br>a.m. (n=80)<br>Control:<br>Patients in the fasting group<br>were given nothing by mouth<br>after midnight. (n=80)  | Sweden<br>Adult patients undergoing<br>elective abdominal, anal,<br>thyroid or parathyroid<br>operations and ASA physical<br>status I–III.<br>Mean age (SD):<br>Glucose: 61±16; CHO:<br>60±15; Fasting: 58±4<br>Finland | <ul> <li>Thirst</li> <li>Anxiety</li> <li>Tiredness</li> <li>(results preoperative)</li> </ul> |          |
| Helminen 2019 <sup>43</sup> | Clear fluids (carbohydrate):<br>200ml of carbohydrate rick<br>drink (Providextra; Fresineus<br>Kabi Ab; Bad Homburg Vor der<br>Hohe, Germany) containing<br>300kcal, 67g carbohydrate and<br>8g protein at home before<br>leaving for the hospital or by<br>6am for surgery scheduled at<br>9am or 8pm at the latest for<br>later surgery (n=57)<br>Control (fasting):<br>Patients were instructed to take<br>nothing by mouth after midnight<br>on the night before surgery<br>(n=56) | Adults aged between 18 - 70<br>with ASA I to II scheduled for<br>day case cholecystectomy.<br>Mean age (SD):<br>CHO: 47 (13); Fasting: 46<br>(11)<br>Finland  | <ul> <li>Thirst</li> <li>Tiredness</li> <li>Nausea</li> </ul>                                  |          |

| Study                    | Intervention and comparison  | Population  | Outcomes   | Comments  |
|--------------------------|--|---|--|---|
| Lee 2018 <sup>58</sup>   | Clear fluids (carbohydrate<br>drink):<br>Received 800ml of a clear<br>carbohydrate beverage (12.8%<br>carbohydrates, 50kcal/100ml,<br>290 mOsm/kg, Daesang<br>WelLife Co, Korea). Patients<br>were instructed to ingest 400ml<br>of this beverage on the evening<br>before surgery (400ml) 2h<br>before any anaesthetic<br>medication was administered<br>(n=51)<br>Control (fasting):<br>Patients within this group were<br>not allowed to drink any<br>solution or fluid after midnight<br>before surgery (n=51) | Patients ASA I – II adults<br>who had a Karnofsky<br>performance status scale<br>greater than 70 undergoing<br>laparoscopic<br>cholecystectomy<br>Mean age (SD):<br>CHO: 50 (13)<br>Fasting: 49 (12)<br>Korea | Postoperative global<br>QoR-40 score   | The QoR-40 is a global measure<br>of quality of recovery. It<br>incorporates five dimensions of<br>health: patient support, comfort,<br>emotions, physical independenc<br>and pain; each item is graded or<br>a five-point Likert scale. QoR-40<br>scores range from 40 (extremely<br>poor quality of recovery) to 200<br>(excellent quality of recovery) |
| Melis 2006 <sup>73</sup> | Clear fluids (carbohydrate drink<br>A):<br>Drink was poured out into a<br>class 4 hours before surgery<br>and had to be consumed 3<br>hours before surgery. Drink A<br>was Nutricia preOp (Nutricia,<br>Zoetermeer, the Netherlands),<br>which contained 50.4g of the<br>carbohydrates; consisting of<br>0.8g glucose, 5.2g<br>polysaccharides and a small<br>amount of organic acids and<br>200mg sodium, 488mg<br>Potassium, 24mg chloride,<br>24mg calcium, 4mg of  | Adult patients undergoing<br>elective orthopaedic surgery<br>Mean age (SD):<br>Drink A: 59 (9)<br>Drink B: 47 (17)<br>Fasting: 56 (13)<br>Netherlands   | <ul> <li>Thirst</li> <li>Nausea</li> <li>Anxiety</li> <li>Tiredness</li> </ul> | Outcomes given are a difference<br>n baseline and preoperative<br>scores of well-being, expressed<br>as a median increase or decreas<br>and inter-quartile range in mm o<br>a 100mm visual analogue scale.  |

| Study                     | Intervention and comparison   | Population  | Outcomes                                 | Comments  |
|---------------------------|---|---|--|---|
| Study                     | Intervention and comparison<br>phosphor, and 4mg of<br>Magnesium in a solution of<br>400ml with an osmolality of<br>260mOsm/kg (n=9)<br>Clear fluids (carbohydrate drink<br>B):<br>Drink was poured out into a<br>class 4 hours before surgery<br>and had to be consumed 3<br>hours before surgery. Drink B<br>was Roosvicee vruchtenmix<br>(Heinz, Zeist, the Netherlands),<br>a syrup of rosehip and other<br>fruits, which was diluted in<br>water (70ml syrup : 330ml<br>water) and contained 48mg of<br>carbohydrates, consisting of<br>6.2g fructose, 6.2g of glucose<br>and furthermore carbohydrate<br>with unidentified chemical<br>structure of 0.2g fibre, 0.2g<br>protein, 6.4mg sodium, 73mg<br>potassium, 6.9mg calcium,<br>7.mg phosphor, 0.1mg iron and<br>41mg Vitamin C in a solution of<br>400ml with an osmolality of 574<br>mOsm/kg (n=10) | Population  | Outcomes                                 | Comments  |
|                           | Control (fasting):<br>Fasted after midnight on the<br>day of surgery (n=10)   |   |  |   |
| Onalan 2018 <sup>84</sup> | Clear fluids (carbohydrate<br>drink):<br>the patients were given an oral  | Patients aged >18 years but<br><65 years undergoing<br>laparoscopic | <ul><li>Thirst</li><li>Anxiety</li></ul> | High values from the general<br>comfort scale are indicative of<br>increased comfort. |

Perioperative care: FINAL Preoperative fasting strategy

| Study                               | Intervention and comparison  | Population   | Outcomes   | Comments   |
|-------------------------------------|--|--|--|--|
|                                     | glucose solution (Nutricia<br>preop) containing 12.5%<br>glucose, first 800 mL at 12<br>a.m., and then 400 mL at 6<br>a.m., 2 hours before the<br>surgery. The solution was<br>ingested in 10 minutes.Nutricia preop, one of the<br>OCSs containing maltodextrin<br>and electrolytes, contains<br>12.5% glucose. It passes<br>through the stomach in 90<br>minutes. Its osmolality is 285<br>mosm/kg/H2O and it<br>has 50 kcal/100 mL. In<br>addition, it contains 0.46<br>mg/mL sodium and 1.93 mg/mL<br>potassium. (n=25)Control (fasting):<br>Food and water were cut off in<br>the control group as of 12 a.m.<br>the night before surgery. (n=25) | cholecystectomy<br>Median age (IQR):<br>CHO: 53 (16)<br>Fasting: 54 (14)<br>Turkey   |  |  |
| Raksakietisak<br>2014 <sup>96</sup> | Clear fluids (carbohydrate<br>drink):<br>Assigned to drink 400ml of 10%<br>carbohydrate rich orange juice<br>(Greenmate) between 18:00<br>and 24:00 and another 400ml<br>at about 2 hour before<br>anaesthesia (6:00 to 7:00am)<br>(n=48)<br>Control group (fasting):<br>The control group had to starve   | Patients aged 50 – 80 years<br>with unilateral total knee<br>replacement<br>Mean age (SD):<br>CHO: 69.8 (7.3)<br>Fasting: 70.8 (8.5)<br>Thailand | <ul> <li>Thirst</li> <li>Anxiety</li> <li>Nausea &amp; vomiting</li> </ul> | Preoperative thirst and anxiety measured on a 0-10 scale |

| Study                           | Intervention and comparison  | Population  | Outcomes  | Comments   |
|---------------------------------|--|---|---|--|
|                                 | from midnight (n=50)   |   |   |  |
| Read 1991 <sup>97</sup>         | Clear fluids (water):<br>Permitted to drink water up until<br>2 hours before the operation<br>(n=25)   | Patients ASA I or II, between<br>the ages of 18-60 and<br>scheduled to have elective<br>surgery normally requiring<br>tracheal intubation   | <ul><li>Nausea</li><li>Vomiting</li><li>Headache</li></ul>                |  |
|                                 | Control (fasting):<br>Abstain from eating and<br>drinking from midnight (morning<br>operation) or after a light<br>breakfast at 6:30am (afternoon<br>operation) (n=29)   | Median age (range):<br>Water: 30 (17-56)<br>Fasting: 32 (18-50)<br>Wales  |   |  |
| Sada 2014 <sup>98</sup>         | Clear fluids (carbohydrate):<br>The study group received 800<br>mL (per os) of carbohydrate<br>beverage in the evening before<br>surgery (22:00) and an<br>additional 400 mL 2 h before<br>anaesthesia induction. (n=44)<br>Control:<br>The control group did not<br>receive any of these drinks and<br>were subject to the traditional<br>preoperative fasting.(n=52) | Patients were older than 18<br>years, undergoing an<br>operation of the colon and<br>rectum for benign and<br>malignant diseases,<br>or open abdominal<br>cholecystectomy for chronic<br>cholecystitis<br>Mean age (SD):<br>CHO: 56.85 (12.8); Placebo:<br>55 (14.1); Fasting: 56.45<br>(14.28)<br>Kosovo | <ul> <li>Thirst</li> <li>Anxiety</li> <li>Nausea</li> </ul>               | CHO vs Fasting<br>All outcomes given as a median<br>(range) at two different time<br>points (0-24h & 36-48h)   |
| Wang 2010 {Wang,<br>2010 #4285} | Clear fluids (carbohydrate):<br>Patients in the CHO group<br>consumed 400ml Nutricia<br>PreOp (12.5% carbohydrate,<br>0.5kcal/ml, 240mOsm/kg, pH 4<br>- 9, Nutricia Zoetermeer,<br>Netherlands) 3h before  | Patients undergoing elective<br>open colorectal cancer<br>resection surgery<br>Age – Median (range):<br>CHO 66 (48 - 74);   | <ul><li>Anxiety</li><li>Tiredness</li><li>Nausea</li><li>Thirst</li></ul> | Some outcomes from this study<br>have been included with Smith<br>2014 {Smith, 2014 #3480}.<br>Outcomes not included in this<br>systematic review have been<br>extracted separately. |

| Study                         | Intervention and comparison   | Population  | Outcomes  | Comments   |
|-------------------------------|---|---|---|--|
|                               | induction of anesthesia<br>completing CHO ingestion<br>within 1h. Patients were nil by<br>mouth after 2100 hours apart<br>from single morning dose of<br>400ml carbohydrate drink.<br>(n=18)<br>Control (fasting):<br>Patients were fasted from<br>midnight before surgery (n=17)   | Fasting 63 (37 - 74);<br>China  |   |  |
| Yagmurdur 2011 <sup>110</sup> | Clear fluids (carbohydrate):<br>During the evening before<br>surgery, patients in the CHO<br>group ingested 800 mL of an<br>iso-osmolar carbohydrate-rich<br>drink [12.5% carbohydrates<br>(glucose: 0.2 g, maltose: 0.7 g,<br>polysaccharides: 10 g), 50<br>kcal/100 ml, 290 mOsm/kg, pH<br>5.0; Nutricia Preop ; Numico,<br>Zoetermeer, The Netherlands].<br>Nothing per os was allowed<br>from midnight except another<br>400 mL of CHO in the morning<br>at least 90 minutes before<br>spinal anesthesia in the CHO<br>group. (n=22)<br>Control:<br>The patients in the control<br>group underwent spinal<br>anesthesia after the routine fast<br>from midnight. (n=22) | Patients ASA classes I-II<br>adult patients scheduled<br>for elective inguinal hernia<br>repair surgery under spinal<br>anaesthesia<br>Mean age (SD):<br>CHO: 45 (7); Fasting: 43 (8)<br>Turkey | <ul> <li>Thirst</li> <li>Nausea</li> <li>Anxiety</li> </ul> | All results in median (interquartile range) form |
| Zhang 2019 <sup>115</sup>     | Clear fluids (carbohydrate  | Patients aged 18 – 55, ASA I  | Thirst  | Thirst and tiredness outcomes are                |

| Study Interver  | ntion and comparison   | Population   | Outcomes  | Comments  |
|---|--|--|---|---|
| consume<br>carbohy<br>mOsm/k<br>Nutricia,<br>Netherla<br>on the e<br>(betwee<br>400ml 2<br>schedule<br>Control of<br>Patients<br>were for<br>anything | s in the CHO group<br>ned CHO (12.5g of<br>/drate per 100ml, 285<br>kg; Nutricia Preop,<br>l, Zoetermeer, The<br>ands) in doses of 800ml<br>evening before surgery<br>en 8pm and 10pm) and | <ul> <li>I scheduled to undergo<br/>elective open gynaecological<br/>surgery</li> <li>Mean age (SD):<br/>CHO: 42.64 (5.26)<br/>Fasting: 43.57 (5.60)</li> <li>China</li> </ul> | <ul> <li>Tiredness</li> <li>Nausea</li> <li>Headache</li> </ul> | given as a median value (range)<br>from a 100 point VAS scale |

See appendix D for full evidence tables.

#### 4 Quality assessment of clinical studies included in the evidence review

#### Table 3: Clinical evidence summary: Carbohydrate drinks versus fasting

|                             | No of                                      |  |                                    | Anticipated absolute effects  |   |  |
|-----------------------------|--|--|------------------------------------|---|---|--|
| Outcomes                    | Participant<br>s<br>(studies)<br>Follow up | Quality of the<br>evidence<br>(GRADE)                              | Relativ<br>e effect<br>(95%<br>CI) | Risk with Fasting   | Risk difference with CHO (95% CI)   |  |
| Patient Satisfaction (0-10) | 58<br>(1 study)<br>24 hours                | $\oplus \oplus \oplus \ominus$<br>MODERATE1<br>due to risk of bias |                                    | The mean patient satisfaction (0-<br>10) in the control groups was<br>6 | The mean patient satisfaction (0-10)<br>in the intervention groups was<br>2 higher<br>(1.67 to 2.33 higher) |  |
| Postoperative global        | 95   | $\oplus \oplus \ominus \ominus$                                    |                                    | The mean postoperative global qor-                                      | The mean postoperative global qor-  |  |

|  | No of                                      |  |                                    | Anticipated absolute effects   |  |  |
|--|--|--|------------------------------------|--|--|--|
| Outcomes   | Participant<br>s<br>(studies)<br>Follow up | Quality of the<br>evidence<br>(GRADE)  | Relativ<br>e effect<br>(95%<br>CI) | Risk with Fasting  | Risk difference with CHO (95% CI)  |  |
| QoR-40 score   | (1 study)<br>24 hours                      | LOW1,2<br>due to risk of bias,<br>imprecision                                    |                                    | 40 score in the control groups was 194.5   | 40 score in the intervention groups<br>was<br>7.8 lower<br>(13.09 to 2.51 lower)   |  |
| Length of hospital stay  | 673<br>(11 studies)                        | ⊕⊕⊖⊖<br>LOW1,3<br>due to risk of bias,<br>inconsistency                          |                                    | The mean length of hospital stay in<br>the control groups was<br>5.962 days                                    | The mean length of hospital stay in<br>the intervention groups was<br>0.37 lower<br>(0.68 lower to 0.06 higher)                                      |  |
| Length of hospital stay -<br>Major abdominal surgery           | 334<br>(6 studies)                         | ⊕⊖⊖⊖<br>VERY LOW1,2,3<br>due to risk of bias,<br>inconsistency,<br>imprecision   |                                    | The mean length of hospital stay -<br>major abdominal surgery in the<br>control groups was<br>10 days          | The mean length of hospital stay -<br>major abdominal surgery in the<br>intervention groups was<br>1.43 lower<br>(2.68 to 0.18 lower)                |  |
| Length of hospital stay -<br>Intermediate Abdominal<br>Surgery | 97<br>(1 study)                            | ⊕⊕⊖⊖<br>LOW1,2<br>due to risk of bias,<br>imprecision                            |                                    | The mean length of hospital stay -<br>intermediate abdominal surgery in<br>the control groups was<br>2.38 days | The mean length of hospital stay -<br>intermediate abdominal surgery in<br>the intervention groups was<br>0.21 higher<br>(0.52 lower to 0.94 higher) |  |
| Length of hospital stay -<br>Minor abdominal surgery           | 203<br>(3 studies)                         | ⊕⊕⊕⊖<br>MODERATE1<br>due to risk of bias   |                                    | The mean length of hospital stay -<br>minor abdominal surgery in the<br>control groups was<br>1.182 days       | The mean length of hospital stay -<br>minor abdominal surgery in the<br>intervention groups was<br>0.07 lower<br>(0.18 lower to 0.03 higher)         |  |
| Length of hospital stay -<br>Orthopaedic surgery               | 39<br>(1 study)                            | $\oplus \oplus \ominus \ominus$<br>LOW1,2<br>due to risk of bias,<br>imprecision |                                    | The mean length of hospital stay -<br>orthopaedic surgery in the control<br>groups was<br>6 days               | The mean length of hospital stay -<br>orthopaedic surgery in the<br>intervention groups was<br>1.00 lower<br>(1.73 to 0.27 lower)                    |  |
| Thirst (0-10)<br>(preoperative)                                | 98<br>(1 study)                            | $\oplus \oplus \bigcirc \bigcirc$<br>LOW1,2<br>due to risk of bias,              |                                    | The mean thirst (0-10)<br>(preoperative) in the control groups<br>was  | The mean thirst (0-10) (preoperative)<br>in the intervention groups was<br>0.2 higher  |  |

|   | No of                                      |  |                                    | Anticipated absolute effects  |  |  |
|---|--|--|------------------------------------|---|--|--|
| Outcomes                                  | Participant<br>s<br>(studies)<br>Follow up | Quality of the<br>evidence<br>(GRADE)  | Relativ<br>e effect<br>(95%<br>CI) | Risk with Fasting   | Risk difference with CHO (95% CI)  |  |
|   |  | imprecision  |                                    | 2.2   | (0.71 lower to 1.11 higher)  |  |
| Thirst (0-10)<br>(postoperative)          | 50<br>(1 study)                            | ⊕⊕⊕⊖<br>MODERATE1<br>due to risk of bias   |                                    | The mean thirst (0-10)<br>(postoperative) in the control<br>groups was<br>7.8     | The mean thirst (0-10)<br>(postoperative) in the intervention<br>groups was<br>7.16 lower<br>(8.2 to 6.12 lower)                       |  |
| Thirst (mild)                             | 50   | $\oplus \oplus \ominus \ominus$  | RR 0.46                            | Moderate  |  |  |
|   | (1 study)                                  | ,  | (0.21 to<br>1.02)                  | 520 per 1000  | 281 fewer per 1000<br>(from 411 fewer to 10 more)  |  |
| Thirst (moderate)                         | 50   | $\oplus \oplus \ominus \ominus$  | RR 0.09                            | Moderate  |  |  |
|   | (1 study)                                  | LOW1,2<br>due to risk of bias,<br>imprecision                                    | (0.01 to<br>1.56)                  | 200 per 1000  | 182 fewer per 1000<br>(from 198 fewer to 112 more)   |  |
| Headache (postoperative)                  | 58   | $\oplus \oplus \ominus \ominus$  | RR 0.33                            | Moderate  |  |  |
|   | (1 study)                                  | LOW1,2<br>due to risk of bias,<br>imprecision                                    | risk of bias, 1.11)                | 310 per 1000  | 208 fewer per 1000<br>(from 279 fewer to 34 more)  |  |
| Complication rate                         | 348  | $\oplus \Theta \Theta \Theta$  | RR 1.05                            | Moderate  |  |  |
|   | (5 studies)                                | VERY LOW1,2<br>due to risk of bias,<br>imprecision                               | (0.59 to<br>1.87)                  | 148 per 1000  | 7 more per 1000<br>(from 61 fewer to 129 more)   |  |
| Well-being<br>(postoperative)             | 87<br>(2 studies)                          | ⊕⊕⊕⊖<br>MODERATE1<br>due to risk of bias   |                                    | The mean well-being<br>(postoperative) in the control<br>groups was<br>15.4       | The mean well-being (postoperative)<br>in the intervention groups was<br>0.04 standard deviations higher<br>(0.4 lower to 0.47 higher) |  |
| Nausea & Vomiting 0-10<br>(postoperative) | 58<br>(1 study)                            | $\oplus \oplus \ominus \ominus$<br>LOW1,2<br>due to risk of bias,<br>imprecision |                                    | The mean nausea & vomiting 0-10<br>(postoperative) in the control<br>groups was 6 | The mean nausea & vomiting 0-10<br>(postoperative) in the intervention<br>groups was<br>2.0 lower (2.58 to 1.42 lower)                 |  |

|                                   | No of                                      |  |                                    | Anticipated absolute effects  |  |
|-----------------------------------|--|--|------------------------------------|---|--|
| Outcomes                          | Participant<br>s<br>(studies)<br>Follow up | Quality of the<br>evidence<br>(GRADE)              | Relativ<br>e effect<br>(95%<br>CI) | Risk with Fasting   | Risk difference with CHO (95% CI)  |
|                                   |  |  |                                    |   |  |
| Nausea & Vomiting -               | 138  | $\oplus \Theta \Theta \Theta$                      | RR 0.77                            | Moderate  |  |
| Nausea & Vomiting                 | (2 studies)                                | VERY LOW1,2<br>due to risk of bias,<br>imprecision | (0.38 to<br>1.54)                  | 219 per 1000  | 50 fewer per 1000<br>(from 136 fewer to 118 more)  |
| Nausea & Vomiting -               | 98   | $\oplus \Theta \Theta \Theta$                      | RR 0.94                            | Moderate  |  |
| Nausea                            | (1 study)                                  | VERY LOW1,2<br>due to risk of bias,<br>imprecision | risk of bias, 2.1)                 | 200 per 1000  | 12 fewer per 1000<br>(from 116 fewer to 220 more)  |
| Nausea & Vomiting -               | 232  | $\oplus \oplus \ominus \ominus$                    | RR 0.61                            | Moderate  |  |
| Vomiting                          | (3 studies)                                | LOW1,2<br>due to risk of bias,<br>imprecision      | (0.34 to<br>1.1)                   | 240 per 1000  | 94 fewer per 1000<br>(from 158 fewer to 24 more)   |
| Anxiety (0-10)<br>(preoperative)  | 98<br>(1 study)                            | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias           |                                    | The mean anxiety (0-10)<br>(preoperative) in the control groups<br>was<br>3.3   | The mean anxiety (0-10)<br>(preoperative) in the intervention<br>groups was<br>0.3 higher<br>(1.05 lower to 1.65 higher) |
| Anxiety (0-10)<br>(postoperative) | 50<br>(1 study)                            | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias           |                                    | The mean anxiety (0-10)<br>(postoperative) in the control<br>groups was<br>5.12 | The mean anxiety (0-10)<br>(postoperative) in the intervention<br>groups was<br>5 lower<br>(6.1 to 3.9 lower)            |
| Fatigue                           | 108<br>(2 studies)                         | ⊕⊕⊕⊖<br>MODERATE1<br>due to risk of bias           |                                    | The mean fatigue in the control<br>groups was<br>10.77                          | The mean fatigue in the intervention<br>groups was<br>0.08 standard deviations lower<br>(0.47 lower to 0.31 higher)      |

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

|          | No of       |                |          | Anticipated absolute effects |                                   |
|----------|-------------|----------------|----------|------------------------------|-----------------------------------|
|          | Participant |                | Relativ  |                              |                                   |
|          | S           | Quality of the | e effect |                              |                                   |
|          | (studies)   | evidence       | (95%     |                              |                                   |
| Outcomes | Follow up   | (GRADE)        | ĊI)      | Risk with Fasting            | Risk difference with CHO (95% CI) |

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs 3 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

|  | No of                                      |  |                                   | Anticipated absolute effects   |  |
|--|--|--|-----------------------------------|--|--|
| Outcomes   | Participant<br>s<br>(studies)<br>Follow up | Quality of the<br>evidence<br>(GRADE)                        | Relative<br>effect<br>(95%<br>CI) | Risk with placebo  | Risk difference with CHO (95% CI)  |
| Length of hospital stay                              | 674<br>(10 studies)                        | ⊕⊕⊝⊝<br>LOW1,2<br>due to risk of bias,<br>inconsistency      |                                   | The mean length of hospital stay in the control groups was 6.9 days                                    | The mean length of hospital stay in<br>the intervention groups was<br>0.04 lower<br>(0.21 lower to 0.14 higher)                              |
| Length of hospital stay -<br>Major abdominal surgery | 441<br>(6 studies)                         | ⊕⊖⊖⊖<br>VERY LOW1,2<br>due to risk of bias,<br>inconsistency |                                   | The mean length of hospital stay -<br>major abdominal surgery in the<br>control groups was<br>9.4 days | The mean length of hospital stay -<br>major abdominal surgery in the<br>intervention groups was<br>0.59 lower<br>(1.82 lower to 0.64 higher) |
| Length of hospital stay -<br>Minor abdominal surgery | 144<br>(2 studies)                         | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias                     |                                   | The mean length of hospital stay -<br>minor abdominal surgery in the<br>control groups was<br>1.2 days | The mean length of hospital stay -<br>minor abdominal surgery in the<br>intervention groups was<br>0.06 lower<br>(0.12 lower to 0.01 higher) |

|  | No of   |  |                                   | Anticipated absolute effects   |  |
|--|---|--|-----------------------------------|--|--|
| Outcomes   | Participant<br>s<br>(studies)<br>Follow up                | Quality of the<br>evidence<br>(GRADE)                        | Relative<br>effect<br>(95%<br>CI) | Risk with placebo  | Risk difference with CHO (95% CI)  |
| Length of hospital stay -<br>Orthopaedic surgery | 89<br>(3 studies)   | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias                     |                                   | The mean length of hospital stay -<br>orthopaedic surgery in the control<br>groups was<br>3.9 days | The mean length of hospital stay -<br>orthopaedic surgery in the intervention<br>groups was<br>0.1 higher<br>(0.32 lower to 0.53 higher) |
| Complication rate                                | 554   | $\oplus \oplus \ominus \ominus$                              | RR 0.92                           | Moderate   |  |
|  | (8 studies) LOW1,3<br>due to risk of bias,<br>imprecision | (0.73 to<br>1.17)  | 192 per 1000                      | 15 fewer per 1000<br>(from 52 fewer to 33 more)  |  |
| Fatigue (postoperative)                          | 268<br>(3 studies)  | ⊕⊖⊖⊖<br>VERY LOW1,2<br>due to risk of bias,<br>inconsistency |                                   | The mean fatigue (postoperative) in the control groups was 25.44                                   | The mean fatigue (postoperative) in<br>the intervention groups was<br>0.28 standard deviations higher<br>(0.22 lower to 0.78 higher)     |
| Well-being<br>(postoperative)                    | 205<br>(2 studies)  | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias                     |                                   | The mean well-being (postoperative)<br>in the control groups was<br>61.2                           | The mean well-being (postoperative)<br>in the intervention groups was<br>0 standard deviations higher<br>(0.27 lower to 0.28 higher)     |
| Nausea (24 h)                                    | 234<br>(2 studies)  | ⊕⊕⊕⊝<br>MODERATE1<br>due to risk of bias                     |                                   | The mean nausea (24 h) in the control groups was 13.1  | The mean nausea (24 h) in the<br>intervention groups was<br>1.71 lower<br>(4.06 lower to 0.64 higher)                                    |
| Vomiting (postoperative)                         | 248   | $\oplus \Theta \Theta \Theta$                                | RR 1.18                           | Moderate   |  |
| <i>,</i>   | (3 studies) VERY LOW1,3                                   | (0.65 to<br>2.12)  | 85 per 1000                       | 15 more per 1000<br>(from 30 fewer to 95 more)   |  |

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

#### Table 5: Clinical evidence summary: Clear fluids (water) versus fasting

| No of   |  |  |                                | Anticipated absolute effects |   |
|---|--|--|--------------------------------|------------------------------|---|
| (   | Participants<br>(studies)<br>Follow up | Quality of the evidence<br>(GRADE)   | Relative<br>effect<br>(95% CI) | Risk with<br>Fasting         | Risk difference with Clear fluids (Water)<br>(95% Cl) |
| Nausea (POD1)                                       | 54                                     | 54 ⊕⊕⊝⊝  |                                | Moderate                     |   |
|   | due t                                  | LOW1,2 (<br>due to risk of bias,<br>imprecision                                    | (0.16 to 0.91)                 | 517 per 1000                 | 315 fewer per 1000<br>(from 47 fewer to 434 fewer)    |
| Vomiting (POD1)                                     | 54                                     | $\oplus \oplus \bigcirc \bigcirc$<br>LOW1,2<br>due to risk of bias,<br>imprecision | RR 0.35<br>(0.11 to 1.13)      | Moderate                     |   |
|   | (1 study)                              |  |                                | 345 per 1000                 | 224 fewer per 1000<br>(from 307 fewer to 45 more)     |
| Headache (POD1) 54 $\oplus \ominus \ominus \ominus$ |  | $\oplus \Theta \Theta \Theta$  | RR 0.58                        | Moderate                     |   |
|   | (1 study)                              | VERY LOW1,2<br>due to risk of bias,<br>imprecision                                 | (0.26 to 1.32)                 | 414 per 1000                 | 174 fewer per 1000<br>(from 306 fewer to 132 more)    |

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

| Table 6: | Evidence not suitable fo | or GRADE analysis: CHO vers | sus fasting |
|----------|--------------------------|-----------------------------|-------------|
|----------|--------------------------|-----------------------------|-------------|

| Outcome | Study         | Risk of bias | Comparison results | Intervention results | <i>P</i> value |
|---------|---------------|--------------|--------------------|----------------------|----------------|
|         | (no. of       |              |                    |                      |                |
|         | participants) |              |                    |                      |                |

| Outcome   | Study<br>(no. of<br>participants) | Risk of bias | Comparison results   | Intervention results   | <i>P</i> value |
|---|-----------------------------------|--------------|--|--|----------------|
| Global QoR-40<br>score<br>(Scale 40 – 200)                                      | n=91<br>Asakura 2015 <sup>7</sup> | High         | Median (IQR)<br>Fasting: 197 (189.5–200)                       | Median (IQR)<br>CHO: 196 (191–198)   | -              |
| Length of stay<br>(days)  | n=91<br>Asakura 2015 <sup>7</sup> | High         | Median (IQR)<br>Fasting: 3 (2–6)                               | Median (IQR)<br>CHO: 3 (2–3)   |                |
|   | n=65<br>Yuill 2005 <sup>113</sup> | High         | Median (IQR)<br>Fasting: 8 (4)                                 | Median (IQR)<br>CHO: 10 (6)  |                |
| Patient Satisfaction<br>(preoperative)<br>Scale (1-5)                           | n=50<br>Doo 2018 <sup>30</sup>    | Very High    | Median (IQR)<br>Fasting: 4 (3-4)                               | Median (IQR)<br>CHO: 4 (3-4)   | 1              |
| Patient Satisfaction<br>(postoperative)<br>Scale (1-5)                          | n=50<br>Doo 2018 <sup>30</sup>    | Very High    | Median (IQR)<br>Fasting: 4 (3-4)                               | Median (IQR)<br>CHO: 4 (3-4)   | 0.715          |
| Thirst<br>VAS (0-100)   | n=60<br>Cakar 2014 <sup>17</sup>  | High         | Incidence Rate Ratio (range):<br>Fasting: 11.23 (9.41 to 3.40) | Incidence Rate Ratio:<br>CHO: 1.0 (reference)  | 0              |
| Thirst<br>(preoperative)<br>NRS (0-10)  | n=50<br>Doo 2018 <sup>30</sup>    | High         | Median (IQR)<br>Fasting: 2 (1-2)                               | Median (IQR)<br>CHO: 1 (0-2)   | 0.099          |
| Thirst<br>(postoperative)<br>NRS (0-10)   | n=50<br>Doo 2018 <sup>30</sup>    | High         | Median (IQR)<br>Fasting: 3 (1.5-4)                             | Median (IQR)<br>CHO: 2 (1-3)   | 0.456          |
| Thirst (difference in<br>baseline and<br>preoperative<br>scores)<br>VAS (0-100) | n=29<br>Melis 2006 <sup>73</sup>  | High         | Median difference (IQR)<br>Fasting: +34 (34)<br>(increase)     | Median difference (IQR)<br>CHOA: -7 (39) (decrease);<br>CHOB: 0 (18) (no difference) | -              |

| Outcome   | Study<br>(no. of<br>participants)     | Risk of bias | Comparison results  | Intervention results  | <i>P</i> value                               |
|---|---------------------------------------|--------------|---|---|--|
|   |                                       |              |   |   |  |
| Thirst (6 hours<br>postoperative)<br>VAS (0-100)  | n=56<br>Zhang 2019 <sup>115</sup>     | High         | Median (range)<br>Fasting: 40 (20-55)   | Median (range)<br>CHO: 20 (10-30)   | <0.001                                       |
| Thirst (24 hours<br>postoperative)<br>VAS (0-100) | n=56<br>Zhang 2019 <sup>115</sup>     | High         | Median (range)<br>Fasting: 40 (20-50)   | Median (range)<br>CHO: 30 (25-40)   | -  |
| Thirst VAS (0-10)<br>Preoperative                 | n=160<br>Helminen 2009 <sup>44</sup>  | High         | Median (IQR)<br>Fasting: 3 (0-5)  | Median (IQR)<br>CHO: 1 (0-4.5)  | -  |
| Thirst (0-10)<br>0-24 hours<br>Postoperatively    | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>Fasting: 4 (1-7)<br>Cholecystectomy patients:<br>Fasting: 4 (1-7) | Median (range)<br>Colorectal patients:<br>CHO: 3 (1-5)<br>Cholecystectomy patients:<br>CHO: 3 (1-5) | P value > 0.05                               |
| Thirst (0-10)<br>36-48 hours<br>Postoperatively   | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>Fasting: 2 (1-5)<br>Cholecystectomy patients:<br>Fasting: 2 (1-5) | Median (range)<br>Colorectal patients:<br>CHO: 2 (1-3)<br>Cholecystectomy patients:<br>CHO: 2 (1-3) | Colorectal <0.05<br>Cholecystectomy<br>>0.05 |
| Thirst (0-100)<br>90 minutes post<br>CHO          | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 60 (56-64)   | Median (IQR)<br>CHO: 20 (16-24)   | -  |
| Thirst (0-100)<br>60 minutes post<br>anesthesia   | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 64 (59-69)   | Median (IQR)<br>CHO: 18 (13-23)   | -  |
| Thirst (before induction)                         | n=113<br>Helminen 2019 <sup>43</sup>  | High         | Median (IQR):<br>Fasting: 40 (8 - 63)   | Median (IQR):<br>CHO: 22 (6 - 50)   | -  |

| Outcome   | Study<br>(no. of<br>participants)    | Risk of bias | Comparison results                                       | Intervention results  | <i>P</i> value |
|---|--------------------------------------|--------------|--|---|----------------|
| Thirst (2 hours post op)  | n=113<br>Helminen 2019 43            | High         | Median (IQR):<br>Fasting: 46 (24-70)                     | Median (IQR):<br>CHO: 41 (20 - 61)  | -              |
| Thirst (4 hours post op)  | n=113<br>Helminen 2019 <sup>43</sup> | High         | Median (IQR):<br>Fasting: 20(0-50)                       | Median (IQR):<br>CHO: 28 (9-61)   | -              |
| Thirst (1hr<br>preoperative)  | n=35<br>Wang 2010 <sup>107</sup>     | High         | Median (range)<br>Fasting: 24 (19-60)                    | Median (range)<br>CHO: 20 (8-59)  |                |
| Nausea & Vomiting<br>(preoperative)<br>NRS (0-10)                               | n=50<br>Doo 2018 <sup>30</sup>       | High         | Median (IQR)<br>Fasting: 0 (0-0)                         | Median (IQR)<br>CHO: 0 (0-1)  | 0.192          |
| Nausea & Vomiting<br>(postoperative)<br>NRS (0-10)                              | n=50<br>Doo 2018 <sup>30</sup>       | High         | Median (IQR)<br>Fasting: 1 (1-2)                         | Median (IQR)<br>CHO: 1 (0.5-2)  | 0.926          |
| Nausea (difference<br>in baseline and<br>preoperative<br>scores)<br>VAS (0-100) | n=29<br>Melis 2006 <sup>73</sup>     | High         | Median difference (IQR)<br>Fasting: 0 (7)<br>(no change) | Median difference (IQR)<br>CHOA: 0 (6) (no differece);<br>CHOB: +1 (6) (increase) | -              |
| Nausea (0-10)<br>40 minutes post<br>CHO drink                                   | n=166<br>Hausel 2001 <sup>41</sup>   | High         | Median (IQR)<br>Fasting: 3 (2–10)                        | Median (IQR)<br>CHO: 4 (2–6)  | -              |
| Nausea (0-10)<br>90 minutes post<br>CHO drink                                   | n=166<br>Hausel 2001 <sup>41</sup>   | High         | Median (IQR)<br>Fasting: 4 (2–12)                        | Median (IQR)<br>CHO: 3 (2–7)  | -              |
| Nausea (before induction)   | n=113<br>Helminen 2019 <sup>43</sup> | High         | Median (IQR):<br>Fasting: 0 (0-2)                        | Median (IQR):<br>CHO: 0 (0-0)   | -              |

| Outcome   | Study<br>(no. of<br>participants)     | Risk of bias | Comparison results  | Intervention results  | <i>P</i> value |
|---|---------------------------------------|--------------|---|---|----------------|
| Nausea (2 hours<br>post op)                     | n=113<br>Helminen 2019 <sup>43</sup>  | High         | Median (IQR):<br>Fasting: 0 (0-6)   | Median (IQR):<br>CHO: 0 (0-14)  | -              |
| Nausea (4 hours<br>post op)                     | n=113<br>Helminen 2019 <sup>43</sup>  | High         | Median (IQR):<br>Fasting: 0 (0-10)  | Median (IQR):<br>CHO: 0 (0-4)   | -              |
| Nausea (2 hours<br>postoperative)<br>VAS 0-100  | n=95<br>Gilbert 1995 <sup>37</sup>    | High         | Median<br>Water: 1.0  | Median<br>Fasting: 0  | 0.32           |
| Nausea (0-10)<br>0-24 hours<br>Postoperatively  | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>Fasting: 3 (1-6)<br>Cholecystectomy patients:<br>Fasting: 3 (1-6) | Median (range)<br>Colorectal patients:<br>CHO: 1 (1-5)<br>Cholecystectomy patients:<br>CHO: 1 (1-5) | >0.05          |
| Nausea (0-10)<br>36-48 hours<br>Postoperatively | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>2 (1-5)<br>Cholecystectomy patients:<br>Fasting: 2 (1-5)          | Median (range)<br>Colorectal patients:<br>CHO: 1 (1-3)<br>Cholecystectomy patients:<br>CHO: 1 (1-3) | >0.05          |
| Nausea (1hr<br>preoperative)                    | n=35<br>Wang 2010 <sup>107</sup>      | High         | Median (range)<br>Fasting: 8 (2-14)   | Median (range)<br>CHO: 8 (4-11)   |                |
| Nausea (0-100)<br>60 minutes post<br>anesthesia | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 9 (5-13)   | Median (IQR)<br>CHO: 8 (4-12)   | -              |
| Nausea (0-100)<br>90 minutes post<br>CHO        | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 8 (4-12)   | Median (IQR)<br>CHO: 10 (7-13)  | -              |
| Anxiety<br>(postoperative)<br>NRS (0-10)        | n=50<br>Doo 2018 <sup>30</sup>        | High         | Median (IQR)<br>Fasting: 0 (0-1)  | Median (IQR)<br>CHO: 0 (0-0)  | 0.50           |

| Outcome  | Study<br>(no. of<br>participants)     | Risk of bias | Comparison results  | Intervention results  | <i>P</i> value |
|--|---------------------------------------|--------------|---|---|----------------|
| Anxiety (difference<br>in baseline and<br>preoperative<br>scores)<br>VAS (0-100) | n=29<br>Melis 2006 <sup>73</sup>      | High         | Median difference (IQR)<br>Fasting: +3 (51) (increase)  | Median difference (IQR)<br>CHOA: -15 (49) (decrease);<br>CHOB: 0 (15) (no difference)               | -              |
| Anxiety<br>(preoperative)<br>VAS (0-100)   | n=56<br>Zhang 2019 <sup>115</sup>     | High         | Median (range)<br>Fasting: 60 (50-70)   | Median (range)<br>CHO: 30 (30-30)   | -              |
| Anxiety VAS (0-10)<br>Preoperative   | n=160<br>Helminen 2009 <sup>44</sup>  | High         | Median (IQR)<br>Fasting: 3 (1-5)  | Median (IQR)<br>CHO: 2 (1-5)  |                |
| Anxiety (0-10)<br>0-24 hours<br>Postoperatively                                  | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>Fasting: 2 (1-6)<br>Cholecystectomy patients:<br>Fasting: 2 (1-6)     | Median (range)<br>Colorectal patients:<br>CHO: 3 (1-3)<br>Cholecystectomy patients:<br>CHO: 2 (1-3) | >0.05          |
| Anxiety (0-10)<br>36-48 hours<br>Postoperatively                                 | n=96<br>Sada 2014 <sup>98</sup>       | High         | Median (range)<br>Colorectal patients:<br>Fasting: 1.5 (1-5)<br>Cholecystectomy patients:<br>Fasting: 1.5 (1-5) | Median (range)<br>Colorectal patients:<br>CHO: 1 (1-3)<br>Cholecystectomy patients:<br>CHO: 1 (1-3) | >0.05          |
| Anxiety (0-100)<br>90 minutes post<br>CHO  | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 48 (43-53)   | Median (IQR)<br>CHO: 20 (18-22)   | -              |
| Anxiety (0-100)<br>60 minutes post<br>anesthesia                                 | n=44<br>Yagmurdur 2011 <sup>110</sup> | High         | Median (IQR)<br>Fasting: 46 (44-48)   | Median (IQR)<br>CHO: 43 (41-45)   | -              |
| Anxiety (1hr<br>preoperative)  | n=35<br>Wang 2010 <sup>107</sup>      | High         | Median (range)<br>Fasting: 28 (16-61)   | Median (range)<br>CHO: 22 (11-47)   |                |

| Outcome   | Study<br>(no. of<br>participants)  | Risk of bias | Comparison results  | Intervention results   | <i>P</i> value |
|---|------------------------------------|--------------|---|--|----------------|
| Anxiety<br>(preoperative)<br>NRS (0-10)   | n=50<br>Doo 2018 <sup>30</sup>     | High         | Median (IQR)<br>Fasting: 2 (1-2)                              | Median (IQR)<br>CHO: 2 (1-3)   | 0.288          |
| Headache<br>VAS (0-100)   | n=60<br>Cakar 2014 <sup>17</sup>   | High         | Incidence Rate Ratio (range):<br>Fasting: 2.70 (1.69 to 4.32) | Incidence Rate Ratio:<br>CHO: 1.0 (reference)  | 0              |
| Fatigue<br>(preoperative)<br>NRS (0-10)   | n=50<br>Doo 2018 <sup>30</sup>     | High         | Median (IQR)<br>Fasting: 2 (1-2)                              | Median (IQR)<br>CHO: 2 (0-2)   | 0.512          |
| Fatigue<br>(postoperative)<br>NRS (0-10)  | n=50<br>Doo 2018 <sup>30</sup>     | High         | Median (IQR)<br>Fasting: 1 (0-2)                              | Median (IQR)<br>CHO: 1 (0.5-2)   | 0.630          |
| Malaise (0-10)<br>40 minutes post<br>CHO drink  | n=166<br>Hausel 2001 <sup>41</sup> | High         | Median (IQR)<br>Fasting: 12 (3–30)                            | Median (IQR)<br>CHO: 8 (4–20)  |                |
| Malaise (0-10)<br>90 minutes post<br>CHO drink  | n=166<br>Hausel 2001 <sup>41</sup> | High         | Median (IQR)<br>Fasting: 10 (3–30)                            | Median (IQR)<br>CHO: 7 (3–17)  | -              |
| Tiredness<br>VAS (0-100)  | n=60<br>Cakar 2014 <sup>17</sup>   | High         | Incidence Rate Ratio (range):<br>Fasting: 1.18 (0.64 to 2.17) | Incidence Rate Ratio:<br>CHO: 1.0 (reference)  | 0.592          |
| Tiredness<br>(difference in<br>baseline and<br>preoperative<br>scores)<br>VAS (0-100) | n=29<br>Melis 2006 <sup>73</sup>   | High         | Median difference (IQR)<br>Fasting: -19 (27)<br>(decrease)    | Median difference (IQR)<br>CHOA: 0 (20) (no difference);<br>CHOB: -7 (29) (decrease) | -              |
| Tiredness (6 hours<br>postoperative)<br>VAS (0-100)                                   | n=56<br>Zhang 2019 <sup>115</sup>  | High         | Median (range)<br>Fasting: 30 (20-40)                         | Median (range)<br>CHO: 30 (20-40)  | -              |

| Outcome   | Study<br>(no. of<br>participants)    | Risk of bias | Comparison results                    | Intervention results              | P value |
|---|--------------------------------------|--------------|---------------------------------------|-----------------------------------|---------|
| Tiredness<br>(24 hours<br>postoperative)<br>VAS (0-100) | n=56<br>Zhang 2019 <sup>115</sup>    | High         | Median (range)<br>Fasting: 30 (20-30) | Median (range)<br>CHO: 40 (30-40) | -       |
| Tiredness VAS (0-<br>10)<br>Preoperative                | n=160<br>Helminen 2009 <sup>44</sup> | High         | Median (IQR)<br>Fasting: 3 (0-5)      | Median (IQR)<br>CHO: 2 (0–5)      | -       |
| Tiredness (before induction)                            | n=113<br>Helminen 2019 <sup>43</sup> | High         | Median (IQR):<br>Fasting: 20 (5-46)   | Median (IQR):<br>CHO: 30 (10-54)  | -       |
| Tiredness (2 hours post op)                             | n=113<br>Helminen 2019 <sup>43</sup> | High         | Median (IQR):<br>Fasting: 53 (30-61)  | Median (IQR):<br>CHO: 49 (20-70)  | -       |
| Tiredness (4 hours post op)                             | n=113<br>Helminen 2019 <sup>43</sup> | High         | Median (IQR):<br>Fasting: 40 (10-50)  | Median (IQR):<br>CHO: 42 (8-70)   | -       |
| Tiredness (1hr<br>preoperative)                         | n=35<br>Wang 2010 <sup>107</sup>     | High         | Median (range)<br>Fasting: 23(10-53)  | Median (range)<br>CHO: 20 (11-60) |         |

| Outcome   | Study<br>(no. of<br>participants)  | Risk of bias | Comparison results   | Intervention results    | <i>P</i> value |
|---|------------------------------------|--------------|----------------------|-------------------------|----------------|
| Thirst (2 hours<br>postoperative)<br>VAS 0-100    | n=95<br>Gilbert 1995 <sup>37</sup> | High         | Median<br>Water: 5   | Median<br>Fasting: 21.0 | 0.0149         |
| Vomiting ( 2 hours<br>postoperative)<br>VAS 0-100 | n=95<br>Gilbert 1995 <sup>37</sup> | High         | Median<br>Water: 1.0 | Median<br>Fasting: 0    | 0.21           |

| Outcome   | Study<br>(no. of<br>participants)  | Risk of bias | Comparison results    | Intervention results   | <i>P</i> value |
|---|------------------------------------|--------------|-----------------------|------------------------|----------------|
| Drowsiness<br>(2 hours<br>postoperative)<br>VAS 0-100 | n=95<br>Gilbert 1995 <sup>37</sup> | High         | Median<br>Water: 13.0 | Median<br>Fasting: 7.0 | 0.42           |
| Headache ( 2 hours<br>postoperative)<br>VAS 0-100     | n=95<br>Gilbert 1995 <sup>37</sup> | High         | Median<br>Water: 2.5  | Median<br>Fasting: 2.0 | 0.99           |

See appendix F for full GRADE tables.

#### 1.5 Economic evidence

#### 1.5.1 Included studies

No health economic studies were included.

#### 1.5.2 Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix G:.

#### 1.5.3 Unit costs

Relevant unit costs of carbohydrate loading drinks are provided below to aid consideration of cost effectiveness.

| Brand                                       | Description  | Cost per unit |
|---|--|---------------|
| Nutricia                                    | Preop 0.5kcal/ml clear non- carbonated lemon flavoured iso-<br>osmolar carbohydrate drink 200ml carton | £1.50         |
| Polycal                                     | Carbohydrate liquid ready to drink neutral 200ml 2.47kcal/ml plastic bottles                           | £1.44         |
| Source: NHS Supply Chain 2018 <sup>77</sup> |  |               |

#### **1.6 Evidence statements**

#### 1.6.1 Clinical evidence statements

No evidence was found for mortality; patient, family and carer experience of care; unplanned ICU admission and cancellation of surgery.

#### Carbohydrate drinks versus fasting

#### Quality of life

One study showed a clinically important benefit with carbohydrate drinks for postoperative patient satisfaction on a scale of 0 - 10 compared to fasting (1 study, n=58, moderate quality evidence)

One study showed a clinically important harm with carbohydrate drinks when measuring postoperative global QoR-40 score, a quality of life measure, compared to fasting (1 study, n=95, low quality of evidence)

Two studies found no clinically important difference between carbohydrate drinks and fasting in postoperative wellbeing (2 studies, n=87, moderate quality of evidence).

One study found no difference in between carbohydrate drinks and fasting in preoperative anxiety (1 study, n=98, moderate quality).

One study found a clinically important benefit with carbohydrate drinks for postoperative anxiety compared to fasting (1 study, n=50, moderate quality of evidence).

#### Length of stay

Eleven studies looked at length of hospital stay, comparing carbohydrate drinks versus fasting. Overall, there was no clinically important difference between carbohydrate drinks versus fasting. (11 studies, n=673, low quality of evidence).

Broken down into the different types of surgery types, six studies showed a clinically important benefit for length of stay with carbohydrate drinks in major surgery compared to fasting (6 studies, n=334, very low quality of evidence).

One study showed a clinically important benefit with carbohydrate drinks for length of stay in orthopaedic surgery compared to fasting (1 study, n=39, low quality of evidence).

one study showed no clinically important difference between carbohydrate drinks and fasting for length of stay in intermediate abdominal surgery (1 study, n=97, low quality of evidence).

Three studies showed no clinically important difference between carbohydrate drinks and fasting for length of stay in minor abdominal surgery (3 studies, n=203, moderate quality of evidence).

#### Adverse events

Thirst was measured by several studies. One study measured preoperative thirst on a scale of 0-10 which found no clinically important difference between carbohydrate drinks and fasting (1 study, n=98, low quality of evidence).

Three studies found a clinically important benefit with carbohydrate drinks. for postoperative thirst on a scale of 0 - 10 (1 study, n=50, moderate quality), thirst mild (1 study, n=50, low quality) and thirst moderate (1 study, n=50, very low quality)

One study found a clinically important benefit with carbohydrate drinks for reducing postoperative headache compared to fasting (1 study, n=58, low quality).

Five studies showed no clinically important difference between carbohydrate drinks and fasting for complication rates (5 studies, n=348, very low quality).

One study showed a clinically important benefit with carbohydrate drinks when assessing postoperative nausea and vomiting measured on a VAS scale of 0 - 10 compared to fasting (1 study, n=58, low quality of evidence).

Two studies found no clinically important difference between carbohydrate drinks and fasting in nausea and vomiting overall (2 studies, n=138, very low quality evidence).

One study found no clinically important difference between carbohydrate drinks and fasting for nausea (1 study, n=98, very low quality)

Three studies found no clinically important difference for vomiting with carbohydrate drinks compared to fasting (n=232, low quality evidence)

One study found no clinically important difference between carbohydrate drinks and fasting in fatigue rates (1 study, n=108, moderate quality evidence)

#### Carbohydrate drinks versus placebo

#### Quality of life

Two studies showed no clinically important difference between carbohydrate drinks and placebo drinks when measuring postoperative well-being (2 studies, n=205, moderate quality of evidence)

#### Length of stay

Six studies found no clinically important difference between carbohydrate drinks and placebo drinks for length of stay after major abdominal surgery (6 studies, n=441, very low quality of evidence).

Two studies found no found no clinically important difference between carbohydrate drinks and placebo drinks for length of stay after minor abdominal surgery (2 studies, n=144, moderate quality of evidence).

Three studies found no clinically important difference between carbohydrate drinks and placebo drinks for length of stay after orthopaedic surgery (3 studies, n=89, moderate quality of evidence).

#### Adverse events

Eight studies found no clinically important difference between carbohydrate drinks and placebo drinks when assessing complication rates (8 studies, n=554, low quality evidence).

Three studies found no clinically important difference between carbohydrate drinks and placebo drinks in rates of postoperative fatigue (3 studies, n=268, very low quality evidence).

Two studies showed no clinically important difference between carbohydrate drinks and placebo drink in postoperative nausea rates (2 studies, n=234, moderate quality evidence)

Three studies showed no clinically important difference between carbohydrate drinks and placebo drinks in postoperative vomiting (3 studies, n=248, very low quality evidence)

#### Water versus fasting

#### **Adverse events**

One study found a clinically important benefit with water in postoperative nausea, vomiting and headache, compared to fasting (1 study, n=54, very low quality evidence)

#### Evidence not suitable for GRADE

#### Carbohydrate drinks versus fasting

One study showed no notable difference between carbohydrate drinks and fasting for quality of life via the global QoR-40 score (1 study, n=91, high risk of bias)

Two studies found no notable difference between carbohydrate drink and fasting when assessing length of stay (2 studies, n=156, high risk of bias)

One study showed no notable difference between carbohydrate drinks and fasting in preoperative or postoperative patient satisfaction rates on a scale of one to five (1 study, n=50, very high risk of bias)

Seven studies found no notable difference between carbohydrate drinks and fasting in preoperative anxiety (7 studies, n=418, high risk of bias)

Three studies found no clinically important difference between carbohydrate drinks and fasting for postoperative anxiety (3 studies, n=242, high risk of bias)

One study showed no notable difference between carbohydrate drinks and fasting in preoperative and postoperative fatigue (1 study, n=50, high risk of bias)

One study found no notable difference between carbohydrate drinks and fasting for rates of headache (1 study, n=60, high risk of bias)

One study showed no notable difference between carbohydrate drinks and fasting in preoperative malaise (1 study, n=166, high risk of bias)

One study found no notable difference between carbohydrate drinks and fasting in levels of preoperative or postoperative nausea and vomiting (combined) (1 study, n=50, high risk of bias)

Two studies showed no notable difference between carbohydrate drinks and fasting in preoperative nausea (2 studies, n=204, high risk of bias)

Five studies showed no notable difference between carbohydrate drinks and fasting in postoperative nausea (5 studies, n=317, high risk of bias)

One study showed a trend to benefit with carbohydrate drinks in overall thirst rates compared to fasting (1 study, n=60, high risk of bias)

Four studies showed no notable difference between carbohydrate drinks and fasting in preoperative thirst (4 studies, n=315, high risk of bias)

Five studies showed no notable difference between carbohydrate drinks and fasting for postoperative thirst (5 studies, n=431, high risk of bias)

One study showed no notable difference between carbohydrate drinks and fasting with overall levels of tiredness (1 study, n=60, high risk of bias)

Four studies showed no notable difference between carbohydrate drinks and fasting in preoperative tiredness (4 studies, n=337, high risk of bias)

Two studies showed no clinically important difference in postoperative tiredness with carbohydrate drinks compared to fasting (n=169, high risk of bias)

### Water versus fasting

One study showed no statistically significant difference between water and fasting for drowsiness, vomiting or headache (1 study, n=95, high risk of bias)

One study showed a statistically significant benefit with water for postoperative compared to fasting (1 study, n=95, high risk of bias)

### 1.6.2 Health economic evidence statements

• No relevant economic evaluations were identified.

### **1.7** The committee's discussion of the evidence

Please see recommendations 1.4.1 – 1.4.2 in the guideline.

### 1.7.1 Interpreting the evidence

### 1.7.1.1 The outcomes that matter most

The committee considered that the focus of this evidence review was to better understand the optimal time and duration of fasting for people undergoing surgery, to improve patient experience while minimising the risk of adverse events from surgery. Subsequently, the committee agreed critical outcomes for decision making to be health related quality of life, mortality, patient, family and carer experience of care and adverse events and complications. The committee also considered length of hospital stay, unplanned ICU admission, thirst, headache and cancellation of surgery to be important outcomes.

No evidence was found for mortality, unplanned ICU admission and cancellation of surgery.

### 1.7.1.2 The quality of the evidence

The quality of evidence that was suitable for GRADE analysis ranged from very low to moderate. The majority of the evidence was graded at low quality. This was mostly due to imprecision of data, reducing the certainty with which the committee could make conclusions from the evidence. The committee felt that the quality of the evidence limited the strength with which they could make any recommendations, particularly given that any recommendation for the use of carbohydrate drinks would have a significant resource impact.

### 1.7.1.3 Benefits and harms

The committee reviewed the body of evidence comparing preoperative carbohydrate drinks to fasting, carbohydrate drinks to placebo drinks and water to fasting.

#### Carbohydrate drinks versus fasting:

Two studies reporting patient satisfaction postoperatively. One study reported patient satisfaction using a 0 - 10 Likert scale which showed better patient satisfaction. The second study using the QoR-40 score showed a reduction in patient satisfaction with a carbohydrate drink. The committee considered the variation may be due to the taste of the carbohydrate drinks given.

Six studies of patients undergoing major abdominal surgery and one study of patients undergoing orthopaedic surgery, showed a reduction in the length of hospital stay when preoperatively given a carbohydrate drink. However, one study looking at intermediate abdominal surgery and three studies reviewing minor abdominal surgery showed no clinically important difference when participants were given carbohydrate drinks.

When patients were given carbohydrate drinks, the outcome of preoperative thirst showed no clinical difference. However, one study which assessed postoperative thirst and another study which grouped thirst into mild or moderate postoperative thirst showed a clinically important benefit by reducing the number of patients who experienced thirst.

There was a clinically important benefit with carbohydrate drinks in the reduction of postoperative headache shown by one study. Evidence from five studies showed no difference in complication rate for participants who were given a carbohydrate drink.

Nausea and vomiting grouped together in one study showed a clinically important benefit with carbohydrate drinks. As individual outcomes from six studies, there was no clinically important difference with the use of carbohydrate drinks. When assessing postoperative wellbeing, one study showed clinically important benefit with carbohydrate drinks in reducing postoperative anxiety. But one study looking at preoperative anxiety and another study assessing fatigue showed no clinically important benefit with carbohydrate drinks. Two studies assessed wellbeing overall, which showed no clinically important benefit. The committee agreed that on the balance of evidence carbohydrate drinks preoperatively may have a benefit in the context of major abdominal surgery both for patient comfort with reduced thirst and improved satisfaction and for operative outcomes with a shorter length of stay, The committee noted that there were no observed harms of carbohydrate drinks.

### Carbohydrate drinks versus placebo drinks:

Evidence from eleven studies showed no difference in length of hospital stay and evidence from eighteen studies showed no difference in complication rate, nausea, vomiting or postoperative well-being.

### Water versus fasting:

One study showed evidence of clinically important benefit through the reduction of nausea, vomiting and headache postoperatively when given water preoperatively.

No evidence was found for mortality, unplanned ICU admission and cancellation of surgery for either of the three comparison groups

The committee considered that on the balance of all the evidence and considering the increased cost of carbohydrate drinks compared to clear fluids, people should be told that can take clear fluids two hours before surgery and to consider carbohydrate drinks before complex abdominal surgery.

### 1.7.2 Cost effectiveness and resource use

No economic evaluations were identified for this review; therefore, unit costs were presented to aid committee consideration of cost effectiveness.

There are different types of carbohydrate loading drinks in the NHS but the cost per carton is approximately £1.50. The committee highlighted that these costs can vary across trusts as prices are usually negotiable. Although this is a low cost, if all adults having surgery are prescribed carbohydrate drinks, this affects a large population and therefore the overall costs would be very high.

The clinical evidence showed that both carbohydrate loading and water were associated with some improvements in comparison to fasting, for example, less people had headaches and felt nauseous. This can temporarily improve the adult's quality of life post-surgery. However, there was no evidence of complications being reduced. For major abdominal surgery, five studies showed a reduction in hospital length of stay of 1.26 days which could have significant cost-savings.

The committee highlighted that current practice varies but that in recent years more hospitals have been prescribing carbohydrate drinks to adults undergoing surgery.

As water showed similar effectiveness to carbohydrate drinks when compared to fasting, the committee made a recommendation to offer water to people undergoing surgery. The committee highlighted this may lead to cost-savings as some hospitals routinely offer carbohydrate drinks to people. A recommendation was also made to consider carbohydrate drinks in adults having abdominal surgery, as there was an indication that postoperative length of stay could be reduced. Also, the committee highlighted that adults are usually unable to eat after major abdominal surgery, therefore carbohydrate drinks may have some clinical benefits in this population.

### 1.7.3 Other factors the committee took into account

The committee agreed that the recommendation to offer clear fluids before surgery is consistent with current practice. Clear fluids can include water, fruit juice without pulp, coffee or tea without milk, and ice lollies/popsicles. Clear fluids do not include carbonated drinks,

milk, or yoghurt. The committee highlighted the importance of preoperative fasting in preventing intraoperative and postoperative complications. Historically, patients have been asked to fast from midnight or up to six hours prior to surgery to prevent such complications. Therefore, the committee suggested that telling patients they can drink water until up to two hours prior to surgery as well as the benefits of doing so will need to be clearly explained. The committee also noted that in some units and ahead of certain types of surgery, people are allowed to drink clear fluids less than two hours before surgery. The committee noted that the amount of clear fluid that can be drunk before surgery is not limited but that is should not be excessive.

The committee noted that the recommendations are applicable to all people undergoing surgery and not just those requiring a general anaesthetic. It also applies to people undergoing dental surgery.

## References

- 1. Adamova Z, Slovacek R. Effects of preoperative carbohydrate drinks on postoperative outcome after colorectal surgery. European Surgery Acta Chirurgica Austriaca. 2017; 49(4):180-186
- 2. Agarwal A, Chari P, Singh H. Fluid deprivation before operation. The effect of a small drink. Anaesthesia. 1989; 44(8):632-4
- 3. Ajuzieogu OV, Amucheazi AO, Nwagha UI, Ezike HA, Luka SK, Abam DS. Effect of routine preoperative fasting on residual gastric volume and acid in patients undergoing myomectomy. Nigerian Journal of Clinical Practice. 2016; 19(6):816-820
- 4. Amer MA, Smith MD, Herbison GP, Plank LD, McCall JL. Network meta-analysis of the effect of preoperative carbohydrate loading on recovery after elective surgery. British Journal of Surgery. 2017; 104(3):187-197
- 5. Anonymous. Erratum: Randomized controlled trial of liberal versus restricted fluid management in patients undergoing pancreatectomy (Annals of Surgery 264:4 (591-598) DOI: 10.1097/SLA.00000000001846). Annals of Surgery. 2018; 267(3):e61
- Aronsson A, Al-Ani NA, Brismar K, Hedstrom M. A carbohydrate-rich drink shortly before surgery affected IGF-I bioavailability after a total hip replacement. A doubleblind placebo controlled study on 29 patients. Aging-Clinical & Experimental Research. 2009; 21(2):97-101
- 7. Asakura A, Mihara T, Goto T. The effect of preoperative oral carbohydrate or oral rehydration solution on postoperative quality of recovery: A randomized, controlled clinical trial. PloS One. 2015; 10(8):e0133309
- 8. Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clinical Nutrition. 2013; 32(1):34-44
- Azagury DE, Ris F, Pichard C, Volonte F, Karsegard L, Huber O. Does perioperative nutrition and oral carbohydrate load sustainably preserve muscle mass after bariatric surgery? A randomized control trial. Surgery for Obesity and Related Diseases. 2015; 11(4):920-6
- Bhaskaran K, Arumugam G, Vinay Kumar PV. A prospective, randomized, comparison study on effect of perioperative use of chloride liberal intravenous fluids versus chloride restricted intravenous fluids on postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass grafting surgeries. Annals of Cardiac Anaesthesia. 2018; 21(4):413-418
- 11. Bilku DK, Dennison AR, Hall TC, Metcalfe MS, Garcea G. Role of preoperative carbohydrate loading: a systematic review. Annals of the Royal College of Surgeons of England. 2014; 96(1):15-22
- 12. Bisgaard T, Kristiansen VB, Hjortso NC, Jacobsen LS, Rosenberg J, Kehlet H. Randomized clinical trial comparing an oral carbohydrate beverage with placebo before laparoscopic cholecystectomy. British Journal of Surgery. 2004; 91(2):151-8
- 13. Bopp C, Hofer S, Klein A, Weigand MA, Martin E, Gust R. A liberal preoperative fasting regimen improves patient comfort and satisfaction with anesthesia care in day-stay minor surgery. Minerva Anestesiologica. 2011; 77(7):680-6

- 14. Borges Dock-Nascimento D, Aguilar-Nascimento JE, Caporossi C, Sepulveda Magalhaes Faria M, Bragagnolo R, Caporossi FS et al. Safety of oral glutamine in the abbreviation of preoperative fasting: a double-blind, controlled, randomized clinical trial. Nutricion Hospitalaria. 2011; 26(1):86-90
- 15. Brady M, Kinn S, Stuart P, Ness V. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004423. DOI: 10.1002/14651858.CD004423.
- 16. Breuer JP, von Dossow V, von Heymann C, Griesbach M, von Schickfus M, Mackh E et al. Preoperative oral carbohydrate administration to ASA III-IV patients undergoing elective cardiac surgery. Anesthesia and Analgesia. 2006; 103(5):1099-108
- 17. Cakar E, Yilmaz E, Cakar E, Baydur H. The effect of preoperative oral carbohydrate solution intake on patient comfort: a randomized controlled study. Journal of Perianesthesia Nursing. 2017; 32(6):589-599
- 18. Campos SBG, Barros-Neto JA, Guedes GDS, Moura FA. Pre-operative fasting: Why abbreviate? Arquivos Brasileiros de Cirurgia Digestiva. 2018; 31(2):e1377
- 19. Canbay O, Adar S, Karagoz AH, Celebi N, Bilen CY. Effect of preoperative consumption of high carbohydrate drink (Pre-Op) on postoperative metabolic stress reaction in patients undergoing radical prostatectomy. International Urology and Nephrology. 2014; 46(7):1329-1333
- Celiksular MC, Saracoglu A, Yentur E. The influence of oral carbohydrate solution intake on stress response before total hip replacement surgery during epidural and general anaesthesia. Turkish Journal of Anaesthesiology and Reanimation. 2016; 44(3):117-23
- 21. Chen J. The effect of the preoperative oral intake of 10% glucose solution on postoperative insulin resistance in patients undergoing gastric cancer resection. Journal of Practical Medicine. 2014; 10(12):1562-1565
- 22. Chen J, Cheng L, Xie Z, Li Z. Impact of preoperative oral liquid carbohydrate on postoperative insulin resistance in gastric cancer patients and its associated study. Chinese Journal of Gastrointestinal Surgery. 2015; 18(12):1256-1260
- 23. Chinese Clinical Trials Register. Randomized clinical trial of the effect of preoperative oral carbohydrate on postoperative cognitive function in elderly patients undergoing colorectal surgery. 2018. Available from: http://www.chictr.org.cn/hvshowproject.aspx?id=12495 Last accessed: 20/06/2019
- 24. de Aguilar-Nascimento JE, Caporossi C, Metelo JS, Tanajura GH, Canevari-de-Oliveira M, da Cunha Costa R. Safe intake of an oral supplement containing carbohydrates and whey protein shortly before sedation to gastroscopy; a double blind, randomized trial. Nutricion Hospitalaria. 2014; 29(3):681-6
- de Aguilar-Nascimento JE, Dock-Nascimento DB. Reducing preoperative fasting time: A trend based on evidence. World Journal of Gastrointestinal Surgery. 2010; 2(3):57-60
- de Aguilar-Nascimento JE, Perrone F, de Assunção Prado LÍ. Preoperative fasting of 8 hours or 2 hours: what does evidence reveal? Revista do Colegio Brasileiro Cirurgioes. 2009; 36(4):350-352
- 27. Dilmen OK, Yentur E, Tunali Y, Balci H, Bahar M. Does preoperative oral carbohydrate treatment reduce the postoperative surgical stress response in lumbar disc surgery? Clinical Neurology and Neurosurgery. 2017; 153:82-86

- 28. Dock-Nascimento DB, de Aguilar-Nascimento JE, Magalhaes Faria MS, Caporossi C, Slhessarenko N, Waitzberg DL. Evaluation of the effects of a preoperative 2-hour fast with maltodextrine and glutamine on insulin resistance, acute-phase response, nitrogen balance, and serum glutathione after laparoscopic cholecystectomy: a controlled randomized trial. Journal of Parenteral & Enteral Nutrition. 2012; 36(1):43-52
- 29. Does preoperative oral carbohydrate intake improve postoperative outcomes in patients undergoing coronary artery bypass grafts? Journal of Cardiothoracic and Vascular Anesthesia. 2017; Conference: 32nd Annual Meeting of the European Association of Cardiothoracic Anaesthelologists. Germany. 31(Supplement 1):S58-S59
- 30. Doo AR, Hwang H, Ki MJ, Lee JR, Kim DC. Effects of preoperative oral carbohydrate administration on patient well-being and satisfaction in thyroid surgery. Korean Journal of Anesthesiology. 2018; 71(5):394-400
- 31. Faria MS, de Aguilar-Nascimento JE, Pimenta OS, Alvarenga LC, Jr., Dock-Nascimento DB, Slhessarenko N. Preoperative fasting of 2 hours minimizes insulin resistance and organic response to trauma after video-cholecystectomy: a randomized, controlled, clinical trial. World Journal of Surgery. 2009; 33(6):1158-64
- 32. Feguri GR, de Lima PRL, de Cerqueira Borges D, Toledo LR, Batista LN, TC ES et al. Preoperative carbohydrate load and intraoperatively infused omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary artery bypass grafting: a double-blind controlled randomized trial. Nutrition Journal. 2017; 16(1):24
- 33. Feng SY, Zhang JR, Chen YL. Three-hour fluid fasting before anesthesia is safe and beneficial to patients. Beijing Medical Journal. 1995; 17(2):92-94
- 34. Gava MG, Castro-Barcellos HM, Caporossi C, Aguilar-Nascimento JE. Enhanced muscle strength with carbohydrate supplement two hours before open cholecystectomy: a randomized, double-blind study. Revista do Colegio Brasileiro de Cirurgioes. 2016; 43(1):54-9
- 35. Ghorashi Z, Ashori V, Aminzadeh F, Mokhtari M. The effects of oral fluid intake an hour before cesarean section on regurgitation incidence. Iranian Journal of Nursing and Midwifery Research. 2014; 19(4):439-42
- Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R et al. Preoperative oral carbohydrate load versus placebo in major elective abdominal surgery (PROCY): A randomized, placebo-controlled, multicenter, phase III trial. Annals of Surgery. 2018; 267(4):623-630
- 37. Gilbert SS, Easy WR, Fitch WW. The effect of pre-operative oral fluids on morbidity following anaesthesia for minor surgery. Anaesthesia. 1995; 50(1):79-81
- 38. Gonik N, Tassler A, Ow TJ, Smith RV, Shuaib S, Cohen HW et al. Randomized controlled trial assessing the feasibility of shortened fasts in intubated ICU patients undergoing tracheotomy. Otolaryngology Head & Neck Surgery. 2016; 154(1):87-93
- Goodwin AP, Rowe WL, Ogg TW, Samaan A. Oral fluids prior to day surgery. The effect of shortening the pre-operative fluid fast on postoperative morbidity. Anaesthesia. 1991; 46(12):1066-8
- 40. Harsten A, Hjartarson H, Toksvig-Larsen S. Total hip arthroplasty and perioperative oral carbohydrate treatment: a randomised, double-blind, controlled trial. European Journal of Anaesthesiology. 2012; 29(6):271-4

- 41. Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C et al. A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. Anesthesia and Analgesia. 2001; 93(5):1344-50
- 42. Hausel J, Nygren J, Thorell A, Lagerkranser M, Ljungqvist O. Randomized clinical trial of the effects of oral preoperative carbohydrates on postoperative nausea and vomiting after laparoscopic cholecystectomy. British Journal of Surgery. 2005; 92(4):415-21
- 43. Helminen H, Branders H, Ohtonen P, Saarnio J. Effect of pre-operative oral carbohydrate loading on recovery after day-case cholecystectomy: A randomised controlled trial. European Journal of Anaesthesiology. 2019; 36(8):605-611
- 44. Helminen H, Viitanen H, Sajanti J. Effect of preoperative intravenous carbohydrate loading on preoperative discomfort in elective surgery patients. European Journal of Anaesthesiology. 2009; 26(2):123-7
- 45. Henriksen MG, Hessov I, Dela F, Hansen HV, Haraldsted V, Rodt SA. Effects of preoperative oral carbohydrates and peptides on postoperative endocrine response, mobilization, nutrition and muscle function in abdominal surgery. Acta Anaesthesiologica Scandinavica. 2003; 47(2):191-9
- 46. Hosny H, Ibrahim M, El-Siory W, Abdel-Monem A. Comparative study between conventional fasting versus overnight infusion of lipid or carbohydrate on insulin and free fatty acids in obese patients undergoing elective on-pump coronary artery bypass grafting: a prospective randomized trial. Journal of Cardiothoracic and Vascular Anesthesia. 2018; 32(3):1248-1253
- 47. Hutchinson A, Maltby JR, Reid CR. Gastric fluid volume and pH in elective inpatients. Part I: Coffee or orange juice versus overnight fast. Canadian Journal of Anaesthesia. 1988; 35(1):12-5
- 48. Itou K, Fukuyama T, Sasabuchi Y, Yasuda H, Suzuki N, Hinenoya H et al. Safety and efficacy of oral rehydration therapy until 2 h before surgery: a multicenter randomized controlled trial. Journal of Anesthesia. 2012; 26(1):20-7
- 49. Jones C, Badger SA, Hannon R. The role of carbohydrate drinks in pre-operative nutrition for elective colorectal surgery. Annals of the Royal College of Surgeons of England. 2011; 93(7):504-7
- 50. Karlsson A, Wendel K, Polits S, Gislason H, Hedenbro JL. Preoperative nutrition and postoperative discomfort in an ERAS setting: A randomized study in gastric bypass surgery. Obesity Surgery. 2016; 26(4):743-8
- 51. Kaska M, Grosmanová T, Havel E, Hyspler R. Preparation of patients for operation with per-oral intake on the day of the planned surgery. Rozhledy v Chirurgii. 2006; 85(11):554-559
- 52. Kaska M, Grosmanova T, Havel E, Hyspler R, Petrova Z, Brtko M et al. The impact and safety of preoperative oral or intravenous carbohydrate administration versus fasting in colorectal surgery--a randomized controlled trial. Wiener Klinische Wochenschrift. 2010; 122(1-2):23-30
- 53. Kwon SA, Lee KC, Song YK, Kim TY, Yun JS. Effects of preoperative oral water intake on gastric content and emotional state of patients. Korean Journal of Anesthesiology. 1994; 27(3):220-226
- 54. Lagerkranser M, Nygren J, Almström C, Thorell, Hellström. Oral intake of a carbohydrate rich beverage preoperatively improves safety and well-being. Anesthesiology. 1997; 87(3A):A952

- 55. Lam KK, So HY, Gin T. Gastric pH and volume after oral fluids in the postpartum patient. Canadian Journal of Anaesthesia. 1993; 40(3):218-21
- 56. Lambert E, Carey S. Practice guideline recommendations on perioperative fasting: A systematic review. Journal of Parenteral & Enteral Nutrition. 2016; 40(8):1158-1165
- 57. Lauwick SM, Kaba A, Maweja S, Hamoir EE, Joris JL. Effects of oral preoperative carbohydrate on early postoperative outcome after thyroidectomy. Acta Anaesthesiologica Belgica. 2009; 60(2):67-73
- 58. Lee JS, Song Y, Kim JY, Park JS, Yoon DS. Effects of preoperative oral carbohydrates on quality of recovery in laparoscopic cholecystectomy: A randomized, double blind, placebo-controlled trial. World Journal of Surgery. 2018; 18:18
- Li L, Wang Z, Ying X, Tian J, Sun T, Yi K et al. Preoperative carbohydrate loading for elective surgery: a systematic review and meta-analysis. Surgery Today. 2012; 42(7):613-24
- 60. Li XX, Li YJ, Liu YH, Liu XY. A meta-analysis of preoperative fasting times in elective surgical patients. World Chinese Journal of Digestology. 2015; 23(3):515-520
- 61. Lidder P, Thomas S, Fleming S, Hosie K, Shaw S, Lewis S. A randomized placebo controlled trial of preoperative carbohydrate drinks and early postoperative nutritional supplement drinks in colorectal surgery. Colorectal Disease. 2013; 15(6):737-45
- 62. Liu B, Wang Y, Liu S, Zhao T, Zhao B, Jiang X et al. A randomized controlled study of preoperative oral carbohydrate loading versus fasting in patients undergoing elective craniotomy. Clinical Nutrition. 2018; Epublication
- 63. Ljunggren S, Hahn RG, Nystrom T. Insulin sensitivity and beta-cell function after carbohydrate oral loading in hip replacement surgery: a double-blind, randomised controlled clinical trial. Clinical Nutrition. 2014; 33(3):392-8
- Ljungqvist O, Nygren J, Thorell A. Preoperative carbohydrates instead of overnight fasting reduces hospital stay following elective surgery. Clinical Nutrition. 1998; 17 (Suppl 1):3
- Ljungqvist O, Nygren J, Thorell A, Brodin U, Efendic S. Preoperative nutrition -Elective surgery in the fed or the overnight fasted state. Clinical Nutrition. 2001; 20(Suppl 1):167-171
- Ludwig RB, Paludo J, Fernandes D, Scherer F. Lesser time of preoperative fasting and early postoperative feeding are safe? Arquivos Brasileiros de Cirurgia Digestiva. 2013; 26(1):54-8
- 67. Maltby JR. Fasting from midnight--the history behind the dogma. Best Practice & Research Clinical Anaesthesiology. 2006; 20(3):363-78
- Maltby JR, Sutherland AD, Sale JP, Shaffer EA. Preoperative oral fluids: is a fivehour fast justified prior to elective surgery? Anesthesia and Analgesia. 1986; 65(11):1112-6
- Manchikanti L, Malla Y, Wargo BW, Fellows B. Preoperative fasting before interventional techniques: is it necessary or evidence-based? Pain Physician. 2011; 14(5):459-67
- Mathur S, Plank LD, McCall JL, Shapkov P, McIlroy K, Gillanders LK et al. Randomized controlled trial of preoperative oral carbohydrate treatment in major abdominal surgery. British Journal of Surgery. 2010; 97(4):485-94

- 71. McKenna G, Manton S. Pre-operative fasting for intravenous conscious sedation used in dental treatment: are conclusions based on relative risk management or evidence? British Dental Journal. 2008; 205(4):173-6
- 72. Meisner M, Ernhofer U, Schmidt J. Liberalisation of preoperative fasting guidelines: effects on patient comfort and clinical practicability during elective laparoscopic surgery of the lower abdomen. Zentralblatt für Chirurgie. 2008; 133(5):479-485
- 73. Melis GC, van Leeuwen PA, von Blomberg-van der Flier BM, Goedhart-Hiddinga AC, Uitdehaag BM, Strack van Schijndel RJ et al. A carbohydrate-rich beverage prior to surgery prevents surgery-induced immunodepression: a randomized, controlled, clinical trial. Journal of Parenteral & Enteral Nutrition. 2006; 30(1):21-6
- 74. Miller M, Wishart HY, Nimmo WS. Gastric contents at induction of anaesthesia. Is a 4-hour fast necessary? British Journal of Anaesthesia. 1983; 55(12):1185-8
- 75. Morimoto Y, Kinugawa T, Hayashi M, Iida T, Yamamoto T. Effects of preoperative oral carbohydrate intake on catabolism, nutrition and adipocytokines during minor surgery: A randomized, prospective, controlled clinical phase II trial. PloS One. 2019; 14(5):e0216525
- 76. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual, updated 2018. London. National Institute for Health and Care Excellence, 2014. Available from: https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview
- 77. NHS Supply Chain Catalogue. NHS Supply Chain, 2018. Available from: https://my.supplychain.nhs.uk/catalogue
- Noba L, Wakefield A. Are carbohydrate drinks more effective than preoperative fasting: A systematic review of randomised controlled trials. Journal of Clinical Nursing. 2019; 28(17-18):3096-3116
- 79. Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Preoperative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. Colorectal Disease. 2006; 8(7):563-9
- Nygren J, Soop M, Thorell A, Sree Nair K, Ljungqvist O. Preoperative oral carbohydrates and postoperative insulin resistance. Clinical Nutrition. 1999; 18(2):117-20
- 81. Nygren J, Thorell A, Lagerkranser M, Almstrom C, Hammarqvist F, Ljungqvist O. Safety and patient well-being after preoperative oral intake of carbohydrate rich beverage. Clinical Nutrition. 1996; 15 (Suppl 1):30
- 82. Nygren J, Thorell A, Ljungqvist O. Are there any benefits from minimizing fasting and optimization of nutrition and fluid management for patients undergoing day surgery? Current Opinion in Anaesthesiology. 2007; 20(6):540-544
- 83. Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate therapy. Current Opinion in Anaesthesiology. 2015; 28(3):364-9
- 84. Onalan E, Andsoy II, Ersoy OF. The effect of preoperative oral carbohydrate administration on insulin resistance and comfort level in patients undergoing surgery. Journal of Perianesthesia Nursing. 2018; 34(3):539-550
- 85. Orbey BC, Alanoglu Z, Yilmaz AA, Erkek B, Ates Y, Ayhan Kuzu M. Do we still need to restrict preoperative fluid administration in ambulatory anorectal surgery under spinal anaesthesia? Techniques in Coloproctology. 2009; 13(1):35-40

- 86. Ozdemir F, Eti Z, Dincer P, Yilmaz Gogus F, Bekiroglu N. The effect of preoperative oral carbohydrate loading on stress response in patients undergoing major or minor surgery. Turkiye Klinikleri Journal of Medical Sciences. 2011; 31(6):1392-1400
- 87. Ozkan T, Senturk M, Yavru A, Celebi S, Pembeci K. Does preoperative fluid fasting have a benefit on aspiration prophylaxis in obstetric anaesthesia. Turkish Journal of Anaesthesiology and Reanimation. 2000; 28(8):425-429
- 88. Perrone F, da-Silva-Filho AC, Adorno IF, Anabuki NT, Leal FS, Colombo T et al. Effects of preoperative feeding with a whey protein plus carbohydrate drink on the acute phase response and insulin resistance. A randomized trial. Nutrition Journal. 2011; 10:66
- 89. Pexe-Machado PA, de Oliveira BD, Dock-Nascimento DB, de Aguilar-Nascimento JE. Shrinking preoperative fast time with maltodextrin and protein hydrolysate in gastrointestinal resections due to cancer. Nutrition. 2013; 29(7-8):1054-9
- 90. Pimenta GP, De Aguilar-Nascimento JE. Prolonged preoperative fasting in elective surgical patients: Why should we reduce it? Nutrition in Clinical Practice. 2014; 29(1):22-28
- 91. Popovic M, Schlenker MB, Goldshtein D, Rai A, El-Defrawy S. Preoperative fasting for ambulatory cataract surgery: a systematic review. Canadian Journal of Ophthalmology. 2019; 54(2):145-149
- 92. Pousman RM, Pepper C, Pandharipande P, Ayers GD, Mills B, Diaz J et al. Feasibility of implementing a reduced fasting protocol for critically ill trauma patients undergoing operative and nonoperative procedures. Journal of Parenteral & Enteral Nutrition. 2009; 33(2):176-80
- 93. Power S, Kavanagh DO, McConnell G, Cronin K, Corish C, Leonard M et al. Reducing preoperative fasting in elective adult surgical patients: a case-control study. Irish Journal of Medical Science. 2012; 181(1):99-104
- 94. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011; 114(3):495-511
- 95. Pu XL. Effect of preoperative carbohydrate supplementation on insulin resistance in patients after scar ectomy. Journal of Anatomy Operating Surgery. 2005; 14:368-70
- 96. Raksakietisak M, Chinachoti T, Iamaroon A, Thabpenthai Y, Halilamien P, Siriratwarangkul S et al. Oral rehydration with 10% carbohydrate drink for preventing postoperative nausea and vomiting (PONV) after low dose of spinal morphine. Journal of the Medical Association of Thailand. 2014; 97(5):530-535
- 97. Read MS, Vaughan RS. Allowing pre-operative patients to drink: effects on patients' safety and comfort of unlimited oral water until 2 hours before anaesthesia. Acta Anaesthesiologica Scandinavica. 1991; 35(7):591-5
- Sada F, Krasniqi A, Hamza A, Gecaj-Gashi A, Bicaj B, Kavaja F. A randomized trial of preoperative oral carbohydrates in abdominal surgery. BMC Anesthesiology. 2014; 14:93
- 99. Savluk OF, Kuscu MA, Guzelmeric F, Gurcu ME, Erkilinc A, Cevirme D et al. Do preoperative oral carbohydrates improve postoperative outcomesin patients undergoing coronary artery bypass grafts? Turkish Journal of Medical Sciences. 2017; 47(6):1681-1686

- Singh M, Chaudhary M, Vashistha A, Kaur G. Evaluation of effects of a preoperative 2-hour fast with glutamine and carbohydrate rich drink on insulin resistance in maxillofacial surgery. Journal of Oral Biology & Craniofacial Research. 2015; 5(1):34-39
- 101. Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Soreide E et al. Perioperative fasting in adults and children: Guidelines from the European society of anaesthesiology. Romanian Journal of Anaesthesia and Intensive Care. 2012; 19(1):65-88
- 102. Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD009161. DOI: 10.1002/14651858.CD009161.pub2.
- 103. Soop M, Myrenfors P, Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate intake attenuates metabolic changes immediately after hip replacement. Clinical Nutrition. 1998; 17(Suppl I):3-4
- 104. Soreide E, Hausken T, Soreide JA, Steen PA. Gastric emptying of a light hospital breakfast A study using real time ultrasonography. Acta Anaesthesiologica Scandinavica. 1996; 40(5):549-553
- 105. Tran S, Wolever TM, Errett LE, Ahn H, Mazer CD, Keith M. Preoperative carbohydrate loading in patients undergoing coronary artery bypass or spinal surgery. Anesthesia and Analgesia. 2013; 117(2):305-13
- 106. van Ginhoven TM, Dik WA, Mitchell JR, Smits-te Nijenhuis MA, van Holten-Neelen C, Hooijkaas H et al. Dietary restriction modifies certain aspects of the postoperative acute phase response. Journal of Surgical Research. 2011; 171(2):582-9
- 107. Wang ZG, Wang Q, Wang WJ, Qin HL. Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after colorectal surgery. British Journal of Surgery. 2010; 97(3):317-27
- Xu D, Zhu X, Xu Y, Zhang L. Shortened preoperative fasting for prevention of complications associated with laparoscopic cholecystectomy: a meta-analysis. Journal of International Medical Research. 2017; 45(1):22-37
- 109. Yagci G, Can MF, Ozturk E, Dag B, Ozgurtas T, Cosar A et al. Effects of preoperative carbohydrate loading on glucose metabolism and gastric contents in patients undergoing moderate surgery: a randomized, controlled trial. Nutrition. 2008; 24(3):212-6
- 110. Yagmurdur H, Gunal S, Yildiz H, Gulec H, Topkaya C. The effects of carbohydraterich drink on perioperative discomfort, insulin response and arterial pressure in spinal aesthesia. Journal of Research in Medical Sciences. 2011; 16(11):1483-1489
- 111. Yildiz H, Gunal SE, Yilmaz G, Yucel S. Oral carbohydrate supplementation reduces preoperative discomfort in laparoscopic cholecystectomy. Journal of Investigative Surgery. 2013; 26(2):89-95
- 112. Yilmaz N, Cekmen N, Bilgin F, Erten E, Ozhan MO, Cosar A. Preoperative carbohydrate nutrition reduces postoperative nausea and vomiting compared to preoperative fasting. Journal of Research in Medical Sciences. 2013; 18(10):827-832
- 113. Yuill KA, Richardson RA, Davidson HI, Garden OJ, Parks RW. The administration of an oral carbohydrate-containing fluid prior to major elective upper-gastrointestinal surgery preserves skeletal muscle mass postoperatively--a randomised clinical trial. Clinical Nutrition. 2005; 24(1):32-7

- 114. Zhan C, Dai X, Shen G, Lu X, Wang X, Lu L et al. Preoperative short-term fasting protects liver injury in patients undergoing hepatectomy. Annals of Translational Medicine. 2018; 6(23):449
- 115. Zhang Y, Min J. Preoperative carbohydrate loading in gynecological patients undergoing combined spinal and epidural anesthesia. Journal of Investigative Surgery. 2019; Epublication

# Appendices

# Appendix A: Review protocols

### Table 9: Review protocol: Preoperative fasting strategy

| ID | Field                             | Content  |
|----|-----------------------------------|--|
| 0. | PROSPERO registration number      | Not registered on PROSPERO   |
| 1. | Review title                      | What is the most clinically and cost effective preoperative fasting strategy for adults?   |
| 2. | Review question                   | What is the most clinically and cost effective preoperative fasting strategy for adults?   |
| 3. | Objective                         | To determine the most clinically and cost effective preoperative fasting strategy.   |
| 4. | Searches                          | <ul> <li>Cochrane Central Register of Controlled<br/>Trials (CENTRAL)</li> </ul>   |
|    |                                   | Cochrane Database of Systematic Reviews     (CDSR)   |
|    |                                   | • Embase   |
|    |                                   | MEDLINE  |
|    |                                   | Epistemonikos  |
|    |                                   | The searches may be re-run 6 weeks before<br>the final committee meeting and further studies<br>retrieved for inclusion if relevant.   |
|    |                                   | The full search strategies will be published in the final review.  |
| 5. | Condition or domain being studied | Perioperative care   |
| 6. | Population                        | Inclusion: Adults 18 years and over having surgery.  |
|    |                                   | Exclusion:   |
|    |                                   | <ul> <li>children and young people aged 17<br/>years and younger</li> </ul>  |
|    |                                   | <ul> <li>surgery for burns, traumatic brain injury<br/>or neurosurgery</li> <li>cardiac surgery</li> <li>parenteral feeding</li> <li>emergency surgery</li> <li>pregnant women</li> <li>gastroparesis</li> </ul> |
| 7. | Intervention/Exposure/Test        | <ul> <li>no food for &lt;4 hours</li> <li>no food for 4-6 hours</li> <li>no food for &gt;6 hours</li> <li>no fluids for &lt;2 hours</li> </ul>   |

© NICE 2020. All rights reserved. Subject to Notice of rights.

|     |  | <ul> <li>no fluids for 2-4 hours</li> <li>no fluids for 4-6 hours</li> <li>no fluids for &gt;6 hours</li> <li>maintaining clear fluids (non-milk, non-particulate drinks) before surgery</li> <li>combinations of food and fluid restriction strategies</li> </ul>  |
|-----|--|---|
| 8.  | Comparator/Reference<br>standard/Confounding factors | each other  |
| 9.  | Types of study to be included                        | Randomised controlled trials (RCTs), systematic reviews of RCTs.  |
|     |  | Observational studies if no RCT evidence is<br>identified.  |
| 10. | Other exclusion criteria                             | <ul><li>Exclusions:</li><li>non-English language studies</li><li>studies published before 2000</li></ul>  |
| 11. | Context  | An extended fasting period can be unpleasant<br>for the person undergoing surgery. This review<br>aims to determine the most clinically and cost<br>effective fasting strategy.   |
| 12. | Primary outcomes (critical<br>outcomes)              | <ul> <li>health-related quality of life</li> <li>mortality</li> <li>patient, family and carer experience of care</li> <li>adverse events and complications (Clavien-<br/>Dindo, postoperative morbidity score<br/>(POMS), aspiration – pulmonary<br/>complications, acute kidney injury)</li> <li>The committee did not agree to on any<br/>established minimal clinically important<br/>differences, therefore the default MIDs will be<br/>used and any difference in mortality will be<br/>considered clinically important.</li> </ul> |
| 13. | Secondary outcomes (important<br>outcomes)           | <ul> <li>length of hospital stay</li> <li>unplanned ICU admission</li> <li>thirst</li> <li>headache</li> <li>cancellation of surgery</li> <li>The committee did not agree to on any<br/>established minimal clinically important<br/>differences, therefore the default MIDs will be<br/>used and any difference in mortality will be<br/>considered clinically important.</li> </ul>   |
| 14. | Data extraction (selection and coding)               | EndNote will be used for reference<br>management, sifting, citations and<br>bibliographies. All references identified by the<br>searches and from other sources will be<br>screened for inclusion. 10% of the abstracts will<br>be reviewed by two reviewers, with any<br>disagreements resolved by discussion or, if<br>necessary, a third independent reviewer. The<br>full text of potentially eligible studies will be  |

 $\ensuremath{\textcircled{\sc online \sc on$ 

|     |                                   | retrieved and will be assessed in line with the criteria outlined above.   |
|-----|-----------------------------------|--|
|     |                                   | Data extractions performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)  |
| 15. | Risk of bias (quality) assessment | Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.  |
|     |                                   | <ul> <li>Systematic reviews: Risk of Bias in<br/>Systematic Reviews (ROBIS)</li> </ul>   |
|     |                                   | <ul> <li>Randomised Controlled Trial: Cochrane RoB<br/>(2.0)</li> </ul>  |
|     |                                   | <ul> <li>Non randomised study, including cohort<br/>studies: Cochrane ROBINS-I</li> </ul>  |
|     |                                   | <ul> <li>Case control study: CASP case control<br/>checklist</li> </ul>  |
|     |                                   | <ul> <li>Controlled before-and-after study or<br/>Interrupted time series: Effective Practice and<br/>Organisation of Care (EPOC) RoB Tool</li> </ul>  |
|     |                                   | <ul> <li>Cross sectional study: JBI checklist for cross<br/>sectional study</li> </ul>   |
|     |                                   | <ul> <li>Case series: Institute of Health Economics<br/>(IHE) checklist for case series</li> </ul>   |
|     |                                   | 10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:   |
|     |                                   | • papers were included /excluded appropriately   |
|     |                                   | <ul> <li>a sample of the data extractions</li> </ul>   |
|     |                                   | <ul> <li>correct methods are used to synthesise data</li> </ul>  |
|     |                                   | <ul> <li>a sample of the risk of bias assessments</li> </ul>   |
|     |                                   | Disagreements between the review authors<br>over the risk of bias in particular studies will be<br>resolved by discussion, with involvement of a<br>third review author where necessary.   |
| 16. | Strategy for data synthesis       | Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).  |
|     |                                   | GRADEpro will be used to assess the quality of<br>evidence for each outcome, taking into account<br>individual study quality and the meta-analysis<br>results. The 4 main quality elements (risk of<br>bias, indirectness, inconsistency and<br>imprecision) will be appraised for each<br>outcome. Publication bias is tested for when<br>there are more than 5 studies for an outcome. |
|     |                                   | The risk of bias across all available evidence<br>was evaluated for each outcome using an<br>adaptation of the 'Grading of<br>Recommendations Assessment, Development<br>and Evaluation (GRADE) toolbox' developed by<br>the international GRADE working group   |

© NICE 2020. All rights reserved. Subject to Notice of rights.

| Image: Section 2.1       Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.         • CERQual will be used to synthesise data from qualitative studies.       • WinBUGS will be used for network meta-analysis, if possible given the data identified.         • List any other software planned to be used.       • Heterogeneity between the studies in effect measures will be assessed using the P statistic and visually inspected. An P value greater than 50% will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups         17.       Analysis of sub-groups       Subgroups:         18.       Type and method of review       Intervention         □       Diagnostic   |     |                                  | http://www  | .gradewor  | kinggroup.o  | <u>rg/</u>   |
|--|-----|----------------------------------|---|--|--|--|
| qualitative studies.       • WinBUGS will be used for network meta-<br>analysis, if possible given the data identified.         • List any other software planned to be used.         Heterogeneity between the studies in effect<br>measures will be assessed using the P statistic<br>and visually inspected. An P value greater than<br>50% will be considered indicative of substantial<br>beterogeneity. Sensitivity analyses will be<br>conducted based on pre-specified subgroups<br>using stratified meta-analysis to explore the<br>heterogeneity in effect estimates. If this does<br>not explain the heterogeneity, the results will be<br>presented pooled using random-effects.         17.       Analysis of sub-groups       • Older adults (over 60 years)<br>• people with diabetes         18.       Type and method of review       Intervention         Image:       Prognostic         Qualitative       Diagnostic         Image:       English         20.       Country         19.       Language         21.       Anticipated or actual start date         22.       Anticipated completion date         23.       Stage of review at time of this<br>submission         Proling of the study<br>selection process       Image         Proling of the study<br>selection process       Image         Piloting of the study<br>selection process       Image   |     |                                  | be prese  | nted and o   | quality asse   |  |
| analysis, if possible given the data identified.         • List any other software planned to be used.         Heterogeneity between the studies in effect<br>measures will be assessed using the P statistic<br>and visually inspected. An P value greater than<br>50% will be considered indicative of substantial<br>heterogeneity. Sensitivity analyses will be<br>conducted based on pre-specified subgroups<br>using stratified meta-analysis to explore the<br>heterogeneity in effect estimates. If this does<br>not explain the heterogeneity, the results will be<br>presented pooled using random-effects.         17.       Analysis of sub-groups       Subgroups:         • Older adults (over 60 years)       • people with diabetes         18.       Type and method of review       Intervention         Image:       Output         19.       Language       English         20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this<br>submission       Review stage       Started       Completed         Preliminary<br>searchees       Formal screening<br>of search results<br>against eligibility<br>criteria       Image       Image  |     |                                  |   |  |  | esise data from  |
| Heterogeneity between the studies in effect measures will be assessed using the l² statistic and visually inspected. An l² value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.         17.       Analysis of sub-groups       Subgroups:       • older adults (over 60 years)         • people with diabetes       • people with diabetes         18.       Type and method of review       Intervention         □       Diagnostic         □       Prognostic         □       Qualitative         □       Beidemiologic         □       Service Delivery         □       Other (please specify)         19.       Language       English         20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Pioling of the study   |     |                                  |   |  |  |  |
| measures will be assessed using the P statistic and visually inspected. An P value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.         17.       Analysis of sub-groups       Subgroups: <ul> <li>older adults (over 60 years)</li> <li>people with diabetes</li> </ul> 18.       Type and method of review       Intervention         Image:       Prognostic         Image:       Prognostic         Image:       Qualitative         Image:       English         20.       Country         19.       Language         21.       Anticipated or actual start date         22.       Anticipated completion date         23.       Stage of review at time of this submission         Preliminary searches       Pioling of the study selection process         Pioling of the study selection process       Pioling of the study selection process   |     |                                  | List any  | other softv  | vare planne  | d to be used.  |
| 17.       Analysis of sub-groups       Subgroups:<br>• older adults (over 60 years)<br>• people with diabetes         18.       Type and method of review       Intervention         □       Diagnostic         □       Prognostic         □       Qualitative         □       Epidemiologic         □       Service Delivery         □       Other (please specify)         19.       Language         21.       Anticipated or actual start date         [To be added.]         22.       Anticipated completion date         [To be added.]         23.       Stage of review at time of this submission         Preliminary searches       Image searches         Piloting of the study selection process         Formal screening of search results against eligibility criteria  |     |                                  | measures<br>and visuall<br>50% will be<br>heterogene<br>conducted<br>using strat<br>heterogene<br>not explain | will be ass<br>y inspecte<br>e consider<br>eity. Sensi<br>based on<br>ified meta-<br>eity in effe<br>the heter | eessed using<br>ed. An I <sup>2</sup> valu<br>ed indicative<br>tivity analys<br>pre-specifie<br>-analysis to<br>ct estimates<br>ogeneity, th | g the l <sup>2</sup> statistic<br>ue greater than<br>e of substantial<br>es will be<br>ed subgroups<br>explore the<br>s. If this does<br>e results will be |
| ● people with diabetes         18.       Type and method of review         □       Diagnostic         □       Diagnostic         □       Prognostic         □       Qualitative         □       Epidemiologic         □       Service Delivery         □       Other (please specify)         19.       Language         21.       Anticipated or actual start date         [To be added.]         22.       Anticipated completion date         [To be added.]         23.       Stage of review at time of this submission         Preliminary searches       □         Piloting of the study selection process         Formal screening of search results against eligibility criteria  | 17. | Analysis of sub-groups           |   |  | 0  |  |
| 18.       Type and method of review       ⊠       Intervention         □       Diagnostic         □       Prognostic         □       Qualitative         □       Epidemiologic         □       Service Delivery         □       Other (please specify)         19.       Language         20.       Country         English       Other (please specify)         19.       Anticipated or actual start date         [To be added.]       [To be added.]         22.       Anticipated completion date         [To be added.]       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       □       □       □       □       □         Piloting of the study selection process       □       □       □       □         Formal screening of search results against eligibility criteria       □       □       □   |     |                                  |   | •  | • •  |  |
| Image       Intervention         Image       Diagnostic         Image       Prognostic         Image       Qualitative         Image       Epidemiologic         Image       Service Delivery         Image       Country         Image       English         20.       Country         England       Image         Image       England         Image       Image         Image       Image         Image       Epidemiologic         Image       Image         Image       Epidemiologic         Image </td <td>10</td> <td>Tupo and mathed of roviou</td> <td></td> <td></td> <td></td> <td></td>  | 10  | Tupo and mathed of roviou        |   |  |  |  |
| Image: Prognostic         Image: Prognostic <t< td=""><td>10.</td><td>Type and method of review</td><td></td><td>Intervent</td><td>tion</td><td></td></t<>   | 10. | Type and method of review        |   | Intervent  | tion   |  |
| Qualitative         Qualitative         Epidemiologic         Service Delivery         Other (please specify)         19.       Language         English         20.       Country         England         21.       Anticipated or actual start date         [To be added.]         22.       Anticipated completion date         [To be added.]         23.       Stage of review at time of this submission         Preliminary searches       Image of the study selection process         Piloting of the study selection process       Image of search results against eligibility criteria  |     |                                  |   | Diagnos  | tic  |  |
| Image       Image       English         20.       Country       English         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Piloting of the study selection process       Image       Image       Image         Formal screening of search results against eligibility criteria       Image       Image       Image       Image  |     |                                  |   | Prognos  | tic  |  |
| Image: Service Delivery  |     |                                  |   | Qualitati  | ve   |  |
| 19.       Language       English         20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Preliminary searches       Image: Completed searches       Image: Completed searches       Image: Completed searches         Formal screening of search results against eligibility criteria       Image: Completed searches       Image: Completed searches  |     |                                  |   | Epidemi  | ologic   |  |
| 19.       Language       English         20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Image: Searches       Image: Searches       Image: Searches       Image: Searches         Formal screening of search results against eligibility criteria       Image: Searches       Image: Searches       Image: Searches   |     |                                  |   | Service  | Delivery   |  |
| 20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Piloting of the study selection process       Image: Completed search results against eligibility criteria       Image: Completed search results against eligibility criteria  |     |                                  |   | Other (p   | lease specif   | y)   |
| 20.       Country       England         21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Image: Searches       Image: Searches       Image: Searches       Image: Searches         Piloting of the study selection process       Image: Search results against eligibility criteria       Image: Search results against eligibility criteria       Image: Searches  | 19. | Language                         | English   |  |  |  |
| 21.       Anticipated or actual start date       [To be added.]         22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Image: Started start   | 20. | Country                          |   |  |  |  |
| 22.       Anticipated completion date       [To be added.]         23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Image: Started s   | 21. | Anticipated or actual start date |   | ed.]   |  |  |
| 23.       Stage of review at time of this submission       Review stage       Started       Completed         Preliminary searches       Image: Started searches       Image: Started searches       Image: Started searches         Piloting of the study selection process       Image: Started search results against eligibility criteria       Image: Started search results against eligibility criteria   | 22. | Anticipated completion date      | -   | -  |  |  |
| Preliminary<br>searches       Image: Comparison of the study<br>selection process       Image: Comparison of the study<br>selection process         Formal screening<br>of search results<br>against eligibility<br>criteria       Image: Comparison of the study<br>mage: Comparison of the stud   | 23. |                                  |   | -  | Started  | Completed  |
| selection process       Image: Constraint of the second seco |     | sudinission                      |   | /  |  |  |
| of search results<br>against eligibility<br>criteria   |     |                                  |   |  |  |  |
| Data extraction  |     |                                  | of search r<br>against elig   | esults   |  |  |
|  |     |                                  | Data extra  | ction  |  |  |

|     |                         | Risk of bias<br>(quality)<br>assessment   |  |  |
|-----|-------------------------|---|--|--|
|     |                         | Data analysis   |  |  |
| 24. | Named contact           | 5a. Named contact   |  |  |
|     |                         | National Guideline C  | entre  |  |
|     |                         | 5b Named contact e-<br>perioperativecare@n  |  |  |
|     |                         | F F   |  |  |
|     |                         | 5e Organisational aff   | iliation of the  | e review   |
|     |                         | National Institute for<br>Excellence (NICE) ar<br>Centre  |  |  |
| 25. | Review team members     | From the National G   | uideline Cer   | ntre:  |
|     |                         | Ms Kate Ashmore   |  |  |
|     |                         | Ms Kate Kelley  |  |  |
|     |                         | Ms Sharon Swain   |  |  |
|     |                         | Mr Ben Mayer  |  |  |
|     |                         | Ms Maria Smyth  |  |  |
|     |                         | Mr Vimal Bedia  |  |  |
|     |                         | Mr Audrius Stonkus  |  |  |
|     |                         | Ms Madelaine Zucke  | r  |  |
|     |                         | Ms Margaret Consta  | nti  |  |
|     |                         | Ms Annabelle Davis  |  |  |
|     |                         | Ms Lina Gulhane   |  |  |
| 26. | Funding sources/sponsor | This systematic revie<br>the National Guidelin<br>funding from NICE.  |  |  |
| 27. | Conflicts of interest   | All guideline committ<br>who has direct input<br>(including the eviden<br>witnesses) must decl<br>of interest in line with<br>for declaring and dea<br>interest. Any relevant<br>interests, will also be<br>start of each guidelin<br>Before each meeting<br>interest will be consid<br>committee Chair and<br>development team. A<br>person from all or pa<br>documented. Any cha<br>declaration of interess<br>minutes of the meeting | into NICE g<br>ce review te<br>are any pote<br>NICE's coord<br>along with co<br>t interests, co<br>declared put<br>e committee<br>, any potent<br>dered by the<br>a senior me<br>any decision<br>rt of a meeti<br>anges to a r<br>ts will be re- | uidelines<br>am and expert<br>ential conflicts<br>de of practice<br>nflicts of<br>or changes to<br>ublicly at the<br>e meeting.<br>tial conflicts of<br>e guideline<br>ember of the<br>is to exclude a<br>ing will be<br>nember's<br>corded in the |

|     |  | interests v<br>guideline.  | vill be published with the final  |
|-----|--|--|---|
| 28. | Collaborators  | Development of this systematic review will be<br>overseen by an advisory committee who will<br>use the review to inform the development of<br>evidence-based recommendations in line with<br>section 3 of <u>Developing NICE guidelines: the</u><br><u>manual</u> . Members of the guideline committee<br>are available on the NICE website. |   |
| 29. | Other registration details                               | n/a  |   |
| 30. | Reference/URL for published<br>protocol                  | n/a  |   |
| 31. | Dissemination plans                                      | raise awai   | v use a range of different methods to<br>reness of the guideline. These include<br>approaches such as:  |
|     |  | <ul> <li>notifying<br/>publication</li> </ul>  | registered stakeholders of<br>ion   |
|     |  |  | ng the guideline through NICE's<br>ter and alerts   |
|     |  | appropri   | a press release or briefing as<br>iate, posting news articles on the<br>ebsite, using social media channels,<br>licising the guideline within NICE. |
| 32. | Keywords   | Periopera  | tive care, preoperative, fasting  |
| 33. | Details of existing review of same topic by same authors | n/a  |   |
| 34. | Current review status                                    |  | Ongoing   |
|     |  |  | Completed but not published   |
|     |  |  | Completed and published   |
|     |  |  | Completed, published and being updated  |
|     |  |  | Discontinued  |
| 35  | Additional information                                   | n/a  |   |
| 36. | Details of final publication                             | www.nice.  | .org.uk   |

|                    | alth economic review protocol   |
|--------------------|---|
| Review question    | All questions – health economic evidence  |
| Objectives         | To identify health economic studies relevant to any of the review questions.  |
| Search<br>criteria | <ul> <li>Populations, interventions and comparators must be as specified in the clinical<br/>review protocol above.</li> </ul>  |
|                    | • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).  |
|                    | • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)   |
|                    | <ul> <li>Unpublished reports will not be considered unless submitted as part of a call for<br/>evidence.</li> <li>Studios must be in English</li> </ul>   |
| <b>a</b> .         | Studies must be in English.   |
| Search<br>strategy | A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.  |
| Review<br>strategy | Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.   |
|                    | Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014). <sup>76</sup>  |
|                    | Inclusion and exclusion criteria  |
|                    | • If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.   |
|                    | • If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.   |
|                    | <ul> <li>If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or<br/>both then there is discretion over whether it should be included.</li> </ul>  |
|                    | Where there is discretion   |
|                    | The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below. |
|                    | The health economist will be guided by the following hierarchies.<br>Setting:   |
|                    | <ul> <li>UK NHS (most applicable).</li> <li>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</li> </ul>  |
|                    | <ul> <li>OECD countries with predominantly private health insurance systems (for example,<br/>Switzerland).</li> </ul>  |

#### Table 10: Health economic review protocol

• Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost-utility analysis (most applicable).
- Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.
   Year of analysis:
- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

• The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline. For example, economic evaluations based on observational studies will be excluded, when the clinical review is only looking for RCTs,

## **Appendix B: Literature search strategies**

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018.<sup>76</sup>

For more detailed information, please see the Methodology Review.

### **B.1** Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

| Database                                    | Dates searched  | Search filter used  |
|---|---|---|
| Medline (OVID)                              | 1946 – 31 May 2019  | Exclusions<br>Randomised controlled trials<br>Systematic review studies |
| Embase (OVID)                               | 1974 – 31 May 2019  | Exclusions<br>Randomised controlled trials<br>Systematic review studies |
| The Cochrane Library (Wiley)                | Cochrane Reviews to 2019<br>Issue 5 of 12<br>CENTRAL to 2019 Issue 5 of<br>12<br>DARE, and NHSEED to 2015<br>Issue 2 of 4<br>HTA to 2016 Issue 4 of 4 | None  |
| Epistemonikos (Epistemonikos<br>Foundation) | Inception - 19 February 2019  | Systematic review studies   |

### Table 11: Database date parameters and filters used

### Medline (Ovid) search terms

| 1.  | exp Preoperative Care/ or Preoperative Period/   |
|-----|--|
| 2.  | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.  |
| 3.  | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.         |
| 4.  | or/1-3   |
| 5.  | limit 4 to English language  |
| 6.  | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) |
| 7.  | 5 not 6  |
| 8.  | letter/  |
| 9.  | editorial/   |
| 10. | news/  |
| 11. | exp historical article/  |
| 12. | Anecdotes as Topic/  |
| 13. | comment/   |
| 14. | case report/   |
| 15. | (letter or comment*).ti.   |

© NICE 2020. All rights reserved. Subject to Notice of rights.

| 16. | or/8-15   |
|-----|---|
| 17. | randomized controlled trial/ or random*.ti,ab.  |
| 18. | 16 not 17   |
| 19. | animals/ not humans/  |
| 20. | exp Animals, Laboratory/  |
| 21. | exp Animal Experimentation/   |
| 22. | exp Models, Animal/   |
| 23. | exp Rodentia/   |
| 24. | (rat or rats or mouse or mice).ti.  |
| 25. | or/18-24  |
| 26. | 7 not 25  |
| 27. | Fasting/ or Food deprivation/   |
| 28. | Water deprivation/  |
| 29. | hunger/ or thirst/  |
| 30. | (meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or<br>eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or<br>thirst*).ti,ab.                       |
| 31. | ((fluid* or oral* or consume or consumption) adj4 (restrict* or limit* or stop* or abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or thirst* or intake or intaking or ingest*)).ti,ab. |
| 32. | ("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO).ti,ab.   |
| 33. | or/27-32  |
| 34. | 26 and 33   |
| 35. | randomized controlled trial.pt.   |
| 36. | controlled clinical trial.pt.   |
| 37. | randomi#ed.ab.  |
| 38. | placebo.ab.   |
| 39. | randomly.ab.  |
| 40. | clinical trials as topic.sh.  |
| 41. | trial.ti.   |
| 42. | or/35-41  |
| 43. | Meta-Analysis/  |
| 44. | Meta-Analysis as Topic/   |
| 45. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.  |
| 46. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.   |
| 47. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.  |
| 48. | (search strategy or search criteria or systematic search or study selection or data extraction).ab.   |
| 49. | (search* adj4 literature).ab.   |
| 50. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.  |
| 51. | cochrane.jw.  |
| 52. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.  |
| 53. | or/43-52  |
| 54. | 34 and (42 or 53)   |

### Embase (Ovid) search terms

| 1.  | *preoperative care/ or *preoperative period/  |
|-----|---|
| 2.  | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.   |
| 3.  | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.  |
| 4.  | or/1-3  |
| 5.  | limit 4 to English language   |
| 6.  | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)  |
| 7.  | 5 not 6   |
| 8.  | letter.pt. or letter/   |
| 9.  | note.pt.  |
| 10. | editorial.pt.   |
| 11. | case report/ or case study/   |
| 12. | (letter or comment*).ti.  |
| 13. | or/8-12   |
| 14. | randomized controlled trial/ or random*.ti,ab.  |
| 15. | 13 not 14   |
| 16. | animal/ not human/  |
| 17. | nonhuman/   |
| 18. | exp Animal Experiment/  |
| 19. | exp Experimental Animal/  |
| 20. | animal model/   |
| 21. | exp Rodent/   |
| 22. | (rat or rats or mouse or mice).ti.  |
| 23. | or/15-22  |
| 24. | 7 not 23  |
| 25. | *diet restriction/ or food deprivation/   |
| 26. | water deprivation/  |
| 27. | *hunger/ or thirst/   |
| 28. | (meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or thirst*).ti,ab.                             |
| 29. | ((fluid* or oral* or consume or consumption) adj4 (restrict* or limit* or stop* or abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or thirst* or intake or intaking or ingest*)).ti,ab. |
| 30. | ("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO).ti,ab.   |
| 31. | or/25-30  |
| 32. | 24 and 31   |
| 33. | random*.ti,ab.  |
| 34. | factorial*.ti,ab.   |
| 35. | (crossover* or cross over*).ti,ab.  |
| 36. | ((doubl* or singl*) adj blind*).ti,ab.  |
| 37. | (assign* or allocat* or volunteer* or placebo*).ti,ab.  |
| 38. | crossover procedure/  |
|     | single blind procedure/   |

© NICE 2020. All rights reserved. Subject to Notice of rights.

| 40. | randomized controlled trial/   |
|-----|--|
| 41. | double blind procedure/  |
| 42. | or/33-41   |
| 43. | systematic review/   |
| 44. | Meta-Analysis/   |
| 45. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.   |
| 46. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.  |
| 47. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.   |
| 48. | (search strategy or search criteria or systematic search or study selection or data extraction).ab.  |
| 49. | (search* adj4 literature).ab.  |
| 50. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 51. | cochrane.jw.   |
| 52. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.   |
| 53. | or/43-52   |
| 54. | 32 and (42 or 53)  |

### Cochrane Library (Wiley) search terms

| #1.  | MeSH descriptor: [Preoperative Care] this term only  |
|------|--|
| #2.  | MeSH descriptor: [Preoperative Period] this term only  |
| #3.  | MeSH descriptor: [Perioperative Nursing] this term only  |
| #4.  | (pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*):ti,ab  |
| #5.  | (before or prior or advance) near/3 (surg* or operat* or anaesthes* or anesthes*):ti,ab  |
| #6.  | (or #1-#5)   |
| #7.  | MeSH descriptor: [Fasting] this term only  |
| #8.  | MeSH descriptor: [Food Deprivation] this term only   |
| #9.  | MeSH descriptor: [Water Deprivation] this term only  |
| #10. | MeSH descriptor: [Hunger] this term only   |
| #11. | MeSH descriptor: [Thirst] this term only   |
| #12. | (meal* or solid or solids or drink* or water or liquid* or milk or beverage* or hydrat* or<br>eat* or ate or food* or feed* or carbohyrate* or fasting or fasted or starv* or hung* or<br>thirst*):ti,ab                               |
| #13. | ((fluid* or oral* or consume or consumption) near/4 (restrict* or limit* or stop* or<br>abstinence or abstain* or deprive* or deprivation or lack* or fast* or starve* or hung* or<br>thirst* or intake or intaking or ingest*)):ti,ab |
| #14. | ("nil by mouth" or "nothing by mouth" or NBM or "nil per os" or "nihil per os" or "nulla per os" or "non per os" or NPO):ti,ab   |
| #15. | (or #7-#14)  |
| #16. | #6 and #15   |

### Epistemonikos (Epistemonikos Foundation) search terms

| 1. | (pre-operative* OR preoperative* OR preop* OR pre-op* OR pre-surg* OR presurg*)      |
|----|--|
|    | AND (fasting OR fasted OR starv* OR hung* OR thirst* OR "nil by mouth" OR "nothing   |
|    | by mouth" OR NBM OR "nil per os" OR "nihil per os" OR "nulla per os" OR "non per os" |
|    | OR NPO) [Filters: protocol=no, classification=systematic-review]                     |

### **B.2 Health Economics literature search strategy**

Health economic evidence was identified by conducting a broad search relating to the perioperative care population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional health economics searches were run on Medline and Embase.

#### Table 12: Database date parameters and filters used

| Database                                    | Dates searched   | Search filter used                     |
|---|--|--|
| Medline                                     | 2014 – 30 May 2019   | Exclusions<br>Health economics studies |
| Embase                                      | 2014 – 30 May 2019   | Exclusions<br>Health economics studies |
| Centre for Research and Dissemination (CRD) | HTA - Inception – 02 May<br>2019<br>NHSEED - Inception to 02 May<br>2019 | None                                   |

#### Medline (Ovid) search terms

| 1.  | exp Preoperative Care/ or exp Perioperative Care/ or exp Perioperative Period/ or exp Perioperative Nursing/  |
|-----|---|
| 2.  | ((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3<br>(care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.   |
| 3.  | ((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab. |
| 4.  | ((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.   |
| 5.  | ((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.   |
| 6.  | 1 or 2 or 3 or 4 or 5   |
| 7.  | (intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-<br>operat* or perioperat* or peri-operat*).ti,ab.   |
| 8.  | ((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.  |
| 9.  | 7 or 8  |
| 10. | postoperative care/ or exp Postoperative Period/ or exp Perioperative nursing/  |
| 11. | (postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab.  |
| 12. | (after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.   |
| 13. | (post adj3 (operat* or anaesthes* or anesthes*)).ti,ab.   |
| 14. | 10 or 11 or 12 or 13  |
| 15. | exp Preoperative Care/ or Preoperative Period/  |
| 16. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.   |
| 17. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.  |
| 18. | 15 or 16 or 17  |
| 19. | 6 or 9 or 14 or 18  |
| 20. | letter/   |
| 21. | editorial/  |

| 22.         23.         24.         25.         26.         27.         22. | news/<br>exp historical article/<br>Anecdotes as Topic/<br>comment/<br>case report/<br>(letter or comment*).ti.    |
|---|--|
| 24.<br>25.<br>26.<br>27.  | Anecdotes as Topic/<br>comment/<br>case report/<br>(letter or comment*).ti.  |
| 25.<br>26.<br>27.   | comment/<br>case report/<br>(letter or comment*).ti.   |
| 26.<br>27.  | case report/<br>(letter or comment*).ti.   |
| 27.   | (letter or comment*).ti.   |
|   |  |
| 10  |  |
| 28.<br>29.  | or/20-27   |
| -   | randomized controlled trial/ or random*.ti,ab.   |
| 30.   | 28 not 29  |
| 31.   | animals/ not humans/   |
| 32.   | exp Animals, Laboratory/   |
| 33.   | exp Animal Experimentation/  |
| 34.   | exp Models, Animal/  |
| 35.   | exp Rodentia/  |
| 36.   | (rat or rats or mouse or mice).ti.   |
| 37.   | or/30-36   |
| 38.   | 19 not 37  |
| 39.   | limit 38 to English language   |
| 40.   | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) |
| 41.   | 39 not 40  |
| 42.   | economics/   |
| 43.   | value of life/   |
| 44.   | exp "costs and cost analysis"/   |
| 45.   | exp Economics, Hospital/   |
| 46.   | exp Economics, medical/  |
| 47.   | Economics, nursing/  |
| 48.   | economics, pharmaceutical/   |
| 49.   | exp "Fees and Charges"/  |
| 50.   | exp budgets/   |
| 51.   | budget*.ti,ab.   |
| 52.   | cost*.ti.  |
| 53.   | (economic* or pharmaco?economic*).ti.  |
| 54.   | (price* or pricing*).ti,ab.  |
| 55.   | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.                   |
| 56.   | (financ* or fee or fees).ti,ab.  |
| 57.   | (value adj2 (money or monetary)).ti,ab.  |
| 58.   | or/42-57   |
| 59.   | 41 and 58  |

### Embase (Ovid) search terms

| 1. | *preoperative period/ or *intraoperative period/ or *postoperative period/ or<br>*perioperative nursing/ or *surgical patient/  |
|----|---|
| 2. | ((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3<br>(care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab.         |
| 3. | ((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or |

|     | monitor* or recover* or medicine)).ti,ab.   |  |
|-----|---|--|
| 4.  | ((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |  |
| 5.  | 1 or 2 or 3 or 4  |  |
| 6.  | peroperative care/ or exp peroperative care/ or exp perioperative nursing/  |  |
| 7.  | (intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-<br>operat* or perioperat* or peri-operat*).ti,ab.                                     |  |
| 8.  | ((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.  |  |
| 9.  | 6 or 7 or 8   |  |
| 10. | postoperative care/ or exp postoperative period/ or perioperative nursing/  |  |
| 11. | (postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab.  |  |
| 12. | (after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.   |  |
| 13. | (post adj3 (operat* or anaesthes* or anesthes*)).ti,ab.   |  |
| 14. | 10 or 11 or 12 or 13  |  |
| 15. | exp preoperative care/ or preoperative period/  |  |
| 16. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab.   |  |
| 17. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab.  |  |
| 18. | 15 or 16 or 17  |  |
| 19. | 5 or 9 or 14 or 18  |  |
| 20. | letter.pt. or letter/   |  |
| 21. | note.pt.  |  |
| 22. | editorial.pt.   |  |
| 23. | case report/ or case study/   |  |
| 24. | (letter or comment*).ti.  |  |
| 25. | or/20-24  |  |
| 26. | randomized controlled trial/ or random*.ti,ab.  |  |
| 27. | 25 not 26   |  |
| 28. | animal/ not human/  |  |
| 29. | nonhuman/   |  |
| 30. | exp Animal Experiment/  |  |
| 31. | exp Experimental Animal/  |  |
| 32. | animal model/   |  |
| 33. | exp Rodent/   |  |
| 34. | (rat or rats or mouse or mice).ti.  |  |
| 35. | or/27-34  |  |
| 36. | 19 not 35   |  |
| 37. | limit 36 to English language  |  |
| 38. | (exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)   |  |
| 39. | 37 not 38   |  |
| 40. | health economics/   |  |
| 41. | exp economic evaluation/  |  |

Perioperative care: FINAL Preoperative fasting strategy

| 42. | exp health care cost/  |
|-----|--|
| 43. | exp fee/   |
| 44. | budget/  |
| 45. | funding/   |
| 46. | budget*.ti,ab.   |
| 47. | cost*.ti.  |
| 48. | (economic* or pharmaco?economic*).ti.  |
| 49. | (price* or pricing*).ti,ab.  |
| 50. | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 51. | (financ* or fee or fees).ti,ab.  |
| 52. | (value adj2 (money or monetary)).ti,ab.  |
| 53. | or/40-52   |
| 54. | 39 and 53  |


### NHS EED and HTA (CRD) search terms

| #1.  | MeSH DESCRIPTOR Preoperative Care EXPLODE ALL TREES  |
|------|--|
| #2.  | MeSH DESCRIPTOR Perioperative Care EXPLODE ALL TREES   |
| #3.  | MeSH DESCRIPTOR Perioperative Period EXPLODE ALL TREES   |
| #4.  | MeSH DESCRIPTOR Perioperative Nursing EXPLODE ALL TREES  |
| #5.  | (((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine))) |
| #6.  | (((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)))   |
| #7.  | (((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3<br>(care* or caring or treat* or nurs* or monitor* or recover* or medicine)))   |
| #8.  | (((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)))   |
| #9.  | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8   |
| #10. | (* IN HTA)   |
| #11. | (* IN NHSEED)  |
| #12. | #9 AND #10   |
| #13. | #9 AND #11   |
| #14. | MeSH DESCRIPTOR Intraoperative Care EXPLODE ALL TREES  |
| #15. | #1 OR #2 OR #3 OR #4 OR #14  |
| #16. | ((intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or per-<br>operat* or perioperat* or peri-operat*))   |
| #17. | (((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)))  |
| #18. | ((postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*))  |
| #19. | ((after adj3 (surg* or operat* or anaesthes* or anesthes*)))   |
| #20. | ((post adj3 (operat* or anaesthes* or anesthes*)))   |
| #21. | ((pre-operat* or preoperat* or pre-surg* or presurg*))   |
| #22. | (((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)))  |
| #23. | #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22   |
| #24. | #10 AND #23  |
|      |  |

| #25. | #11 AND #23              |
|------|--------------------------|
| #26. | #12 OR #13 OR #24 OR #25 |

## **Appendix C: Clinical evidence selection**

Figure 1: Flow chart of clinical study selection for the review of preoperative fasting



## **Appendix D: Clinical evidence tables**

| Study                                       | Ajuzieogu 2016 <sup>3</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=90)   |
| Countries and setting                       | Conducted in Nigeria; Setting: Hospital  |
| Line of therapy                             | Unclear  |
| Duration of study                           | Intervention + follow up: 24 hours   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: People scheduled for abdominal myomectomy   |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Stratified then randomised   |
| Inclusion criteria                          | Ninety American Society of Anesthesiologists (ASA) physical status I and II patients aged 18–42 years scheduled for abdominal myomectomy were studied after obtaining a written informed consent from them.  |
| Exclusion criteria                          | Patients with a history of any gastrointestinal disorder, receiving antacids, or H2 receptor blockers, or those who refused general anesthesia were excluded. Other exclusion criteria were a history of diabetes mellitus, body mass index >30 kg/m2 and pregnancy.   |
| Age, gender and ethnicity                   | Age - Range: 18-42 years of age. Gender (M:F): Not specified.  |
| Further population details                  | 1. Age: <60 years 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  | No indirectness  |
| Interventions                               | <ul> <li>(n=30) Intervention 1: Combination of food and fluid restrictions - To be reported. Fasting from midnight until the surgery. Duration 24 hours. Concurrent medication/care: Not stated. Indirectness: No indirectness</li> <li>(n=30) Intervention 2: Maintaining clear fluids before surgery - Non-milk, non-particulate drinks. 800 mL of oral carbohydrate solution containing 12.5% glucose, 50 kcal/100 mL (Nutricia preop®; Nutricia, Zoetermeer, The Netherlands) the night before surgery and an additional 400 mL 2 h before induction of anesthesia Duration 24 hours. Concurrent medication/care: Not stated. Indirectness: No indirectness</li> </ul> |
| Funding                                     | No funding   |

### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FASTING versus CARBOHYDRATE DRINK

Protocol outcome 1: Adverse events and complications

- Actual outcome: Postoperative nausea and vomiting-VAS at 24 hours; Group 1: mean 6 (SD 1.25); n=29, Group 2: mean 4 (SD 1); n=29; VAS 1-10 Top=High is poor outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

- Actual outcome: Postoperative nausea and vomiting-VAS at Postoperative score; Group 1: mean 7 (SD 1); n=29, Group 2: mean 7.5 (SD 0.75); n=29; VAS 1-10 Top=High is poor outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Patient satisfaction at 24 hours; Group 1: mean 6 (SD 0.5); n=29, Group 2: mean 8 (SD 0.75); n=29; VAS 1-10 Top=High is good outcome; Comments: 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed.

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - 2 People dropped out in the overall population due to faulty aspiration techniques, however which groups had these drop-outs is not mentioned. 1 per group has therefore been assumed. ; Indirectness of outcome: No indirectness ;

| Protocol outcomes not reported by the | Quality of life ; Mortality ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery |
|---------------------------------------|---|
| study                                 |   |

| Study                                       | Asakura 2015 <sup>7</sup>   |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=134)   |
| Countries and setting                       | Conducted in Hong Kong (China); Setting: Yokohama City University Hospital in Yokohama, Japan   |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients ASA physical status 1 and 2 adults, age 20 to 79 years, who were scheduled to undergo a surgical procedure of body surface   |
| Exclusion criteria                          | Patients with impaired gastrointestinal motility, poor comprehension of Japanese, or with psychiatric disorders were excluded from enrolment  |
| Recruitment/selection of patients           | scheduled to undergo a surgical procedure of body surface   |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO:63.4 ±13.6; Fasting: 64.5 ± 10.4. Gender (M:F): 33/28.   |
| Further population details                  | 1. Age: >60 years (CHO:63.4 ±13.6; Fasting: 64.5 ± 10.4). 2. People with diabetes: Not stated / Unclear   |
| Indirectness of population                  | No indirectness   |
| Interventions                               | (n=46) Intervention 1: Combination of food and fluid restrictions - To be reported. received 250ml of preoperative CHO (Arginaid Water™, 18% carbohydrates, Nestle Health Science, Tokyo, Japan) between 6.00–6:30 a.m. on the morning of surgery. This is because 250ml of Arginaid Water are approved as a meal. Duration preoperative. Concurrent medication/care: na. Indirectness: No indirectness |
|   | (n=45) Intervention 2: Combination of food and fluid restrictions - To be reported. Control group, did not receive any preoperative CHO, and were fasted starting at midnight on the day of surgical procedure. Duration preoperative. Concurrent medication/care: na. Indirectness: No indirectness  |
| Funding                                     | No funding  |
|   |   |

Protocol outcome 1: Quality of life

- Actual outcome: Global QoR-40 score at 24 hours postoperative; Median (IQR): CHO: 196 (191–198); Fasting: 197 (189.5–200)); Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: lost to follow up; Group 2 Number missing: 5, Reason: lost to follow up

Protocol outcome 2: Adverse events and complications

- Actual outcome: Length of stay at postoperative; median (IQR):: CHO: 3 (2–3); Fasting: 3 (2–6) days);

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: lost to follow up; Group 2 Number missing: 5, Reason: lost to follow up

Protocol outcomes not reported by the study Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Thirst; Headache; Cancellation of surgery

| Study                      |
|----------------------------|
| Study type                 |
| Number of studies (numbe   |
| Countries and setting      |
| Line of therapy            |
| Duration of study          |
| Method of assessment of g  |
| Stratum                    |
| Subgroup analysis within s |
| Inclusion criteria         |
| Exclusion criteria         |

| Study                                       | Cakar 2017 <sup>17</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=95)  |
| Countries and setting                       | Conducted in Turkey; Setting: Medical university hospital, Turkey   |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | adult patients undergoing an elective thyroid operation and American Society of Anesthesiologists (ASA) physical status I or II.  |
| Exclusion criteria                          | The exclusion criteria were aged below 18 or above 80 years, pregnancy, history of delayed gastric emptying, gastrointestinal obstruction, liver cirrhosis, diabetes mellitus, hypertension, severe hepatic or renal failure, or any endocrine disorder that might influence the metabolic parameters and patients requiring urgent or emergent surgery.                                      |
| Recruitment/selection of patients           | undergoing an elective thyroid operation  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 48.17 ± 9.81; Fasting: 50.07 ± 9.95. Gender (M:F): 28/32.   |
| Further population details                  | 1. Age: <60 years (CHO: 48.17 ± 9.81; Fasting: 50.07 ± 9.95). 2. People with diabetes: Non-diabetic   |
| Indirectness of population                  | No indirectness   |
| Interventions                               | (n=30) Intervention 1: Combination of food and fluid restrictions - To be reported. These patients were given<br>an oral carbohydrate solution (PreOp-Nutricia-12.5% carbohydrate, 50 kcal 100 mL21, 290 mOsm kg21,pH:<br>5.0); 800 mL at 12:00 a.m. and 400 mL 2 hours before surgery . Duration preoperative. Concurrent<br>medication/care: na. Indirectness: No indirectness              |
|   | (n=33) Intervention 2: Combination of food and fluid restrictions - To be reported. The routine fasting procedure was implemented, in which patients were instructed not to take any fluid or food by mouth after midnight (12:00 a.m.) preoperatively and were not given an intravenous (IV) injection. Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness |

Funding

Funding not stated

## RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Tiredness at 6am POD 1; Incidence Rate Ratio (range):: CHO: 1.0 (reference); Fasting: 1.18 (0.64 to 2.17) VAS 0-100 Top=High is poor outcome, Comments: p value 0.592;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up

Protocol outcome 2: Thirst

- Actual outcome: Thirst at 6am POD 1; Incidence rate ratio (range): CHO: 1.0 (reference); Fasting: 11.23 (9.41 to 3.40) VAS 0-100 Top=High is poor outcome, Comments: p value 0.0;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up

Protocol outcome 3: Headache

- Actual outcome: Headache at 6am POD 1; Incidence Rate Ratio (range):: CHo: 1.0 (reference): Fasting: 2.70 (1.69 to 4.32) VAS 0-100 Top=High is poor outcome, Comments: p value 0.0;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: lost to follow up

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Cancellation of surgery

| Study                                       | Canbay 2014 <sup>19</sup>   |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=50)  |
| Countries and setting                       | Conducted in Turkey; Setting: Department of Anesthesiology, Faculty of Medicine, Hacettepe University, Turkey   |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | ASA I–II group and would undergo open radical retropubic prosta-<br>tectomy surgery under elective conditions.  |
| Exclusion criteria                          | Patients with metabolic, endocrine, or hepatic disease, fever, and infection were excluded.   |
| Recruitment/selection of patients           | Undergoing open radical retropubic prostatectomy surgery  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 60.00 ± 10.37; Fasting: 58.36 ± 11.19. Gender (M:F): all male.  |
| Further population details                  | 1. Age: >60 years (CHO: 60.00 ± 10.37; Fasting: 58.36 ± 11.19). 2. People with diabetes: Non-diabetic   |
| Indirectness of population                  | No indirectness   |
| Interventions                               | <ul> <li>(n=25) Intervention 1: Combination of food and fluid restrictions - To be reported. Received 800 ml oral glucose solution containing 12.5 % glucose (Nutricia preop) at 24:00 h before surgery and 400 ml at 04:00 h, 2 h prior to the surgery</li> <li>Duration preoperative. Concurrent medication/care: NA</li> </ul> |
|   |   |
|   | (n=25) Intervention 2: Combination of food and fluid restrictions - To be reported. oral intake was restricted starting from 24:00h . Duration preoperative. Concurrent medication/care: NA   |
| Funding                                     | Funding not stated  |
|   |   |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst (Mild) at Unclear; Group 1: 6/25, Group 2: 13/25; Comments: 4 point Likert scale (0 = no sense, 1: mild, 2: moderate, 3: severe)

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; - Actual outcome: Thirst (Moderate) at Unclear; Group 1: 0/25, Group 2: 5/25; Comments: 4-point likert scale (0 = no sense, 1: mild, 2: moderate, 3: severe)

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care ; Unplanned ICU admission ; Headache ; Cancellation of surgery

| Study                                       | Celiksular 2016 <sup>20</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=80)   |
| Countries and setting                       | Conducted in Turkey; Setting:  |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | ASA I-II patients undergoing total hip replacement surgery due<br>to coxarthrosis  |
| Exclusion criteria                          | The exclusion criteria consisted of patients using steroids and/or beta-ad-<br>renergic blockers and those with rheumatologic, endocrine,<br>metabolic, renal and liver disease; tumours; obesity; fever<br>and infection.   |
| Recruitment/selection of patients           | undergoing total hip replacement surgery due to coxarthrosis   |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 53 (14.96); Fasting: 52.8 (17.86). Gender (M:F): 23/57.  |
| Further population details                  | 1. Age: <60 years (CHO: 53 (14.96); Fasting: 52.8 (17.86)). 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  |  |
| Interventions                               | <ul> <li>(n=40) Intervention 1: Combination of food and fluid restrictions - To be reported. The patients were given 800 mL and 400 mL (12.5%) of oral carbohydrate solution (PreopQ, Nutricia, Holland) 8h and two hours before their elective surgery . Duration preoperative. Concurrent medication/care: General anesthesia or epidural anesthesia. Indirectness: No indirectness</li> <li>(n=40) Intervention 2: Combination of food and fluid restrictions - To be reported. This group of patients underwent surgery under general anaesthesia or epidural after an 8-h preoperative fasting period . Duration preoperative. Concurrent medication/care: No indirectness</li> </ul> |
| Funding                                     | Funding not stated   |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications - Actual outcome: Nausea & Vomiting at Unclear; Group 1: 2/40, Group 2: 1/40 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery

| Study                                       | Doo 2018 <sup>30</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=50)  |
| Countries and setting                       |   |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients aged 20–65 years with American Society of Anesthesiologists physical status I or II, who were scheduled to undergo open thyroidectomy under general anaesthesia  |
| Exclusion criteria                          | mellitus, gastric emptying disorders including gastroesophageal<br>reflux disease, contraindications for ketorolac or nefopam, or<br>emergency surgery were excluded. Patients with fasting blood<br>glucose $\geq$ 126 mg/dl or glycosylated hemoglobin $\geq$ 6.5% on pre-<br>operative laboratory test, suggestive of hidden diabetes mellitus,<br>were also excluded.   |
| Recruitment/selection of patients           | scheduled to undergo open thyroidectomy under general anaesthesia   |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO:49.8 ± 7.1 ; Fasting: 51.0 ± 7.5. Gender (M:F): 11/39.   |
| Further population details                  | 1. Age: <60 years (CHO:49.8 ± 7.1 ; Fasting: 51.0 ± 7.5). 2. People with diabetes: Non-diabetic   |
| Indirectness of population                  |   |
| Interventions                               | <ul> <li>(n=25) Intervention 1: Combination of food and fluid restrictions - To be reported. Subjects in the carbohydrate group fasted, but received 400 ml of carbohydrate-rich drink (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO®, Daesang Wellife, Korea) 2 hours before induction of anesthesia Duration preoperative. Concurrent medication/care: General anesthesia with postoperative PCA</li> <li>(n=25) Intervention 2: Combination of food and fluid restrictions - To be reported. Subjects in the control</li> </ul> |
|   | group were requested to obey traditional preoperative fasting after midnight prior to the day of surgery.   |

| Duration preoperative. Concurrent medication/care: general anesthesia with postoperative PCA. |  |
|---|--|
| Indirectness: No indirectness   |  |

Funding

Equipment / drugs provided by industry (This research received carbohydrate beverages (Nucare NONPOR ORCID)

### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea & Vomiting at preoperative; Median (IQR): : CHO: 0 (0-1); Fasting: 0 (0-0) NRS 0-10 Top=High is poor outcome, Comments: p value 0.192;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Nausea & Vomiting at postoperative; Median (IQR):: CHO: 1 (0.5-2); Fasting: 1 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.926;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Fatigue at preoperative; Median (IQR): CHO: 2 (0-2); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.512; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Fatigue at postoperative; Median (IQR):: CHO: 1 (0.5-2); Fasting: 1 (0-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.630;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at preoperative; Median (IQR): CHO: 2 (1-3); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.288; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at postoperative; median (IQR):: CHo: 0 (0-0); Fasting: 0 (0-1) NRS 0-10 Top=High is poor outcome, Comments: p value 0.50; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Patient Satisfaction at preoperative; Mean; (Median (IQR):: CHO: 4 (3-4); Fasting: 4 (3-4)) 5-point scale 0-5 Top=High is good outcome, Comments: p value 1

(5: very satisfied, 4: somewhat satisfied, 3: neutral, 2: somewhat dissatisfied, 1: very dissatisfied);

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Patient Satisfaction at postoperative; Median (IQR) : CHO: 4 (3-4); Fasting: 4 (3-4) 5 point scale 1-5 Top=High is good outcome,

Comments: p value 0.715 5-point scale (5: very satisfied, 4: somewhat satisfied, 3: neutral, 2: somewhat dissatisfied, 1: very dissatisfied); Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 3: Thirst

- Actual outcome: Thirst at preoperative; Median (IQR): CHO: 1 (0-2); Fasting: 2 (1-2) NRS 0-10 Top=High is poor outcome, Comments: p value 0.099; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Thirst at postoperative; Median (IQR) : CHO: 2 (1-3); Fasting: 3 (1.5-4) NRS 0-10 Top=High is poor outcome, Comments: p value 0.456;

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the Quality of life ; Mortality ; Unplanned ICU admission ; Headache ; Cancellation of surgery study

| Study                                       | Faria 2009 <sup>31</sup>   |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=21)   |
| Countries and setting                       | Conducted in Brazil; Setting: Medical centre, Brazil   |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Adult women scheduled to undergo elective laparoscopic cholecystectomy   |
| Exclusion criteria                          | ASA score above II, diabetes mellitus, age below 18 or above 65 years old, renal failure, gastroesophageal reflux, acute cholecystitis, use of corticosteroids up to 6 months previously, and any noncompliance or violation on the assigned protocol of preoperative fasting.   |
| Recruitment/selection of patients           | scheduled to undergo elective laparoscopic cholecystectomy   |
| Age, gender and ethnicity                   | Age - Median (range): CHO: 47 (19–65); Fasting: 48 (29–65). Gender (M:F): all female.  |
| Further population details                  | 1. Age: <60 years (CHO: 47 (19–65); Fasting: 48 (29–65)). 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  | No indirectness  |
| Interventions                               | (n=11) Intervention 1: Combination of food and fluid restrictions - To be reported. receive 200 ml of a carbohydrate beverage containing 12.5% (25 g, 50 kcal per 100 ml and approximately 285 mOsm) of maltodextrine (Nidex, Nestle, Brazil) 2 h before operation. Duration preoperative. Concurrent medication/care: All patients were submitted to general anesthesia without epidural blockage. They received a single dose of 1 g of intravenous cefazolin. A routine prescription of 1,000–1,500 ml of intravenous saline was administered to all patients postoperatively. Postoperative fasting was prescribed until 5:00 p.m., 12 h after the patients had or had not received the carbohydrate drink. After that, all patients received a liquid diet unless they had nausea or vomiting, in which case an antiemetic was prescribed. Postoperative analgesia was provided with both 50 mg of subcutaneous tramadol cloridrate and 500 mg of intravenous dipyrone every 6h Indirectness: No indirectness |
|   | (n=12) Intervention 2: Combination of food and fluid restrictions - To be reported. conventional preoperative fasting of 8 h. Duration preoperative. Concurrent medication/care: All patients were submitted to general  |

|         | anesthesia without epidural blockage. They received a single dose of 1 g of intravenous cefazolin. A routine prescription of 1,000–1,500 ml of intravenous saline was administered to all patients postoperatively. Postoperative fasting was prescribed until 5:00 p.m., 12 h after the patients had or had not received the carbohydrate drink. After that, all patients received a liquid diet unless they had nausea or vomiting, in which case an antiemetic was prescribed. Postoperative analgesia was provided with both 50 mg of subcutaneous tramadol cloridrate and 500 mg of intravenous dipyrone every 6h Indirectness: No indirectness |
|---------|--|
| Funding | (CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) funding the study (grant 401943/2005-4))   |

Protocol outcome 1: Adverse events and complications

- Actual outcome: Vomiting at Postoperative; Group 1: 3/11, Group 2: 7/10

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 2

| Protocol outcomes not reported by the | Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst |
|---------------------------------------|---|
| study                                 | ; Headache ; Cancellation of surgery  |

© NICE 2020. All rights reserved. Subject to Notice of rights. 83

| Study                                       | Gilbert 1995 <sup>37</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=95)  |
| Countries and setting                       | Conducted in United Kingdom; Setting: The Vale of Leven Hospital, Alexandria, Dunbartonshire  |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients scheduled for minor operations who were ASA I or II  |
| Exclusion criteria                          | Patients with gastrointestinal disease, undergoing emergency procedures, pregnant women, children and patients with mental handicap were not studied.   |
| Recruitment/selection of patients           | Patients scheduled for minor operations who were ASA I or II  |
| Age, gender and ethnicity                   | Age - Mean (SD): Water: 45.6 (15.6); Fasting: 48.3 (16.6). Gender (M:F): 35/60.   |
| Further population details                  | 1. Age: <60 years (Water: 45.6 (15.6); Fasting: 48.3 (16.6)). 2. People with diabetes: Not stated / Unclear   |
| Indirectness of population                  | -   |
| Interventions                               | (n=46) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in group A (water) were asked to drink 500 ml- 1L of water over 2 h, before a 3 h pre-operative fast Duration preoperative. Concurrent medication/care: All patients received premedication with temazepam 20mg and ranitidine 150 mg by mouth, 2 h before the scheduled time of operation.  |
|   | (n=49) Intervention 2: Combination of food and fluid restrictions - To be reported. Group B (fasting) followed the standard regimen of fasting from midnight for the morning list or 'tea and toast' before 08.00 h for the afternoon session Duration preoperative. Concurrent medication/care: All patients received premedication with temazepam 20mg and ranitidine 150 mg by mouth, 2 h before the scheduled time of operation Indirectness: No indirectness |
| Funding                                     | Funding not stated  |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WATER versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea at 2 hours post operative; Median: Water: 1.0; FAsting: 0 0-100 Top=High is poor outcome, Comments: p value 0.32; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

- Actual outcome: Vomiting at 2 hours post operative; Median : Water: 1.0; Fasting: 0 0-100 Top=High is poor outcome, Comments: p value 0.21; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

- Actual outcome: Drowsiness at 2 hours post operative; Mean; ;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

#### Protocol outcome 2: Thirst

- Actual outcome: Thirst at 2 hours post operative; Median: Water: 5.0; Fasting: 21.0 VAS 0-100 Top=High is poor outcome, Comments: P value 0.0149; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

### Protocol outcome 3: Headache

- Actual outcome: Headache at 2 hours post operative; Median : Water: 2.5; Fasting: 2.0 0-100 Top=High is poor outcome, Comments: p value 0.99; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - Only median value given; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5, Reason: not enough water taken or given IV fluids; Group 2 Number missing: 1, Reason: given IV fluids

Protocol outcomes not reported by the study

Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Cancellation of surgery

| Study                             |
|-----------------------------------|
| Study type                        |
| Number of studies (numb           |
| Countries and setting             |
| Line of therapy                   |
| Duration of study                 |
| Method of assessment of condition |
| Stratum                           |
| Subgroup analysis within          |
| Inclusion criteria                |
| Exclusion criteria                |
| Recruitment/selection of          |

| Study                                       | Hausel 2001 <sup>41</sup>   |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=252)   |
| Countries and setting                       | Conducted in Sweden; Setting: Three hospitals in the Stockholm area took part in the study.   |
| Line of therapy                             | Not applicable  |
| Duration of study                           | Intervention time:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients who were eligible for intake of preoperative clear fluids, according to the guidelines from the Swedish Association of Anaesthetists (1), were considered for inclusion. These guidelines are similar to the present recommendations given by the American Society of Anesthesiologists (ASA)  |
| Exclusion criteria                          | conditions (including pharmacologic treatments) that might impair gastrointestinal motility, gastroesophageal reflux, pregnancy, and the potential for difficult airway management. In addition, patients with diabetes mellitus and patients in ASA physical status classes ≥III were excluded.  |
| Recruitment/selection of patients           | patients scheduled for elective laparoscopic cholecystectomy or<br>elective major colorectal surgery  |
| Age, gender and ethnicity                   | Age - Median (IQR): Laparoscopic cholecystectomy - Fasted: 48 (37–59); CHO: 49 (36–58); Colorectal surgery: Fasted 52 (34–66); CHO 56 (50–67). Gender (M:F): 84/168.  |
| Further population details                  | 1. Age: <60 years (Laparoscopic cholecystectomy - Fasted: 48 (37–59); CHO: 49 (36–58); Colorectal surgery: Fasted 52 (34–66); CHO 56 (50–67)). 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  | No indirectness   |
| Interventions                               | (n=80) Intervention 1: Combination of food and fluid restrictions - To be reported. During the evening before surgery, the CHO group consumed 800 mL of an iso-osmolar carbohydrate-rich drink (12.5% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg, pH 5.0, Nutricia Preop®; Numico, Zoetermeer, the Netherlands). After midnight, nothing by mouth was allowed, except a single morning dose of 400 mL of the CHO drink. Duration preoperative. Concurrent medication/care: Premedication was standardized to morphine 10 mg IM or ketobemidone 5 mg IM. Epidural analgesia was initiated before general anesthesia (GA) by using bupivacaine with epinephrine. GA was induced IV with fentanyl and thiopental after the administration of glycopyrrolate. |

|  | (n=86) Intervention 2: Combination of food and fluid restrictions - To be reported. patients were fasted from midnight. Duration preoperative. Concurrent medication/care: Premedication was standardized to morphine 10 mg IM or ketobemidone 5 mg IM. Epidural analgesia was initiated before general anesthesia (GA) by using bupivacaine with epinephrine. GA was induced IV with fentanyl and thiopental after the administration of glycopyrrolate Indirectness: No indirectness |
|--|--|
| Funding  | Funding not stated   |
| Funding       Funding not stated         RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING         Protocol outcome 1: Adverse events and complications         - Actual outcome: Malaise at 40 minutes post morning drink; Median (IQR): Fasted: 12 (3–30); CHO: 8 (4–20) visual analogue scale 0-100 Top=High is poor outcome;         Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;         - Actual outcome;         Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;         - Actual outcome;         Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;         - Actual outcome: Nausea at 40 minutes post morning drink; Median (IQR): Fasting: 3 (2–10); CHO: 4 (2–6) visual analogue scale 0-100 Top=High is poor outcome;         Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;         - Actual outcome: Nausea at 40 minutes post morning drink; Median (IQR): Fasting: 3 (2–10); CHO: 4 (2–6) visual analogue scale 0-100 Top=High is poor outcome;         Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Out |  |
| outcome;<br>Risk of bias: All domain - High, Selection -<br>Crossover - Low; Indirectness of outcome:  | High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, No indirectness ;   |
|  |  |
| Protocol outcomes not reported by the study  | Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery   |
|  |  |

© NICE 2020. All rights reserved. Subject to Notice of rights. 87

| Study                                       | Helminen 2009 <sup>44</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=240)  |
| Countries and setting                       | Conducted in Finland; Setting: Department of Surgery and bDepartment of Anaesthesia, Seinajoki Central Hospital, Finland   |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | adult patients undergoing elective abdominal, anal, thyroid or parathyroid operations and ASA physical status I–III.   |
| Exclusion criteria                          | Patients who were pregnant or who had dementia, impairment of gastrointestinal motility or diabetes mellitus were excluded from the study.   |
| Recruitment/selection of patients           | patients undergoing elective abdominal, anal, thyroid or parathyroid operations  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 60±15; Fasting: 58±4. Gender (M:F): 68/137.  |
| Further population details                  | 1. Age: >60 years (CHO: 60±15; Fasting: 58±4). 2. People with diabetes: Not stated / Unclear   |
| Indirectness of population                  | -  |
| Interventions                               | (n=80) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group were given nothing after midnight and a 12.5%CHD(Nutricia Preop; Numici, The Netherlands), that is 400ml (=200 kcal), between 6 and 7 a.m Duration preoperative. Concurrent medication/care: Patients were premedicated and anaesthetized according to the normal practice of our hospital. Oral premedication of hydroxyzine hydrochloride (Atarax; UCB, Belgium) 25–50mg with a small amount of water was given at 7 a.m. in the morning Indirectness: No indirectness |
|   | (n=80) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients in the fasting group were given nothing by mouth after midnight Duration preoperative. Concurrent medication/care: Patients were premedicated and anaesthetized according to the normal practice of our hospital. Oral premedication of hydroxyzine hydrochloride (Atarax; UCB, Belgium) 25–50mg with a small amount of water was given at 7 a.m. in the morning Indirectness: No indirectness  |
| Funding                                     | Funding not stated   |

### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst at Before anesthesia; Median (IQR): CHO: 1 (0-4.5); Fasting: 3 (0-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 10; Group 2 Number missing: 7

- Actual outcome: Tiredness at Before anesthesia; median (IQR): CHO: 2 (0–5); Fasting: 3 (0-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 7

- Actual outcome: Anxiety at Before anesthesia; median (IQR): CHO: 2 (1-5); Fasting: 3 (1-5) visual analogue scale 0-10 Top=High is poor outcome; Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 10; Group 2 Number missing: 7

Protocol outcomes not reported by the study

Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care ; Unplanned ICU admission ; Headache ; Cancellation of surgery

| Study                                       | Helminen 2019 <sup>43</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=113)  |
| Countries and setting                       | Conducted in Finland; Setting: Seinajoki Central hospital, Oulu University hospital, Finland   |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Adults aged between 18 - 70 with ASA I to II scheduled for day case cholecystectomy.   |
| Exclusion criteria                          | bleeding or coagulation disorders, BMI > 40kg/m <sup>2</sup> , insulin dependent diabetes, dementia, migraine or menieres disease or with a history of alcohol or drug abuse   |
| Recruitment/selection of patients           | scheduled for day case cholecystectomy.  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 47 (13); Fasting: 46 (11). Gender (M:F): Define.   |
| Further population details                  | 1. Age: <60 years (CHO: 47 (13); Fasting: 46 (11)). 2. People with diabetes: Diabetic patients (non insulin dependent diabetes patients were included. 5 in each group.).  |
| Indirectness of population                  | No indirectness  |
| Interventions                               | (n=57) Intervention 1: Combination of food and fluid restrictions - To be reported. 200ml of carbohydrate rick drink (Providextra; Fresineus Kabi Ab; Bad Homburg Vor der Hohe, Germany) containing 300kcal, 67g carbohydrate and 8g protein at home before leaving for the hospital or by 6am for surgery scheduled at 9am or 8pm at the latest for later surgery Duration preoperative. Concurrent medication/care: NA (n=56) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients were instructed to |
|   | take nothing by mouth after midnight on the night before surgery Duration preoperative. Concurrent medication/care: NA. Indirectness: No indirectness  |
| Funding                                     | No funding   |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Quality of life - Actual outcome: Tiredness at before induction; Median (IQR): CHO: 30 (10-54); Fasting: 20 (5-46) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Tiredness at 2 hours postoperative; Mean; (Median (IQR): CHO: 49 (20-70); Fasting: 53 (30-61)) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Tiredness at 4 hours postoperative; Median (IQR) : CHO: 42 (8-70); Fasting: 40 (10-50) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at before induction; Median (IQR): CHO: 0 (0-0); Fasting: 0 (0-2) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing:

1, Reason: questionnaire not completed

- Actual outcome: Nausea at 2 hours postoperative; Median (IQR): CHO: 0 (0-14); Fasting: 0 (0-6) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

- Actual outcome: Nausea at 4 hours postoperative; Median (IQR) : CHO: 0 (0-4); Fasting: 0 (0-10) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing: 1, Reason: questionnaire not completed

Protocol outcome 3: Thirst

- Actual outcome: Thirst at before induction; Median (IQR): CHO: 22 (6 - 50); Fasting: 40 (8 - 63));

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4, Reason: questionnaire not completed; Group 2 Number missing:

1, Reason: questionnaire not completed

- Actual outcome: Thirst at 2 hours postoperative; Median (IQR): : CHO: 41 (20 - 61); Fasting: 46 (24-70));

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

- Actual outcome: Thirst at 4 hours postoperative; Median (IQR) : CHO: 28 (9-61); Fasting: 20(0-50));

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

| study | Cancellation of surgery |
|-------|-------------------------|
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |
|       |                         |

Perioperative care: FINAL Preoperative fasting strategy

| Study                                       | Lee 2018 <sup>58</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | (n=153)   |
| Countries and setting                       |   |
| Line of therapy                             | Not applicable  |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients ASA I – II adults who had a Karnofsky<br>performance status scale greater than 70 undergoing laparoscopic cholecystectomy  |
| Exclusion criteria                          | fasting glucose level greater than 120 mg/dL, type I or II diabetes, gastroesophageal reflux disease, history of previous Gi surgery or ASA IV/V  |
| Recruitment/selection of patients           | undergoing laparoscopic cholecystectomy   |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 50 (13); Fasting: 49 (12). Gender (M:F): 49/48.   |
| Further population details                  | 1. Age: <60 years (CHO: 50 (13); Fasting: 49 (12)). 2. People with diabetes: Non-diabetic   |
| Indirectness of population                  | No indirectness   |
| Interventions                               | (n=51) Intervention 1: Combination of food and fluid restrictions - To be reported. Received 800ml of a clear<br>carbohydrate beverage (12.8% carbohydrates, 50kcal/100ml, 290 mOsm/kg, Daesang WelLife Co, Korea)<br>Patients were instructed to ingest 400ml of this beverage on the evening before surgery (400ml) 2h before<br>any anesthetic medication was administered. Duration preoperative. Concurrent medication/care: General<br>anesthesia with IV postoperative pain relief |
|   | (n=51) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients within this group were not allowed to drink any solution or fluid after midnight before surgery. Duration preoperative. Concurrent medication/care: General anesthesia with IV postoperative pain relief   |
| Funding                                     | Equipment / drugs provided by industry (Nos-NPO were provided by the Daesang Corporation, Korea)  |

Protocol outcome 1: Quality of life

- Actual outcome: Postoperative QoR-40 score at POD 1; Group 1: mean 187.7 (SD 17.5); n=46, Group 2: mean 194.5 (SD 5.6); n=51; QoR-40 40-200 Top=High is good outcome

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: prolonged fasting time; Group 2 Number missing: 2, Reason: refusal to complete postoperative data

Protocol outcome 2: Adverse events and complications

- Actual outcome: Length of stay (days) at postoperative; Group 1: mean 2.59 days (SD 1.61); n=46, Group 2: mean 2.38 days (SD 2.05); n=51 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 5, Reason: prolonged fasting time; Group 2 Number missing: 2, Reason: refusal to complete postoperative data

Protocol outcomes not reported by the study Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Thirst; Headache; Cancellation of surgery

 $\odot$ 

| Study                                       | Melis 2006 <sup>73</sup>   |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=29)   |
| Countries and setting                       | Conducted in Netherlands; Setting: VU University Medical Centre, Netherlands   |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Adult patients undergoing elective orthopaedic surgery   |
| Exclusion criteria                          | inability to give informed consent, decreased consciousness, and circumstancex increasing the chance of a full stomach at the moment of induction (diabetes, sliding hernia of the stomach, rolling diaphragmatic hernia, obstruction of GI tract, pregnancy, increased intracranial pressure, obesity and use of medication affecting gastric emptying)   |
| Recruitment/selection of patients           | Adult patients undergoing elective orthopaedic surgery   |
| Age, gender and ethnicity                   | Age - Mean (SD): Drink A: 59 (9); Drink B: 47 (17); Fasting: 56 (13). Gender (M:F): 15/14.   |
| Further population details                  | 1. Age: <60 years (Drink A: 59 (9); Drink B: 47 (17); Fasting: 56 (13)). 2. People with diabetes: Non-diabetic   |
| Indirectness of population                  | No indirectness  |
| Interventions                               | (n=19) Intervention 1: Combination of food and fluid restrictions - To be reported. CHO Drink A: Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink A was Nutricia preOp (Nutricia, Zoetermeer, the Netherlands), which contained 50.4g of the carbohydrates; consisting of 0.8g glucose, 5.2g polysaccharides and a small amount of organic acids and 200mg sodium, 488mg Potassium, 24mg chloride, 24mg calcium, 4mg of phosphor, and 4mg of Magnesium in a solution of 400ml with an osmolality of 260mOsm/kg CHO drink B: Drink was poured out into a class 4 hours before surgery and had to be consumed 3 hours before surgery. Drink B was Roosvicee vruchtenmix (Heinz, Zeist, the Netherlands), a syrup of rosehip and |

|         | other fruits, which was diluted in water (70ml syrup : 330ml water) and contained<br>48mg of carbohydrates, consisting of 6.2g fructose, 6.2g of glucose and furthermore carbohydrate with<br>unidentified chemical structure of 0.2g fiber,<br>0.2g protein, 6.4mg sodium, 73mg potassium, 6.9mg calcium, 7.mg phosphor, 0.1mg iron and 41mg Vitamin<br>C in a solution of 400ml with an osmolality of 574 mOsm/kg . Duration preoperative. Concurrent<br>medication/care: NA. Indirectness: No indirectness<br>(n=10) Intervention 2: Combination of food and fluid restrictions - To be reported. Fasted after midnight on<br>the day of surgery. Duration preoperative. Concurrent medication/care: NA. Indirectness: |
|---------|---|
| Funding | Funding not stated  |
|         |   |

# RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO DRINK A / CHO DRINK B versus FASTING

Protocol outcome 1: Quality of life

- Actual outcome: Anxiety at day before surgery up to preoperative; Median increase/decrease (IQR): CHOA: -15 (49); CHOB: 0 (15) ; Fasting: +3 (51) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at day before surgery up to preoperative; Median increase / decrease (IQR): CHOA: 0 (6); CHOB: +1 (6); Fasting: 0 (7) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Tiredness at day before surgery up to preoperative; Mean; (median increase/decrease (IQR): CHOA: 0 (20); CHOB: -7 (29); Fasting: - 19 (27)) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcome 3: Thirst

- Actual outcome: Feeling of thirst at day before surgery up to preoperative; Median Increase/Decrease (IQR): CHOA: -7 (39); CHOB: 0 (18); Fasting: +34 (34) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Headache;

| study | Cancellation of surgery |  |
|-------|-------------------------|--|
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |
|       |                         |  |

Perioperative care: FINAL Preoperative fasting strategy

| Study                                       | Onalan 2018 <sup>84</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=53)   |
| Countries and setting                       | Conducted in Turkey; Setting: Karabuk University Health Sciences Institute, Karabuk, Turkey;   |
| Line of therapy                             | Unclear  |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Scheduled for LC, Age more than 18 years and less than 65 years. Agreeing to participate in the study and signing the informed consent form.   |
| Exclusion criteria                          | Those with a history of diabetes (type 1 and 2). Those who have ahistory of gestational diabetes. Body mass index (BMI)of 40 kg/m2 or more (BMI 5 body weight/height2). ASA group III or IV. Those who were administered intravenous fluid before surgery. Those with liver and kidney failure. Drug users whose blood glucose levels will be impacted. Those who have previously undergone abdominal surgery. Those with a history of acute cholecystitis or acute pancreatitis. Patients for whom CO2 insufflation is inconvenient in terms of anesthesia (heart failure, chronic obstructive pulmonary disease, and so forth). Those who have bleeding diathesis. Those receiving immuno suppressive treatment. Patients with any infectious disease. |
| Recruitment/selection of patients           | elective laparoscopic cholecystectomy (LC)   |
| Age, gender and ethnicity                   | Age - Median (IQR): CHO: 53 (16); Fasting: 54 (14). Gender (M:F): 13/37.   |
| Further population details                  | 1. Age: <60 years (CHO: 53 (16); Fasting: 54 (14)). 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  | No indirectness  |
| Interventions                               | (n=26) Intervention 1: Combination of food and fluid restrictions - To be reported. the patients were given an oral glucose solution (Nutricia preop) containing 12.5% glucose, first 800 mL at 12 a.m., and then 400 mL at 6 a.m., 2 hours before the surgery. The solution was ingested in 10 minutes. Nutricia preop, one of the  |

OCSs containing maltodextrin and electrolytes, contains 12.5% glucose. It passes through the stomach in 90 minutes. Its osmolality is 285 mosm/kg/H2O and it has 50 kcal/100 mL. In addition, it contains 0.46 mg/mL sodium and 1.93 mg/mL potassium. . Duration preoperative . Concurrent medication/care: To provide the standardization of treatment after surgery, both groups were treated with 2,000 mL 5% dextrose plus 1,500 mL saline solution, cefazolin sodium (according to our country's infection control committee suggestion) 1 g 2 x 1, tenoxicam 20 mg 2 x 1, ranitidine 50 mg 3 x 1, and metocloramide HCL.. Indirectness: No indirectness (n=27) Intervention 2: Combination of food and fluid restrictions - To be reported. Food and water were cut off in the control group as of 12 a.m. the night before surgery. Duration Preoperative. Concurrent medication/care: To provide the standardization of treatment after surgery, both groups were treated with 2,000 mL 5% dextrose plus 1,500 mL saline solution, cefazolin sodium (according to our country's infection control committee suggestion) 1 g 2 x 1, tenoxicam 20 mg 2 x 1, ranitidine 50 mg 3 x 1, and metocloramide HCL.. Indirectness: No indirectness Academic or government funding (This study was carried out as the Scientific Research Project of Karabuk Funding University

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst at 3 hours postoperative; Group 1: mean 0.64 (SD 0.91); n=25, Group 2: mean 7.8 (SD 2.5); n=25; VAS 0-10 Top=High is poor outcome; Comments: P value <0.001

Low values from the visual analog scale are indicative

of recovery.

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low,

Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: prolonged procedure; Group 2 Number missing: 2, Reason: prolonged procedure / change of surgery

- Actual outcome: Anxiety at 3 hours postoperative; Group 1: mean 0.12 (SD 0.44); n=25, Group 2: mean 5.12 (SD 2.77); n=25; VAS 0-10 Top=High is poor outcome; Comments: P value <0.001

Low values from the visual analog scale are indicative of recovery.

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care

study

; Unplanned ICU admission ; Headache ; Cancellation of surgery

| 0  | Study                                       | Raksakietisak 2014 <sup>96</sup>  |
|--|---|---|
| NIC  | Study type                                  | RCT (Patient randomised; Parallel)  |
| m  | Number of studies (number of participants)  | (n=100)   |
| 2020.  | Countries and setting                       | Conducted in Thailand; Setting: Faculty of Medicine Siriraj Hospital, Mahidol Unviersity, Thailand  |
| 0.   | Line of therapy                             | Unclear   |
| All  | Duration of study                           | Intervention + follow up:   |
| All rights                                   | Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| reg  | Stratum                                     | Overall   |
| sen  | Subgroup analysis within study              | Not applicable  |
| reserved. Subject to Notice of rights<br>100 | Inclusion criteria                          | Patients aged 50 – 80 years with unilateral total knee replacement  |
| Ct t   | Exclusion criteria                          | Revision TKR or bilateral TKR, BMI > 30kg/m2, Gi diseases or Gi affecting drugs, diabetes, CKD, and CHF   |
|  | Recruitment/selection of patients           | unilateral total knee replacement   |
| 0 otic                                       | Age, gender and ethnicity                   | Age - Mean (SD): CHO: 69.8 (7.3); Fasting: 70.8 (8.5). Gender (M:F): 10/88.   |
| ce c   | Further population details                  | 1. Age: >60 years (CHO: 69.8 (7.3); Fasting: 70.8 (8.5)). 2. People with diabetes: Non-diabetic   |
| of ri  | Indirectness of population                  | No indirectness   |
| ahts.  | Interventions                               | (n=48) Intervention 1: Combination of food and fluid restrictions - To be reported. Assigned to drink 400ml of 10% carbohydrate rich orange juice (Greenmate) between 18:00 and 24:00 and another 400ml at about 2 hour before anaesthesia (6:00 to 7:00am). Duration preoperative. Concurrent medication/care: Single shot spinal anesthesia |
|  |   | (n=50) Intervention 2: Combination of food and fluid restrictions - To be reported. The control group had to starve from midnight. Duration preoperative. Concurrent medication/care: Single shot spinal anesthesia. Indirectness: No indirectness  |

Funding

-- (Siriraj research development fund)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Adverse events and complications

Actual outcome: Nausea at postoperative; Group 1: 9/48, Group 2: 10/50
Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0
Actual outcome: Vomiting at postoperative; Group 1: 8/48, Group 2: 12/50
Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low, Comments - ; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Anxiety at Preoperative; Group 1: mean 3.6 (SD 3); n=48,

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0

Protocol outcome 3: Thirst

- Actual outcome: Thirst at Preoperative; Group 1: mean 2.4 (SD 2.2); n=48,

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: inadequate spinal block; Group 2 Number missing: 0

Protocol outcomes not reported by the Quality of life; Mortality; Unplanned ICU admission; Headache; Cancellation of surgery study

| Study                                       | Read 1991 <sup>97</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=54)   |
| Countries and setting                       | Conducted in United Kingdom; Setting: University Hospital of Wales   |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Patients ASA I or II, between the ages of 18-60 and scheduled to have elective surgery normally requiring tracheal intubation  |
| Exclusion criteria                          | Pregnant, GI abnormality, or any medications known to affect gastric emptying  |
| Recruitment/selection of patients           | scheduled to have elective surgery normally requiring tracheal intubation  |
| Age, gender and ethnicity                   | Age - Median (range): Water: 30 (17-56); Fasting: 32 (18-50). Gender (M:F): 18/36.   |
| Further population details                  | 1. Age: <60 years (Water: 30 (17-56); Fasting: 32 (18-50)). 2. People with diabetes: Not stated / Unclear  |
| Indirectness of population                  | No indirectness  |
| Interventions                               | <ul> <li>(n=25) Intervention 1: Preoperative food restriction for - 4-6 hours. Permitted to drink water up until 2 hours before the operation. Duration preoperative. Concurrent medication/care: Premedication of oral temazepam 20mg given 2h preoperatively. Indirectness: No indirectness</li> <li>(n=29) Intervention 2: Combination of food and fluid restrictions - To be reported. Abstain from eating and drinking from midnight (morning operation) or after a light breakfast at 6:30am (afternoon operation). Duration preoperative. Concurrent medication/care: Premedication of oral temazepam 20mg given 2h preoperatively. Indirectness</li> </ul> |
| Funding                                     | Funding not stated   |
| i unung                                     |  |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: WATER versus FASTING

Protocol outcome 1: Adverse events and complications
- Actual outcome: Nausea at POD1; Group 1: 5/25, Group 2: 15/29
Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;
- Actual outcome: Vomiting at POD1; Group 1: 3/25, Group 2: 10/29
Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;
Protocol outcome 2: Headache

- Actual outcome: Headache at POD1; Group 1: 6/25, Group 2: 12/29 Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Cancellation of surgery

| Study  | Sada 2014 <sup>98</sup>   |
|--|---|
| Study type                                     | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)     | (n=142)   |
| Countries and setting                          |   |
| Line of therapy                                | Not applicable  |
| Duration of study                              | Intervention + follow up: 48 hours postoperative  |
| Method of assessment of guideline<br>condition | Adequate method of assessment/diagnosis   |
| Stratum  | Overall   |
| Subgroup analysis within study                 | Not applicable  |
| Inclusion criteria                             | patients were older than 18 years, undergoing an operation of the colon and rectum for benign and malignant diseases, or open abdominal cholecystectomy for chronic cholecystitis   |
| Exclusion criteria                             | type 1 or 2 diabetes mellitus, stomach emptying disorders or documented gastric esophageal reflex disease, emergency surgery interventions, or refusal of the patient to participate in the trial   |
| Recruitment/selection of patients              | undergoing an operation of the colon and rectum   |
| Age, gender and ethnicity                      | Age - Mean (SD): CHO: 56.85 (12.8); Fasting: 56.45 (14.28). Gender (M:F): 53/89.  |
| Further population details                     | 1. Age: <60 years (CHO: 56.85 (12.8); Fasting: 56.45 (14.28)). 2. People with diabetes: Non-diabetic (Type 1 and 2 diabetes an exclusion criterion).  |
| Indirectness of population                     | No indirectness   |
| Interventions                                  | <ul> <li>(n=44) Intervention 1: Combination of food and fluid restrictions - To be reported. The study group received 800 mL (per os) of carbohydrate beverage in the evening before surgery (22:00) and an additional 400 mL 2 h before anesthesia induction. Duration preoperative. Concurrent medication/care: General anesthesia for surgery. Indirectness: No indirectness</li> <li>(n=52) Intervention 2: Combination of food and fluid restrictions - To be reported. The control group did not</li> </ul> |
|  | receive any of these drinks and were subject to the traditional preoperative fasting Duration preoperative.<br>Concurrent medication/care: General anesthesia for surgery. Indirectness: No indirectness  |
| Funding  | Funding not stated  |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CARBOHYDRATE DRINK versus FASTING

Protocol outcome 1: Adverse events and complications

- Actual outcome: Thirst at 0-24h postoperatively; Mean; (Median (range): see below) visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 3 (1-5): Fasting: 4 (1-7) p value >0.05

Cholecystectomy patients: CHO: 3 (1-5): Fasting: 4 (1-7) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Anxiety at 0-24h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 3 (1-3): Fasting: 2 (1-6) p value >0.05

Cholecystectomy patients: CHO: 2 (1-3): Fasting: 2 (1-6) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Nausea at 0-24h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-5): Fasting: 3 (1-6) p value >0.05

Cholecystectomy patients: CHO: 1 (1-5): Fasting: 3 (1-6) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

Protocol outcome 2: Thirst

- Actual outcome: Thirst at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 2 (1-3): Fasting: 2 (1-5) p value <0.05

Cholecystectomy patients: CHO: 2 (1-3): Fasting: 2 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Anxiety at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-3): Fasting: 1.5 (1-5) p value >0.05

Cholecystectomy patients: CHO: 1 (1-3): Fasting: 1.5 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2 Number missing: 2, Reason: excluded from analysis/lost to follow up

- Actual outcome: Nausea at 36-48h postoperatively; median (range): see below visual analogue scale 0-10 Top=High is poor outcome, Comments: Colorectal patients: CHO: 1 (1-3): Fasting: 2 (1-5) p value >0.05

Cholecystectomy patients: CHO: 1 (1-3): Fasting: 2 (1-5) p value >0.05;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 1, Reason: excluded from analysis/lost to follow up; Group 2

| Protocol outcomes not reported by the | Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; |
|---------------------------------------|--|
| study                                 | Headache ; Cancellation of surgery   |

| Study                                       | Smith 2014 <sup>102</sup>   |
|---|---|
| Study type                                  | Cochrane Review   |
| Number of studies (number of participants)  | 27 (n=1976)   |
| Line of therapy                             | preoperative carbohydrate supplementation   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis. Cochrane review of randomised controlled trials (RCTs) that compared the effects on postoperative recovery and well-being when preoperative carbohydrate treatment was used versus placebo or preoperative fasting in adults (18 years of age or older)  |
| Stratum                                     | Overall   |
| Selection of studies                        | Assessed RCTs evaluating the effects of preoperative carbohydrate treatment was used versus placebo or preoperative fasting, and included:<br>a clearly defined clinical question<br>details of inclusion and exclusion criteria<br>details of databases searched and relevant search strategies<br>length of hospital stay, complication rate, patient reported well-being scores and adverse events<br>summary results for at least one desired outcome   |
| Inclusion criteria                          | Included adult patients (18 years of age or older) undergoing any type of elective surgical procedure while under general, spinal or epidural anaesthesia. We included patients who underwent spinal or epidural blockade in addition to general anaesthesia.   |
| Exclusion criteria                          | Excluded patients who required urgent or emergency surgery (cases in which surgery is required within 24 hours after the first physician contact for a potentially life-threatening condition).   |
| Indirectness of population                  | No indirectness   |
| Interventions                               | Intervention 1: The intervention group included all participants who were given at least 45 g of carbohydrate by oral beverage or by the intravenous route. To be included, studies must have planned to administer the carbohydrates within four hours of surgery start time, or induction of anaesthesia. Co-intervention with other oral substances in the four hours before surgery was permitted so long as the dose of carbohydrate was at least 45 g (n=935)<br>Intervention 2: The intervention group was compared with a control group consisting of participants who received less than 45 g of carbohydrate in the four hours before anaesthesia. Control participants may have received a placebo drink containing less than 45 g of carbohydrate, clear liquids or nothing by mouth during |
|   | this time. The control group may have received intravenous fluid therapy during the four hours before surgery start time, so long as the total combined dose of carbohydrates given by oral and intravenous routes remained less than 45 g (n=1041)   |

| Outcomes reported                 | Length of hospital stay: measured in days.   |
|-----------------------------------|--|
| editecines reported               |  |
|                                   | Postoperative complication rate  |
|                                   | Fatigue: measured by such instruments as ordinal or visual analogue scales.                                    |
|                                   | General well-being: measured by such instruments as ordinal, visual analogue or composite scales.              |
|                                   | Nausea 24 hours postoperatively: measured by such instruments as ordinal, visual analogue or composite scales. |
|                                   | Vomiting within 24 hours postoperatively: measured as an incidence rate.                                       |
| Evidence included for 21 studies: |  |

An 2008; Bisgaard 2004; Braga 2012; Harsten 2012; Hausel 2005; Henriksen 2003; Kaska 2010; Lidder 2013; Ljunggren 2012; Ljunggvist 1994; Mathur 2010; Noblett 2006; Ozdemir 2011; Pexe-Machado 2013; Soop 2001; Soop 2004; Wang 2010; Yang 2012; Yildiz 2013; Yuill 2005; Zelic 2012

Six studies from this Cochrane review were not included for analysis as they included populations or interventions not suitable for this review :

Breuer 2006 – cardiac surgery Jarvela 2008 - cardiac surgery Lauwick 2009 - comparison with water only Perrone 2011 - comparison with water only Rapp-Kasek 2007 – cardiac surgery Tran 2013 – cardiac surgery Overall risk of bias - low risk of bias, Study eligibility criteria - low concern, Identification and selection of Risk of bias assessment studies - low concern, Data collection and study appraisal - low concern, Synthesis and findings - low concern

| Study                            |
|----------------------------------|
| Study type                       |
| Number of studies (nu            |
| Countries and setting            |
| Line of therapy                  |
| Duration of study                |
| Method of assessmen<br>condition |
| Stratum                          |
| Subgroup analysis wit            |
| Inclusion criteria               |
| Exclusion criteria               |
| Recruitment/selection            |
| Age, gender and ethn             |
| Further population det           |
|                                  |

| Study                                       | Wang 2010 <sup>107</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel) – Included in Smith 2014 <sup>102</sup>  |
| Number of studies (number of participants)  | (n=48)  |
| Countries and setting                       | Conducted in China; Setting: Departments of general surgery at Medical University Hospitals in China  |
| Line of therapy                             | Unclear   |
| Duration of study                           | Intervention + follow up:   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Overall   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients undergoing elective open colorectal cancer resection surgery   |
| Exclusion criteria                          | Diabetes Mellitus or impaired glucose tolerance, medication affecting insulin sensitivity, weight loss greater than 10 per cent during the previous 6 months, presence of distant metastasis on CT, renal insufficiency, hepatic insufficiency, GORD, gastrointestinal obstruction or conditions known to affect gastric emptying rate and age more than 75 or less than 25 years   |
| Recruitment/selection of patients           | Patients undergoing elective open colorectal cancer resection surgery   |
| Age, gender and ethnicity                   | Age - Median (range): CHO 66 (48 - 74); Fasting 63 (37 - 74);. Gender (M:F): 28/20.   |
| Further population details                  | 1. Age: >60 years (CHO 66 (48 - 74); Fasting 63 (37 - 74);). 2. People with diabetes: Non-diabetic  |
| Indirectness of population                  | -   |
| Interventions                               | <ul> <li>(n=18) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group consumed 400ml Nutricia PreOp (12.5% carbohydrate, 0.5kcal/ml, 240mOsm/kg, pH 4 - 9, Nutricia Zoetermeer, Netherlands) 3h before induction of anesthesia completing CHO ingestion within 1h. Patients were nil by mouth after 2100 hours apart from single morning dose of 400ml carbohydrate drink. Duration perioperative. Concurrent medication/care: Oral bowel preparation with polyethylene glycol electrolyte solution administered to all patients. All patients received a low residue liquid diet freely before 2100 hours on the day before surgery.</li> </ul> |
|   | (n=17) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients were fasted from midnight before surgery. Duration perioperative. Concurrent medication/care: Oral bowel preparation with polyethylene glycol electrolyte solution administered to all patients. All patients received a low residue liquid diet freely before 2100 hours on the day before surgery.   |
| Funding                                     | Funding not stated  |
|   |   |

#### RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO versus FASTING

Protocol outcome 1: Quality of life

- Actual outcome: Anxiety at 1 hour preoperative; Median (range): CHO: 22 (11-47); Fasting: 28 (16-61) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

#### Protocol outcome 2: Adverse events and complications

- Actual outcome: Nausea at 1 hour preoperative; Median (range): CHO: 8 (4-11); Fasting: 8 (2-14) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

- Actual outcome: Tiredness at 1 hour preoperative; Median (range): CHO: 20 (11-60); Fasting: 23(10-53) VAs 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

#### Protocol outcome 3: Thirst

- Actual outcome: Thirst at 1 hour preoperative; Median (range) : CHO: 20 (8-59); Fasting: 24 (19-60) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2, Reason: complications found during surgery; Group 2 Number missing: 1, Reason: complications found during surgery

| Protocol outcomes not reported by the | Mortality; Patient, family and carer experience of care; Unplanned ICU admission; Headache; |
|---------------------------------------|---|
| study                                 | Cancellation of surgery   |

| Study                                       | Yagmurdur 2011 <sup>110</sup>  |
|---|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |
| Number of studies (number of participants)  | (n=44)   |
| Countries and setting                       | Conducted in Turkey; Setting: The Ministry of Health Ankara Research and Training Hospital, Ankara, Turkey.  |
| Line of therapy                             | Not applicable   |
| Duration of study                           | Intervention + follow up:  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |
| Stratum                                     | Overall  |
| Subgroup analysis within study              | Not applicable   |
| Inclusion criteria                          | Patients ASA classes I-II adult patients scheduled for elective inguinal hernia repair surgery under spinal anesthesia   |
| Exclusion criteria                          | not specified  |
| Recruitment/selection of patients           | scheduled for elective inguinal hernia repair surgery under spinal anesthesia  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 45 (7); Fasting: 43 (8). Gender (M:F): 26/18.  |
| Further population details                  | 1. Age: <60 years (CHO: 45 (7); Fasting: 43 (8)). 2. People with diabetes: Not stated / Unclear  |
| Indirectness of population                  |  |
| Interventions                               | <ul> <li>(n=22) Intervention 1: Combination of food and fluid restrictions - To be reported. During the evening before surgery, patients in the CHO group ingested 800 mL of an iso-osmolar carbohydrate-rich drink [12.5% carbohydrates (glucose: 0.2 g, maltose: 0.7 g, polysaccharides: 10 g), 50 kcal/100 ml, 290 mOsm/kg, pH 5.0; Nutricia Preop ; Numico, Zoetermeer, The Netherlands]. Nothing per os was allowed from midnight except another 400 mL of CHO in the morning at least 90 minutes before spinal anesthesia in the CHO group Duration preoperative. Concurrent medication/care: spinal anesthesia</li> <li>(n=22) Intervention 2: Combination of food and fluid restrictions - To be reported. The patients in the control group underwent spinal anesthesia after the routine fast from midnight Duration preoperative. Concurrent</li> </ul> |
| Funding                                     | medication/care: spinal anesthesia<br>Funding not stated   |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CHO DRINK versus FASTING

Protocol outcome 1: Thirst

- Actual outcome: Thirst at 90 minutes post ingestion of CHO drink; median (IQR): CHO: 20 (16-24); Fasting: 60 (56-64) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Thirst at 60 minutes post anesthesia; median (IQR): CHO: 18 (13-23): Fasting: 64 (59-69) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Nausea at 90 minutes post ingestion of CHO drink; Median (IQR) : CHO: 10 (7-13); Fasting: 8 (4-12) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Nausea at 60 minutes post anesthesia; Median (IQR): CHO: 8 (4-12); Fasting: 9 (5-13) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

- Actual outcome: Anxiety at 90 minutes post ingestion of CHO drink; Median (IQR): CHO: 20 (18-22); Fasting: 48 (43-53) visual analgoue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at 60 minutes post anesthesia; Median (IQR): CHO: 43 (41-45); Fasting: 46 (44-48) visual analogue scale 0-100 Top=High is poor outcome;

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ;

| Protocol outcomes not reported by the | Quality of life ; Mortality ; Adverse events and complications ; Patient, family and carer experience of care |
|---------------------------------------|---|
| study                                 | ; Unplanned ICU admission ; Headache ; Cancellation of surgery  |

| tudies (number of p  |
|----------------------|
| d setting            |
| ру                   |
| tudy                 |
| sessment of guide    |
|                      |
|                      |
| alysis within study  |
| eria                 |
| teria                |
|                      |
| selection of patient |
| and ethnicity        |

| RCT (Patient randomised; Parallel) – Included in Smith 2014 <sup>102</sup>  |
|---|
| (n=35)  |
| Conducted in Netherlands; Setting: Royal infirmary of Edinburgh   |
| Unclear   |
| Intervention + follow up:   |
| Adequate method of assessment/diagnosis   |
| Overall   |
| Not applicable  |
| Patients undergoing elective abdominal surgery  |
| Existing impaired renal function, liver cirrhosis, diabetes, metabolic abnormalities, or gastric stasis / obstruction were excluded as were all patients undergoing emergency or laparoscopic procedures  |
| Patients undergoing elective abdominal surgery  |
| Age - Mean (SD): CHO: 52.1 (2.4); Fasting: 52.8 (2.5). Gender (M:F): 39/26.   |
| 1. Age: <60 years (CHO: 52.1 (2.4); Fasting: 52.8 (2.5)). 2. People with diabetes: Non-diabetic   |
|   |
| (n=34) Intervention 1: Combination of food and fluid restrictions - To be reported. Placebo drink (fluid and electrolytes; potassium; sodium; chloride; calcium; magnesium) of 800ml on the evening prior to surgery approximately 12 hours before anesthesia and a further 400ml 2 - 3 hours before the induction of anesthesia. It was stipulated that the 400ml drink on the morning of surgery should be consumed over 20 minutes Duration preoperative. Concurrent medication/care: NA   |
| (n=31) Intervention 2: Combination of food and fluid restrictions - To be reported. Carbohydrate drink (containing 12.6g carbohydrates 100ml with electrolytes, potassium, sodium, chloride, calcium and magnesium) of 800ml on the evening prior to surgery approximately 12 hours before anesthesia and a further 400ml 2 - 3 hours before the induction of anesthesia. It was stipulated that the 400ml drink on the morning of surgery should be consumed over 20 minutes Duration preoperative. Concurrent medication/care: NA |
| Study funded by industry (Study supported by Numico research, Wageningen, Netherlands)  |
|   |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PLACEBO versus CHO

Yuill 2005<sup>113</sup>

Study

Protocol outcome 1: Adverse events and complications

- Actual outcome: Length of stay at Perioperative period; Median (IQR) : CHO: 10 (6); Fasting: 8 (4) days );

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the study Quality of life ; Mortality ; Patient, family and carer experience of care ; Unplanned ICU admission ; Thirst ; Headache ; Cancellation of surgery

| Study                                       | Zhang 2019 <sup>115</sup>  |  |  |  |  |  |  |  |  |
|---|--|--|--|--|--|--|--|--|--|
| Study type                                  | RCT (Patient randomised; Parallel)   |  |  |  |  |  |  |  |  |
| Number of studies (number of participants)  | (n=58)   |  |  |  |  |  |  |  |  |
| Countries and setting                       | Conducted in China; Setting: First affiliated Hospital of Nanchang University, China   |  |  |  |  |  |  |  |  |
| Line of therapy                             | Not applicable   |  |  |  |  |  |  |  |  |
| Duration of study                           | Intervention + follow up:  |  |  |  |  |  |  |  |  |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis  |  |  |  |  |  |  |  |  |
| Stratum                                     | Overall  |  |  |  |  |  |  |  |  |
| Subgroup analysis within study              | Not applicable   |  |  |  |  |  |  |  |  |
| Inclusion criteria                          | Patients aged 18 – 55, ASA I – II scheduled to undergo elective open gynaecological surgery  |  |  |  |  |  |  |  |  |
| Exclusion criteria                          | Not specified  |  |  |  |  |  |  |  |  |
| Recruitment/selection of patients           | scheduled to undergo elective open gynaecological surgery  |  |  |  |  |  |  |  |  |
| Age, gender and ethnicity                   | Age - Mean (SD): CHO: 42.64 (5.26); Fasting: 43.57 (5.60). Gender (M:F): all female.   |  |  |  |  |  |  |  |  |
| Further population details                  | 1. Age: <60 years (CHO: 42.64 (5.26); Fasting: 43.57 (5.60)). 2. People with diabetes: Not stated / Unclear  |  |  |  |  |  |  |  |  |
| Indirectness of population                  | No indirectness  |  |  |  |  |  |  |  |  |
| Interventions                               | (n=29) Intervention 1: Combination of food and fluid restrictions - To be reported. Patients in the CHO group consumed CHO (12.5g of carbohydrate per 100ml, 285 mOsm/kg; Nutricia Preop, Nutricia, Zoetermeer, The Netherlands) in doses of 800ml on the evening before surgery (between 8pm and 10pm) and 400ml 2h before their scheduled operation. Duration preoperative . Concurrent medication/care: combined spinal epidural anesthesia for the procedure |  |  |  |  |  |  |  |  |
|   | (n=29) Intervention 2: Combination of food and fluid restrictions - To be reported. Patients in the fasting group were forbidden from eating anything after midnight before the induction of anaesthesia. Duration preoperative. Concurrent medication/care: combined spinal epidural anesthesia for the procedure. Indirectness: No indirectness  |  |  |  |  |  |  |  |  |
| Funding                                     | Funding not stated   |  |  |  |  |  |  |  |  |

Protocol outcome 1: Adverse events and complications

- Actual outcome: Nausea & vomiting at Postoperative; Group 1: 8/29, Group 2: 12/29; Comments: p value 0.2646

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Tiredness at 6h postoperative; median (range): CHO: 30 (20-40); Fasting: 30 (20-40) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Tiredness at 24h postoperative; median (range): CHO: 40 (30-40); Fasting: 30 (20-30) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety at Preoperative; median (range): CHO: 30 (30-30); Fasting: 60 (50-70) VAS 0-100 Top=High is poor outcome, Comments: p value <0.001;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 2: Patient, family and carer experience of care

- Actual outcome: Length of hospital stay at Postoperative; Group 1: mean 3.82 days (SD 0.67); n=29, Group 2: mean 4.36 days (SD 0.78); n=29; Comments: 0.0079

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 3: Thirst

- Actual outcome: Thirst at 6h postoperative; Median (range):: CHO: 20 (10-30); Fasting: 40 (20-55) VAS 0-100 Top=High is poor outcome, Comments: p value < 0.001;

Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Thirst at 24h postoperative; median (range): CHO: 30 (25-40); Fasting: 40 (20-50) VAS 0-100 Top=High is poor outcome; Risk of bias: All domain - High, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 4: Headache

- Actual outcome: Headache at Postoperative; Group 1: 3/29, Group 2: 9/29; Comments: P value 0.0507

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcomes not reported by the Quality of life ; Mortality ; Unplanned ICU admission ; Cancellation of surgery study

### Table 13: Risk of bias summary from Cochrane review

| Study: Smith 2014 <sup>102</sup>        |                  |
|---|------------------|
| Domain                                  | Outcome          |
| Study eligibility criteria              | Low concern      |
| Identification and selection of studies | Low concern      |
| Data collection and study appraisal     | Low concern      |
| Synthesis and findings                  | Low concern      |
| Overall risk of bias                    | Low risk of bias |

# **Appendix E: Forest plots**

## E.1 Carbohydrate drinks versus Fasting

#### Figure 2: Patient Satisfaction (0-10) (24 hours postoperative)

|  |      | сно     |        | Fa   | asting | 9     |        | Mean Difference   | Mean Difference                            |
|--|------|---------|--------|------|--------|-------|--------|-------------------|--|
| Study or Subgroup                                  | Mean | SD      | Total  | Mean | SD     | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI                          |
| Ajuzieogu 2016                                     | 8    | 0.75    | 29     | 6    | 0.5    | 29    | 100.0% | 2.00 [1.67, 2.33] |  |
| Total (95% CI)                                     |      |         | 29     |      |        | 29    | 100.0% | 2.00 [1.67, 2.33] | •  |
| Heterogeneity: Not app<br>Test for overall effect: |      | 95 (P < | 0.0000 | )1)  |        |       |        |                   | -2 -1 0 1 2<br>Favours Fasting Favours CHO |

#### Figure 3: Postoperative global QoR-40 score

|  |       | сно    |        | Fa    | sting | 9     |        | Mean Difference       |     | Mean D                 | ifference           |    |
|--|-------|--------|--------|-------|-------|-------|--------|-----------------------|-----|------------------------|---------------------|----|
| Study or Subgroup                                    | Mean  | SD     | Total  | Mean  | SD    | Total | Weight | IV, Fixed, 95% CI     |     | IV, Fixe               | d, 95% Cl           |    |
| Lee 2018   | 186.7 | 17.5   | 46     | 194.5 | 5.6   | 49    | 100.0% | -7.80 [-13.09, -2.51] |     |                        |                     |    |
| Total (95% CI)                                       |       |        | 46     |       |       | 49    | 100.0% | -7.80 [-13.09, -2.51] |     |                        |                     |    |
| Heterogeneity: Not app<br>Test for overall effect: 2 |       | (P = 0 | ).004) |       |       |       |        |                       | -20 | -10<br>Favours Fasting | 0 10<br>Favours CHO | 20 |

#### Figure 4: Length of hospital stay (days)

| -  |                              | phydrate      |                 | Fa                          | sting |          |                     | Mean Difference                          |      | Mean Difference                       |
|--|------------------------------|---------------|-----------------|-----------------------------|-------|----------|---------------------|--|------|---------------------------------------|
| Study or Subgroup  |                              |               | Total           |                             |       | Total    | Weight              | IV, Random, 95% CI [days]                | Year | IV, Random, 95% CI [days]             |
| 2.3.1 Major abdomina   |                              |               |                 |                             |       |          |                     |  |      |                                       |
| Voblett 2006   | 7.5                          | 2.81          | 12              | 10                          | 2.74  | 12       | 1.8%                | -2.50 [-4.72, -0.28]                     | 2006 | <b>←</b>                              |
| An 2008  | 11                           | 1.2           | 27              | 15.1                        | 3.8   | 24       | 3.2%                | -4.10 [-5.69, -2.51]                     |      | •                                     |
| <aska 2010<="" td=""><td>11</td><td>2.22</td><td>74</td><td>11</td><td>2.96</td><td>75</td><td>7.8%</td><td>0.00 [-0.84, 0.84]</td><td>2010</td><td></td></aska> | 11                           | 2.22          | 74              | 11                          | 2.96  | 75       | 7.8%                | 0.00 [-0.84, 0.84]                       | 2010 |                                       |
| Ozdemir 2011   | 3.86                         | 2.17          | 15              | 3.39                        | 1.795 | 15       | 3.8%                | 0.47 [-0.96, 1.90]                       | 2011 |                                       |
| Pexe-Machado 2013  | 8.1                          | 3.82          | 10              | 15.6                        | 8.72  | 12       | 0.3%                | -7.50 [-12.97, -2.03]                    | 2013 | •                                     |
| Zhang 2019   | 3.82                         | 0.67          | 29              | 4.36                        | 0.78  | 29       | 14.4%               | -0.54 [-0.91, -0.17]                     | 2019 |                                       |
| Subtotal (95% CI)  |                              |               | 167             |                             |       | 167      | 31.3%               | -1.43 [-2.68, -0.18]                     |      |                                       |
| Heterogeneity: Tau² = *<br>Fest for overall effect: 2  |                              |               | < 0.00          | 001); I² = 84%              |       |          |                     |  |      |                                       |
| .3.2 Intermediate Ab   | dominal Surge                | ry -          |                 |                             |       |          |                     |  |      |                                       |
| _ee 2018<br>Subtotal (95% CI)  | 2.59                         | 1.61          | 46<br><b>46</b> | 2.38                        | 2.05  | 51<br>51 | 9.1%<br><b>9.1%</b> | 0.21 [-0.52, 0.94]<br>0.21 [-0.52, 0.94] | 2018 |                                       |
| Heterogeneity: Not app   | olicable                     |               |                 |                             |       |          |                     |  |      |                                       |
| est for overall effect: 2  |                              | 57)           |                 |                             |       |          |                     |  |      |                                       |
| 2.3.3 Minor abdomina   | l surgery                    |               |                 |                             |       |          |                     |  |      |                                       |
| Hausel 2005  | 1.2                          | 0.7           | 55              | 1.3                         | 0.9   | 58       | 15.6%               | -0.10 [-0.40, 0.20]                      | 2005 |                                       |
| zdemir 2011  | 0.96                         | 0.085         | 15              | 1.09                        | 0.277 | 15       | 17.5%               | -0.13 [-0.28, 0.02]                      | 2011 |                                       |
| 'ildiz 2013  | 1                            | 0.32          | 30              | 1                           | 0.32  | 30       | 17.4%               | 0.00 [-0.16, 0.16]                       | 2013 |                                       |
| Subtotal (95% CI)  |                              |               | 100             |                             |       | 103      | 50.5%               | -0.07 [-0.18, 0.03]                      |      | ◆                                     |
| Heterogeneity: Tau <sup>2</sup> = 1<br>Test for overall effect: 2  |                              |               | = 0.50);        | I <sup>2</sup> = 0%         |       |          |                     |  |      |                                       |
| 2.3.4 Orthopaedic sur  | gery                         |               |                 |                             |       |          |                     |  |      |                                       |
| _junggren 2012   | 5                            | 0.74          | 19              | 6                           | 1.48  | 20       | 9.1%                | -1.00 [-1.73, -0.27]                     | 2012 | <b>←</b>                              |
| Subtotal (95% CI)  |                              |               | 19              |                             |       | 20       | 9.1%                | -1.00 [-1.73, -0.27]                     |      |                                       |
| leterogeneity: Not app<br>est for overall effect: 2  |                              | 1071          |                 |                             |       |          |                     |  |      |                                       |
| contor overall effect. 2   | - 2.00 () - 0.0              |               |                 |                             |       |          |                     |  |      |                                       |
| Fotal (95% CI)   |                              |               | 332             |                             |       | 341      | 100.0%              | -0.37 [-0.68, -0.06]                     |      |                                       |
| Heterogeneity: Tau <sup>2</sup> = I  | 0.14; Chi <sup>2</sup> = 49. | 60. df = 10 ( | P < 0.0         | 0001); I <sup>2</sup> = 80% |       |          |                     |  |      |                                       |
| est for overall effect: 2  |                              |               |                 |                             |       |          |                     |  |      | -0.5 -0.25 0 0.25 0.5                 |
|  |                              |               |                 | 01), I <sup>2</sup> = 73.0% |       |          |                     |  |      | Favours carbohydrates Favours fasting |

#### Figure 5: Thirst (0-10) (preoperative)

|   | 0    | сно    |       | Fa   | sting | 9     |        | Mean Difference    | Mean Difference                            |
|---|------|--------|-------|------|-------|-------|--------|--------------------|--|
| Study or Subgroup                                 | Mean | SD     | Total | Mean | SD    | Total | Weight | IV, Fixed, 95% CI  | IV, Fixed, 95% CI                          |
| Raksakietisak 2014                                | 2.4  | 2.4    | 48    | 2.2  | 2.2   | 50    | 100.0% | 0.20 [-0.71, 1.11] |  |
| Total (95% CI)                                    |      |        | 48    |      |       | 50    | 100.0% | 0.20 [-0.71, 1.11] |  |
| Heterogeneity: Not ap<br>Test for overall effect: |      | 6 (P = | 0.67) |      |       |       |        | -                  | -2 -1 0 1 2<br>Favours CHO Favours Fasting |

#### Figure 6: Thirst (0-10) (postoperative)

|   |      | сно     |        | Fa   | sting | 9     |        | Mean Difference      | Mean Difference                            |
|---|------|---------|--------|------|-------|-------|--------|----------------------|--|
| Study or Subgroup                                 | Mean | SD      | Total  | Mean | SD    | Total | Weight | IV, Fixed, 95% CI    | IV, Fixed, 95% CI                          |
| Onalan 2018                                       | 0.64 | 0.91    | 25     | 7.8  | 2.5   | 25    | 100.0% | -7.16 [-8.20, -6.12] |  |
| Total (95% CI)                                    |      |         | 25     |      |       | 25    | 100.0% | -7.16 [-8.20, -6.12] | ◆  |
| Heterogeneity: Not ap<br>Test for overall effect: |      | l6 (P < | 0.0000 | )1)  |       |       |        |                      | -4 -2 0 2 4<br>Favours CHO Favours Fasting |

#### Figure 7: Thirst (mild)

| 0  | •      | ,       |        |       |        |                    |   |
|--|--------|---------|--------|-------|--------|--------------------|---|
|  | CHC    | )       | Fastir | ng    |        | Risk Ratio         | Risk Ratio  |
| Study or Subgroup                                  | Events | Total   | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI                                  |
| Canbay 2014  | 6      | 25      | 13     | 25    | 100.0% | 0.46 [0.21, 1.02]  |   |
| Total (95% CI)                                     |        | 25      |        | 25    | 100.0% | 0.46 [0.21, 1.02]  |   |
| Total events                                       | 6      |         | 13     |       |        |                    |   |
| Heterogeneity: Not app<br>Test for overall effect: |        | P = 0.0 | 6)     |       |        |                    | 0.1 0.2 0.5 1 2 5 10<br>Favours CHO Favours Fasting |

#### Figure 8: Thirst (moderate)

| _   | СНС    | )       | Fasti  | ng    |        | Risk Ratio         | Risk Ratio                            |
|---|--------|---------|--------|-------|--------|--------------------|---------------------------------------|
| Study or Subgroup                                 | Events | Total   | Events | Total | Weight | M-H, Fixed, 95% Cl | M-H, Fixed, 95% Cl                    |
| Canbay 2014                                       | 0      | 25      | 5      | 25    | 100.0% | 0.09 [0.01, 1.56]  |                                       |
| Total (95% CI)                                    |        | 25      |        | 25    | 100.0% | 0.09 [0.01, 1.56]  |                                       |
| Total events                                      | 0      |         | 5      |       |        |                    |                                       |
| Heterogeneity: Not ap<br>Test for overall effect: |        | P = 0.1 | 0)     |       |        |                    | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |

#### Figure 9: Headache (postoperative)

| -   | CHC    | )       | Fasti  | ng    |        | Risk Ratio         | Risk Ratio                                       |
|---|--------|---------|--------|-------|--------|--------------------|--|
| Study or Subgroup                                 | Events | Total   | Events | Total | Weight | M-H, Fixed, 95% Cl | M-H, Fixed, 95% CI                               |
| Zhang 2019  | 3      | 29      | 9      | 29    | 100.0% | 0.33 [0.10, 1.11]  |  |
| Total (95% CI)                                    |        | 29      |        | 29    | 100.0% | 0.33 [0.10, 1.11]  |  |
| Total events                                      | 3      |         | 9      |       |        |                    |  |
| Heterogeneity: Not ap<br>Test for overall effect: |        | P = 0.0 | 7)     |       |        |                    | 0.01 0.1 1 10 100<br>Favours CHO Favours Fasting |

| Figure 10:                        | Comp                     |           |             |        |        |                     |      |  |
|-----------------------------------|--------------------------|-----------|-------------|--------|--------|---------------------|------|--|
|                                   | Carbohy                  | drate     | Fastir      | ıg     |        | Risk Ratio          |      | Risk Ratio   |
| Study or Subgroup                 | Events                   | Total     | Events      | Total  | Weight | M-H, Random, 95% CI | Year | M-H, Random, 95% Cl                                    |
| Hausel 2005                       | 0                        | 55        | 0           | 58     |        | Not estimable       | 2005 |  |
| Noblett 2006                      | 2                        | 12        | 1           | 12     | 6.6%   | 2.00 [0.21, 19.23]  | 2006 |  |
| Kaska 2010                        | 7                        | 74        | 11          | 75     | 42.4%  | 0.64 [0.26, 1.57]   | 2010 |  |
| Zelic 2012                        | 4                        | 20        | 3           | 20     | 18.1%  | 1.33 [0.34, 5.21]   | 2012 |  |
| Pexe-Machado 2013                 | 5                        | 10        | 4           | 12     | 32.9%  | 1.50 [0.55, 4.13]   | 2013 |  |
| Total (95% CI)                    |                          | 171       |             | 177    | 100.0% | 1.05 [0.59, 1.87]   |      |  |
| Total events                      | 18                       |           | 19          |        |        |                     |      |  |
| Heterogeneity: Tau <sup>2</sup> = | 0.00; Chi <sup>2</sup> = | : 2.08, c | lf = 3 (P = | 0.56); | I²=0%  |                     |      |  |
| Test for overall effect:          | Z = 0.15 (P              | = 0.88)   |             |        |        |                     |      | 0.2 0.5 1 2 5<br>Favours carbohydrates Favours fasting |

#### Figure 11: Well-being (postoperative)

| Carb     | ohydra                        | ate  | Fa                               | asting  |  |   | Std. Mean Difference   |  | Std. Mean Difference   |  |  |
|----------|-------------------------------|--|----------------------------------|---|--|---|--|--|--|--|--|
| Mean     | SD                            | Total  | Mean                             | SD  | Total  | Weight  | IV, Random, 95% CI   | Year   | IV, Random, 95% CI   |  |  |
| 2.97     | 3.16                          | 32   | 3.4                              | 3.33  | 16   | 52.4%   | -0.13 [-0.73, 0.47]  | 2003   |  |  |  |
| 26       | 5.19                          | 19   | 25                               | 3.7   | 20   | 47.6%   | 0.22 [-0.41, 0.85]   | 2012   |  |  |  |
|          |                               | 51   |                                  |   | 36   | 100.0%  | 0.04 [-0.40, 0.47]   |  |  |  |  |
| 0.00; C  | hi² = 0.                      | 62, df=  | = 1 (P =                         | 0.43);  | I² = 0%  |   |  |  |  |  |  |
| Z = 0.16 | i (P = 0                      | .87)   |                                  |   |  |   |  |  | Favours fasting Favours carbohydrates  |  |  |
|          | Mean<br>2.97<br>26<br>0.00; C | <u>Mean</u> <u>SD</u><br>2.97 3.16<br>26 5.19<br>0.00; Chi <sup>z</sup> = 0. | 2.97 3.16 32<br>26 5.19 19<br>51 | Mean         SD         Total         Mean           2.97         3.16         32         3.4           26         5.19         19         25           51           0.00; Chi² = 0.62; df = 1 (P = | Mean         SD         Total         Mean         SD           2.97         3.16         32         3.4         3.33           26         5.19         19         25         3.7           51           0.00; Chi <sup>a</sup> = 0.62; df = 1 (P = 0.43); | Mean         SD         Total         Mean         SD         Total           2.97         3.16         32         3.4         3.33         16           26         5.19         19         25         3.7         20           51         36           0.00; Chi <sup>2</sup> = 0.62; df = 1 (P = 0.43); l <sup>2</sup> = 0%         36         36 | Mean         SD         Total         Mean         SD         Total         Weight           2.97         3.16         32         3.4         3.33         16         52.4%           26         5.19         19         25         3.7         20         47.6%           51         36         100.0%           0.00; Chi² = 0.62, df = 1 (P = 0.43); l² = 0%         54         56         56 | Mean         SD         Total         Mean         SD         Total         Weight         IV, Random, 95% CI           2.97         3.16         32         3.4         3.33         16         52.4%         -0.13 [-0.73, 0.47]           26         5.19         19         25         3.7         20         47.6%         0.22 [-0.41, 0.85]           51         36         100.0%         0.04 [-0.40, 0.47]         0.00; Chi <sup>2</sup> = 0.62, df = 1 (P = 0.43); l <sup>2</sup> = 0%         100.0%         0.04 [-0.40, 0.47] | Mean         SD         Total         Mean         SD         Total         Weight         IV, Random, 95% CI         Year           2.97         3.16         32         3.4         3.33         16         52.4%         -0.13 [-0.73, 0.47]         2003           26         5.19         19         25         3.7         20         47.6%         0.22 [-0.41, 0.85]         2012           51         36         100.0%         0.04 [-0.40, 0.47]         0.00 [-0.40, 0.47]         0.00 [-0.40, 0.47]           0.00; Chi² = 0.62, df = 1 (P = 0.43); P = 0%         - |  |  |


#### Figure 12: Nausea & Vomiting (0-10) (postoperative)

|   | 0    | сно    |       | Fa   | asting |       |        | Mean Difference     | Mean Difference   |
|---|------|--------|-------|------|--------|-------|--------|---------------------|-------------------|
| Study or Subgroup                                 | Mean | SD     | Total | Mean | SD     | Total | Weight | IV, Fixed, 95% CI   | IV, Fixed, 95% CI |
| Ajuzieogu 2016                                    | 5.75 | 2      | 29    | 6.5  | 1.24   | 29    | 100.0% | -0.75 [-1.61, 0.11] |                   |
| Total (95% CI)                                    |      |        | 29    |      |        | 29    | 100.0% | -0.75 [-1.61, 0.11] |                   |
| Heterogeneity: Not ap<br>Test for overall effect: |      | ? (P = | 0.09) |      |        |       |        |                     |                   |

#### Figure 13: Nausea & Vomiting

|   | CHO          | )               | Fastir                  | ng              |                          | Risk Ratio   |          | Risk Ratio                 |     |
|---|--------------|-----------------|-------------------------|-----------------|--------------------------|--|----------|----------------------------|-----|
| Study or Subgroup   | Events       | Total           | Events                  | Total           | Weight                   | M-H, Fixed, 95% C                                      |          | M-H, Fixed, 95% Cl         |     |
| 2.12.1 Nausea & Von   | niting       |                 |                         |                 |                          |  |          |                            |     |
| Celiksular 2016   | 2            | 40              | 1                       | 40              | 7.7%                     | 2.00 [0.19, 21.18]                                     |          |                            | -   |
| Zhang 2019<br>Subtotal (95% CI)                                   | 8            | 29<br><b>69</b> | 12                      | 29<br><b>69</b> | 92.3%<br>1 <b>00.0%</b>  | 0.67 [0.32, 1.39]<br><b>0.77 [0.38</b> , 1 <b>.54]</b> |          |                            |     |
| Total events  | 10           |                 | 13                      |                 |                          |  |          |                            |     |
| Heterogeneity: Chi <sup>2</sup> =                                 | 0.78, df = 1 | 1 (P = 0        | 0.38); l <sup>2</sup> = | 0%              |                          |  |          |                            |     |
| Test for overall effect:  | Z = 0.74 (F  | P = 0.4         | 6)                      |                 |                          |  |          |                            |     |
| 2.12.2 Nausea   |              |                 |                         |                 |                          |  |          |                            |     |
| Raksakietisak 2014<br>Subtotal (95% CI)                           | 9            | 48<br>48        | 10                      | 50<br><b>50</b> | 100.0%<br>1 <b>00.0%</b> | 0.94 [0.42, 2.10]<br><b>0.94 [0.42, 2.10]</b>          |          |                            |     |
| Total events<br>Heterogeneity: Not ap<br>Test for overall effect: |              | o _ o o         | 10<br>e)                |                 |                          |  |          |                            |     |
| resciol overall effect.   | 2 = 0.10 (r  | - 0.0           | 0)                      |                 |                          |  |          |                            |     |
| 2.12.3 Vomiting   |              |                 |                         |                 |                          |  |          |                            |     |
| Faria 2009  | 3            | 11              | 7                       | 10              | 31.9%                    | 0.39 [0.14, 1.11]                                      |          |                            |     |
| Hausel 2005   | 3            | 55              | 4                       | 58              | 16.9%                    | 0.79 [0.19, 3.37]                                      |          |                            |     |
| Raksakietisak 2014<br>Subtotal (95% CI)                           | 8            | 48<br>114       | 12                      | 50<br>118       | 51.1%<br>1 <b>00.0%</b>  | 0.69 [0.31, 1.55]<br><b>0.61 [0.34</b> , <b>1.10]</b>  |          | •                          |     |
| Total events  | 14           |                 | 23                      |                 |                          |  |          |                            |     |
| Heterogeneity: Chi <sup>2</sup> =                                 | 0.93, df = 2 | 2 (P = 0        | 0.63); l <sup>2</sup> = | 0%              |                          |  |          |                            |     |
| Test for overall effect:  | Z = 1.64 (F  | P = 0.1         | 0)                      |                 |                          |  |          |                            |     |
|   |              |                 |                         |                 |                          |  | <b> </b> |                            |     |
|   |              |                 |                         |                 |                          |  | 0.01     | 0.1 1 10                   | 100 |
| Test for subaroup diffe   | erences: Ch  | $ni^2 = 0$      | 73 df = 2               | (P = 0)         | 69) I <sup>2</sup> - 0   | %  |          | Favours CHO Favours Fastin | g   |

Test for subgroup differences:  $Chi^2 = 0.73$ , df = 2 (P = 0.69), I<sup>2</sup> = 0%



Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

## E.2 Carbohydrate drinks versus placebo drinks

#### Figure 17: Length of hospital stay (days)

|  | Carbo  | ohydrate  |   | Pla                                 | cebo      |                      |                       | Mean Difference   |      | Mean Difference                                    |
|--|--|---|---|-------------------------------------|-----------|----------------------|-----------------------|---|------|--|
| Study or Subgroup  |  | SD [days]   | Total   | Mean [days]                         | SD [days] | Total                | Weight                | IV, Random, 95% CI [days]                                 | Year | IV, Random, 95% CI [days]                          |
| 3.1.1 Major abdomina   | al surgery   |   |   |                                     |           |                      |                       |   |      |  |
| Yuill 2005   | 8  | 2.96  | 31  | 10                                  | 4.44      | 34                   | 0.9%                  | -2.00 [-3.82, -0.18]                                      | 2005 |  |
| Mathur 2010  | 8.68   | 6.68  | 69  | 9.93                                | 11.89     | 73                   | 0.3%                  | -1.25 [-4.40, 1.90]                                       | 2010 | •  |
| Ozdemir 2011   | 3.86   | 2.17  | 15  | 2.78                                | 1.27      | 15                   | 1.8%                  | 1.08 [-0.19, 2.35]  | 2011 |  |
| Braga 2012   | 14.2   | 3.145   | 18  | 14.3                                | 4.44      | 18                   | 0.5%                  | -0.10 [-2.61, 2.41]                                       | 2012 |  |
| Yang 2012  | 9.7  | 13.72   | 24  | 10.2                                | 18.13     | 24                   | 0.0%                  | -0.50 [-9.60, 8.60]                                       | 2012 | •  |
| Lidder 2013  | 7  | 3.477   | 59  | 8.25                                | 4.906     | 61                   | 1.3%                  | -1.25 [-2.77, 0.27]                                       | 2013 |  |
| Subtotal (95% CI)  |  |   | 216   |                                     |           | 225                  | 4.8%                  | -0.59 [-1.82, 0.64]                                       |      |  |
| Heterogeneity: Tau <sup>2</sup> =  | : 1.02; Chi <b>≃</b> = 9.7   | 70, df = 5 (P   | = 0.08  | ); I² = 48%                         |           |                      |                       |   |      |  |
| Test for overall effect:   | Z = 0.94 (P = 0.   | .35)  |   |                                     |           |                      |                       |   |      |  |
| 3.1.2 Minor abdomina   | 2 3  |   |   |                                     |           |                      |                       |   |      |  |
| Hausel 2005  | 1.2  | 0.7   | 55  | 1.2                                 | 0.6       | 59                   |                       | 0.00 [-0.24, 0.24]  |      | <u>+</u>   |
| Ozdemir 2011   | 0.96   | 0.085   | 15  | 1.02                                | 0.115     | 15                   |                       | -0.06 [-0.13, 0.01]                                       | 2011 | 4  |
| Subtotal (95% CI)  |  |   | 70  |                                     |           | 74                   | 81.8%                 | -0.06 [-0.12, 0.01]                                       |      | •  |
| Heterogeneity: Tau² =  |  |   | = 0.64)                                       | r; I² = 0%                          |           |                      |                       |   |      |  |
| Test for overall effect:   | Z = 1.56 (P = 0.   | .12)  |   |                                     |           |                      |                       |   |      |  |
|  |  |   |   |                                     |           |                      |                       |   |      |  |
| 3.1.3 Orthopaedic su   | irgery   |   |   |                                     |           |                      |                       |   |      |  |
|  | irgery<br>5.5  | 1.41  | 8   | 5.1                                 | 1.85      | 7                    | 1.0%                  | 0.40 [-1.28, 2.08]  | 2001 |  |
| Boop 2001  |  | 1.41<br>0   | 8<br>8  | 5.1<br>6                            | 1.85<br>0 | 7<br>6               | 1.0%                  | 0.40 [-1.28, 2.08]<br>Not estimable                       |      | <u> </u>   |
| Soop 2001<br>Soop 2004<br>Harsten 2012   | 5.5  |   | 8<br>30                                       |                                     |           | 6<br>30              | 12.4%                 | Not estimable<br>0.08 (-0.36, 0.52)                       | 2004 |  |
| Soop 2001<br>Soop 2004<br>Harsten 2012<br>Subtotal (95% CI)  | 5.5<br>5<br>3.33   | 0<br>0.71   | 8<br>30<br><b>46</b>                          | 6<br>3.25                           | 0         | 6                    |                       | Not estimable   | 2004 |  |
| Boop 2001<br>Boop 2004<br>Harsten 2012<br>Subtotal (95% CI)  | 5.5<br>5<br>3.33   | 0<br>0.71   | 8<br>30<br><b>46</b>                          | 6<br>3.25                           | 0         | 6<br>30              | 12.4%                 | Not estimable<br>0.08 (-0.36, 0.52)                       | 2004 | •  |
| Soop 2001<br>Soop 2004<br>Harsten 2012<br>Subtotal (95% CI)<br>Heterogeneity: Tau <sup>2</sup> =   | 5.5<br>5<br>3.33<br>= 0.00; Chi <sup>2</sup> = 0.1   | 0<br>0.71<br>13, df= 1 (P                             | 8<br>30<br><b>46</b>                          | 6<br>3.25                           | 0         | 6<br>30              | 12.4%                 | Not estimable<br>0.08 (-0.36, 0.52)                       | 2004 | •  |
| 3.1.3 Orthopaedic su<br>Soop 2001<br>Soop 2004<br>Harsten 2012<br>Subtotal (95% CI)<br>Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect:<br>Total (95% CI) | 5.5<br>5<br>3.33<br>= 0.00; Chi <sup>2</sup> = 0.1   | 0<br>0.71<br>13, df= 1 (P                             | 8<br>30<br><b>46</b>                          | 6<br>3.25                           | 0         | 6<br>30<br><b>43</b> | 12.4%                 | Not estimable<br>0.08 (-0.36, 0.52)                       | 2004 | •  |
| Soop 2001<br>Soop 2004<br>Harsten 2012<br>Subtotal (95% CI)<br>Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect:<br>Total (95% CI)                         | 5.5<br>5<br>3.33<br>= 0.00; Chi <sup>a</sup> = 0. <sup>4</sup><br>: Z = 0.46 (P = 0.                     | 0<br>0.71<br>13, df = 1 (P<br>.64)                    | 8<br>30<br><b>46</b><br>= 0.72)<br><b>332</b> | 6<br>3.25<br>); I <sup>z</sup> = 0% | 0         | 6<br>30<br><b>43</b> | 12.4%<br><b>13.4%</b> | Not estimable<br>0.08 [-0.36, 0.52]<br>0.10 [-0.32, 0.53] | 2004 |  |
| Soop 2001<br>Soop 2004<br>Harsten 2012<br>Subtotal (95% CI)<br>Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect:   | 5.5<br>5<br>3.33<br>= 0.00; Chi <sup>a</sup> = 0.<br>: Z = 0.46 (P = 0.<br>= 0.01; Chi <sup>a</sup> = 11 | 0<br>0.71<br>13, df = 1 (P<br>.64)<br>1.25, df = 9 () | 8<br>30<br><b>46</b><br>= 0.72)<br><b>332</b> | 6<br>3.25<br>); I <sup>z</sup> = 0% | 0         | 6<br>30<br><b>43</b> | 12.4%<br><b>13.4%</b> | Not estimable<br>0.08 [-0.36, 0.52]<br>0.10 [-0.32, 0.53] | 2004 | -4 -2 0 2<br>Favours carbohydrates Favours placebu |

#### Figure 18: Complication rate

|                                   | Carbohy                  | drate     | Place       | bo     |                     | Risk Ratio             | Risk Ratio  |
|-----------------------------------|--------------------------|-----------|-------------|--------|---------------------|------------------------|---|
| Study or Subgroup                 | Events                   | Total     | Events      | Total  | Weight              | M-H, Random, 95% CI Ye | ear M-H, Random, 95% Cl                                       |
| Soop 2001                         | 1                        | 8         | 0           | 7      | 0.6%                | 2.67 [0.13, 56.63] 200 | 01  |
| Soop 2004                         | 0                        | 8         | 0           | 6      |                     | Not estimable 200      | 04  |
| Hausel 2005                       | 0                        | 55        | 0           | 59     |                     | Not estimable 200      | 05  |
| Yuill 2005                        | 6                        | 31        | 6           | 34     | 5.3%                | 1.10 [0.39, 3.05] 20   | 05  |
| Mathur 2010                       | 23                       | 69        | 30          | 73     | 29.4%               | 0.81 [0.53, 1.25] 20   | 10  |
| Braga 2012                        | 13                       | 18        | 12          | 18     | 29.1%               | 1.08 [0.70, 1.67] 20   | 12  |
| Yang 2012                         | 5                        | 24        | 5           | 24     | 4.5%                | 1.00 [0.33, 3.01] 20   | 12  |
| Lidder 2013                       | 23                       | 59        | 28          | 61     | 31.2%               | 0.85 [0.56, 1.29] 20   | 13  |
| Total (95% CI)                    |                          | 272       |             | 282    | 100.0%              | 0.92 [0.73, 1.17]      | •   |
| Total events                      | 71                       |           | 81          |        |                     |                        |   |
| Heterogeneity: Tau <sup>2</sup> = | 0.00; Chi <sup>2</sup> : | = 1.63, d | lf = 5 (P = | 0.90); | l <sup>2</sup> = 0% |                        |   |
| Test for overall effect:          | Z = 0.66 (P              | = 0.51)   |             |        |                     |                        | 0.1 0.2 0.5 1 2 5 10<br>Favours carbohydrates Favours placebo |

#### Figure 19: Fatigue (postoperative)

|   | Carb     | ohydr  | ate   | Pl       | acebo |                 | ;      | Std. Mean Difference    | Std. Mean Difference                  |
|---|----------|--------|-------|----------|-------|-----------------|--------|-------------------------|---------------------------------------|
| Study or Subgroup   | Mean     | SD     | Total | Mean     | SD    | Total           | Weight | IV, Random, 95% CI Year | IV, Random, 95% CI                    |
| Bisgaard 2004   | 6        | 2.25   | 43    | 6        | 2     | 43              | 33.9%  | 0.00 [-0.42, 0.42] 2004 |                                       |
| Mathur 2010   | 44.6     | 28.3   | 58    | 43.4     | 30.6  | 64              | 36.4%  | 0.04 [-0.31, 0.40] 2010 | <b>_</b>                              |
| Harsten 2012  | 39       | 25     | 30    | 15       | 28    | 30              | 29.7%  | 0.89 [0.36, 1.42] 2012  | <b>_</b>                              |
| Total (95% CI)  |          |        | 131   |          |       | 137             | 100.0% | 0.28 [-0.22, 0.78]      |                                       |
| Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect: |          |        |       | 2 (P = 0 |       | -1 -0.5 0 0.5 1 |        |                         |                                       |
| rest for overall effect.                                      | 2 = 1.09 | (F = 0 | .20)  |          |       |                 |        |                         | Favours carbohydrates Favours placebo |

#### Figure 20: Well-being (postoperative)

| <b>U</b>                          |          |           | ••••     |          |        |         | ,      |                          |  |
|-----------------------------------|----------|-----------|----------|----------|--------|---------|--------|--------------------------|--|
|                                   | Carb     | ohydr     | ate      | PI       | acebo  | )       | ;      | Std. Mean Difference     | Std. Mean Difference   |
| Study or Subgroup                 | Mean     | SD        | Total    | Mean     | SD     | Total   | Weight | IV, Random, 95% CI Year  | IV, Random, 95% CI   |
| Bisgaard 2004                     | 65       | 23        | 43       | 63       | 22.5   | 43      | 42.0%  | 0.09 [-0.34, 0.51] 2004  |  |
| Mathur 2010                       | 24.1     | 15.4      | 56       | 25       | 14.8   | 63      | 58.0%  | -0.06 [-0.42, 0.30] 2010 |  |
| Total (95% CI)                    |          |           | 99       |          |        | 106     | 100.0% | 0.00 [-0.27, 0.28]       |  |
| Heterogeneity: Tau <sup>2</sup> = | 0.00; Ch | ni² = 0.2 | 27, df = | 1 (P = 0 | 0.61); | l² = 0% |        |                          |  |
| Test for overall effect:          | Z = 0.02 | (P = 0    | .99)     |          |        |         |        |                          | -0.5 -0.25 0 0.25 0.5<br>Favours placebo Favours carbohydrates |

#### Figure 21: Nausea (mm) (postoperative)

|           |   |           | Pla   | acebo   |   |   | Mean Difference                                      | Meen D   | Mananaa  |   |  |
|-----------|---|-----------|---|---|---|---|--|--|--|---|--|
| Mean [mm] | Carbohydrate<br>up Mean [mm] SD [mm] Tota |           |   | Placebo   |   |   | weatt Difference                                     | Mean Difference  |  |   |  |
|           | SD [mm]                                   | Total     | Mean [mm]   | SD [mm]   | Total   | Weight  | IV, Random, 95% CI [mm] Year                         | IV, Random   | , 95% CI [mm   | ו]  |  |
| 8         | 6.67                                      | 55        | 10  | 6.67  | 59  | 92.2%   | -2.00 [-4.45, 0.45] 2005                             |  | ÷  |   |  |
| 17.8      | 24.5                                      | 57        | 16.1  | 22.3  | 63  | 7.8%  | 1.70 [-6.71, 10.11] 2010                             |  | -  |   |  |
|           |   | 112       |   |   | 122   | 100.0%  | -1.71 [-4.06, 0.64]                                  | -  | +  |   |  |
|           |   | P = 0.4   | 1); I <sup>2</sup> = 0%                                 |   |   |   |  | -10 -5   |  | 10  |  |
|           | 17.8<br>.00; Chi <sup>2</sup> = 0.        | 17.8 24.5 | 17.8 24.5 57<br>112<br>00; Chi² = 0.68, df = 1 (P = 0.4 | 17.8 24.5 57 16.1 112 00; Chi <sup>2</sup> = 0.68, df = 1 (P = 0.41); l <sup>2</sup> = 0% | $17.8  24.5  57  16.1  22.3$ $112 \\ 00; Chi^2 = 0.68,  df = 1  (P = 0.41);  l^2 = 0\%$ | 17.8 24.5 57 16.1 22.3 63<br>112 122<br>00; Chi <sup>2</sup> = 0.68, df = 1 (P = 0.41); l <sup>2</sup> = 0% | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 17.8         24.5         57         16.1         22.3         63         7.8%         1.70 [-6.71, 10.11]         2010           112         122         100.0%         -1.71 [-4.06, 0.64]           00; Chi² = 0.68, df = 1 (P = 0.41); l² = 0%         -1.71 [-4.06, 0.64]         -1.71 [-4.06, 0.64] | $17.8  24.5  57  16.1  22.3  63  7.8\%  1.70 \ [-6.71, 10.11]  2010$ $112  122  100.0\%  -1.71 \ [-4.06, 0.64]$ $00; Chi^2 = 0.68, df = 1 \ (P = 0.41); l^2 = 0\%$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |  |

#### Figure 22: Postoperative vomiting



Evidence includes data from Smith M, McCall J, Plank L, Herbison G, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database of Systematic Reviews 2014, Issue 8. Copyright Cochrane Collaboration, reproduced with permission.

## E.3 Water versus Fasting

| Figure 23:   | Nausea | I PO    | D 1      |       |        |                    |   |                   |                 |            |
|--|--------|---------|----------|-------|--------|--------------------|---|-------------------|-----------------|------------|
|  | Wate   | r       | Fastir   | ng    |        | Risk Ratio         |   | Risk              | Ratio           |            |
| Study or Subgroup  | Events | Total   | Events   | Total | Weight | M-H, Fixed, 95% CI |   | M-H, Fixe         | ed, 95% Cl      |            |
| Read 1991  | 5      | 25      | 15       | 29    | 100.0% | 0.39 [0.16, 0.91]  |   |                   |                 |            |
| Total (95% CI)   |        | 25      |          | 29    | 100.0% | 0.39 [0.16, 0.91]  |   |                   |                 |            |
| Total events<br>Heterogeneity: Not a<br>Test for overall effec |        | P = 0.0 | 15<br>3) |       |        | -                  | • | 0.5 1<br>rs Water | 2<br>Favours Fa | 5<br>sting |

#### Figure 24: Vomiting POD 1

| -   | Wate   | r       | Fasti  | ng    |        | Risk Ratio         |                | Risl               | Ratio            |             |    |
|---|--------|---------|--------|-------|--------|--------------------|----------------|--------------------|------------------|-------------|----|
| Study or Subgroup                                 | Events | Total   | Events | Total | Weight | M-H, Fixed, 95% Cl |                | M-H, Fix           | ed, 95% Cl       |             |    |
| Read 1991   | 3      | 25      | 10     | 29    | 100.0% | 0.35 [0.11, 1.13]  |                |                    | -                |             |    |
| Total (95% CI)                                    |        | 25      |        | 29    | 100.0% | 0.35 [0.11, 1.13]  |                |                    |                  |             |    |
| Total events                                      | 3      |         | 10     |       |        |                    |                |                    |                  |             |    |
| Heterogeneity: Not ap<br>Test for overall effect: |        | P = 0.0 | 8)     |       |        |                    | 0.1 0.2<br>Fav | 0.5<br>vours Water | 1 2<br>Favours F | 5<br>asting | 10 |

#### Figure 25: **Headache POD 1 Risk Ratio Risk Ratio** Water Fasting Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl Read 1991 6 25 12 29 100.0% 0.58 [0.26, 1.32] Total (95% CI) 25 29 100.0% 0.58 [0.26, 1.32] Total events 12 6 Heterogeneity: Not applicable 0.5 1 2 Favours Water Favours Fasting 5 0.2 Test for overall effect: Z = 1.30 (P = 0.19)

# **Appendix F: GRADE tables**

Table 14: Clinical evidence profile: Carbohydrate drinks versus fasting

|                  |  |                      | Quality as                  | sessment                   |                           |                         | No of patients           |         |                      | Effect                                    |                  |            |
|------------------|--|----------------------|-----------------------------|----------------------------|---------------------------|-------------------------|--------------------------|---------|----------------------|---|------------------|------------|
| No of<br>studies | Design   | Risk of<br>bias      | Inconsistency               | Indirectness               | Imprecision               | Other<br>considerations | CHO<br>versus<br>fasting | Control | Relative<br>(95% Cl) | Absolute                                  | Quality          | Importance |
| Patient Sa       | atisfaction (0-  | 10) (follov          | v-up 24 hours; Be           | tter indicated by          | higher values)            |                         |                          |         |                      |   |                  |            |
|                  | randomised<br>trials   | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none                    | 29                       | 29      | -                    | MD 2 higher (1.67 to<br>2.33 higher)      | ⊕⊕⊕O<br>MODERATE | CRITICAL   |
| Postopera        | ative global Q   | oR-40 sco            | ore (follow-up 24 h         | ours; Better ind           | icated by highe           | r values)               |                          |         |                      |   |                  |            |
|                  | randomised<br>trials   | serious <sup>1</sup> |                             | no serious<br>indirectness | serious <sup>2</sup>      | none                    | 46                       | 49      | -                    | MD 7.8 lower (13.09 to<br>2.51 lower)     | ⊕⊕OO<br>LOW      | CRITICAL   |
| Length of        | hospital stay  | v (Better in         | ndicated by lower           | values)                    |                           |                         |                          |         |                      |   |                  |            |
|                  | randomised<br>trials   | serious <sup>1</sup> | serious <sup>3</sup>        | no serious<br>indirectness | no serious<br>imprecision | none                    | 332                      | 341     | -                    | MD 0.37 lower (0.68 lower to 0.06 higher) | ⊕⊕OO<br>LOW      | CRITICAL   |
| Length of        | Length of hospital stay - Major abdominal surgery (Better indicated by lower values) |                      |                             |                            |                           |                         |                          |         |                      |   |                  |            |
|                  | randomised<br>trials   | serious <sup>1</sup> | very serious <sup>3</sup>   | no serious<br>indirectness | serious <sup>2</sup>      | none                    | 167                      | 167     | -                    | MD 1.43 lower (2.68 to<br>0.18 lower)     | ⊕OOO<br>VERY LOW | CRITICAL   |

| Length        | of hospital stay     | / - Interme          | ediate Abdominal            | Surgery (Better i          | ndicated by low           | ver values) | Γ             |     |                           | Γ  | T                |          |
|---------------|----------------------|----------------------|-----------------------------|----------------------------|---------------------------|-------------|---------------|-----|---------------------------|--|------------------|----------|
| 1             | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none        | 46            | 51  | -                         | MD 0.21 higher (0.52<br>lower to 0.94 higher)        | ⊕⊕OO<br>LOW      | CRITICAI |
| Length        | of hospital stay     | / - Minor a          | bdominal surgery            | (Better indicate           | d by lower valu           | es)         |               |     |                           |  |                  |          |
| 3             | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none        | 100           | 103 | -                         | MD 0.07 lower (0.18<br>lower to 0.03 higher)         | ⊕⊕⊕O<br>MODERATE |          |
| Length        | of hospital stay     | / - Orthop           | aedic surgery (Be           | tter indicated by          | lower values)             |             |               | ·   |                           |  |                  |          |
| 1             | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none        | 19            | 20  | -                         | MD 1.00 lower (1.73 to<br>0.27 lower)                | ⊕⊕OO<br>LOW      | CRITICAL |
| Thirst (      | 0-10) (preopera      | tive) (Bett          | er indicated by lo          | wer values)                | •                         |             |               |     |                           |  | 1                |          |
| 1             | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none        | 48            | 50  | -                         | MD 0.2 higher (0.71<br>lower to 1.11 higher)         | ⊕⊕OO<br>LOW      | IMPORTAN |
| Thirst (      | 0-10) (postoper      | ative) (Be           | tter indicated by I         | ower values)               | •                         |             |               |     |                           |  | 1                | -        |
| 1             | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none        | 25            | 25  | -                         | MD 7.16 lower (8.2 to<br>6.12 lower)                 | ⊕⊕⊕O<br>MODERATE |          |
| Thirst (mild) |                      |                      |                             |                            |                           |             |               |     |                           |  |                  |          |
| 1             | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none        | 6/25<br>(24%) | 52% | RR 0.46<br>(0.21 to 1.02) | 281 fewer per 1000<br>(from 411 fewer to 10<br>more) | ⊕⊕OO<br>LOW      | IMPORTAI |

| Thirst ( | moderate)            | -                    | -                           |                            | -                         | -    | -                 |       | _                         |   | _                | -        |
|----------|----------------------|----------------------|-----------------------------|----------------------------|---------------------------|------|-------------------|-------|---------------------------|---|------------------|----------|
| 1        | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none | 0/25<br>(0%)      | 20%   | RR 0.09<br>(0.01 to 1.56) | 182 fewer per 1000<br>(from 198 fewer to 112<br>more) | ⊕⊕OO<br>LOW      | IMPORTAN |
| Headad   | che (postoperati     | ve)                  |                             |                            |                           |      |                   |       |                           |   |                  |          |
| 1        | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none | 3/29<br>(10.3%)   | 31%   | RR 0.33 (0.1<br>to 1.11)  | 208 fewer per 1000<br>(from 279 fewer to 34<br>more)  | ⊕⊕OO<br>LOW      | IMPORTAN |
| Compli   | cation rate          |                      |                             |                            |                           |      |                   |       |                           |   | •                |          |
| 5        | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | very serious <sup>2</sup> | none | 18/171<br>(10.5%) | 14.8% | RR 1.05<br>(0.59 to 1.87) | 7 more per 1000 (from<br>61 fewer to 129 more)        | ⊕000<br>VERY LOW | IMPORTAN |
| Well-be  | eing (postoperat     | tive) (Bette         | er indicated by lo          | wer values)                |                           |      |                   |       |                           |   |                  |          |
| 2        | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none | 51                | 36    | -                         | SMD 0.04 higher (0.4<br>lower to 0.47 higher)         | ⊕⊕⊕O<br>MODERATE | IMPORTAN |
| Nausea   | a & Vomiting 0-1     | 0 (postop            | erative) (Better in         | ndicated by lowe           | r values)                 |      |                   |       | <u></u>                   |   |                  |          |
| 1        | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none | 29                | 29    | -                         | MD 2.0 lower (2.58 to<br>1.42 lower)                  | ⊕⊕OO<br>LOW      | IMPORTAN |
| Nausea   | a & Vomiting         |                      |                             | 1                          | 1                         |      |                   |       | 1                         |   |                  |          |
|          |                      |                      |                             |                            |                           |      |                   |       |                           |   |                  |          |

|        |                      |                      | T                           |                            |                           |      | 1                 | 1        |                           |   |                  |          |
|--------|----------------------|----------------------|-----------------------------|----------------------------|---------------------------|------|-------------------|----------|---------------------------|---|------------------|----------|
| 2      | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | very serious <sup>2</sup> | none | 10/69<br>(14.5%)  | 21.9%    | RR 0.77<br>(0.38 to 1.54) | 50 fewer per 1000 (from<br>136 fewer to 118 more) | 0000             | IMPORTAN |
| lause  | a & Vomiting - N     | lausea               |                             | -                          | -                         | -    |                   | <b>I</b> |                           |   |                  | F        |
| I      | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | very serious <sup>2</sup> | none | 9/48<br>(18.8%)   | 20%      | RR 0.94<br>(0.42 to 2.1)  | 12 fewer per 1000 (from<br>116 fewer to 220 more) |                  | IMPORTAI |
| Nause  | a & Vomiting - V     | omiting              |                             |                            | -                         | -    |                   |          |                           |   |                  |          |
| 3      | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>2</sup>      | none | 14/114<br>(12.3%) | 24%      | RR 0.61<br>(0.34 to 1.1)  | 94 fewer per 1000 (from<br>158 fewer to 24 more)  | ⊕⊕OO<br>LOW      | IMPORTAI |
| Anxiet | y (0-10) (preope     | rative) (Be          | etter indicated by          | lower values)              | -1                        | 1    |                   | 1        | I                         | L   | I                | <u> </u> |
| I      | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none | 48                | 50       | -                         | MD 0.3 higher (1.05<br>lower to 1.65 higher)      | ⊕⊕⊕O<br>MODERATE | CRITICA  |
| Anxiet | y (0-10) (postop     | erative) (E          | Better indicated b          | y lower values)            |                           | -    |                   |          |                           |   | <u> </u>         | F        |
| 1      | randomised<br>trials | serious <sup>1</sup> | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none | 25                | 25       | -                         | MD 5 lower (6.1 to 3.9<br>lower)                  | ⊕⊕⊕O<br>MODERATE | CRITICA  |
| atigu  | e (Better indicat    | ed by low            | er values)                  |                            |                           | •    |                   |          |                           |   |                  |          |
|        |                      | serious <sup>1</sup> | no serious                  | no serious                 | no serious                | none | 62                | 46       | _                         | SMD 0.08 lower (0.47                              | ⊕⊕⊕O             | IMPORTAI |

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

<sup>3</sup> Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis. The terrogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

#### Table 15: Clinical evidence profile: Carbohydrate drinks versus Placebo

|               |                      |                      | Quality as                | sessment         |                           |                         | No of pati            | ients       |                      | Effect                                    |                  |            |
|---------------|----------------------|----------------------|---------------------------|------------------|---------------------------|-------------------------|-----------------------|-------------|----------------------|---|------------------|------------|
| No of studies | Design               | Risk of<br>bias      | Inconsistency             | Indirectness     | Imprecision               | Other<br>considerations | CHO versus<br>placebo | Control     | Relative<br>(95% CI) | Absolute                                  | Quality          | Importance |
| Length of     | hospital stay        | r (Better in         | ndicated by lower         | values)          |                           |                         |                       | · I         |                      |   | <u> </u>         |            |
| 10            | randomised<br>trials | serious <sup>1</sup> | serious <sup>2</sup>      |                  | no serious<br>imprecision | none                    | 332                   | 342         | -                    | MD 0.04 lower (0.21 lower to 0.14 higher) | ⊕⊕OO<br>LOW      | CRITICAL   |
| Length of     | hospital stay        | - Major a            | bdominal surgery          | (Better indicate | d by lower value          | es)                     |                       | <u> </u>    |                      |   |                  |            |
| 6             | randomised<br>trials | serious <sup>1</sup> | very serious <sup>2</sup> |                  | no serious<br>imprecision | none                    | 216                   | 225         | -                    | MD 0.59 lower (1.82 lower to 0.64 higher) | ⊕OOO<br>VERY LOW | CRITICAL   |
| Length of     | hospital stay        | - Minor a            | bdominal surgery          | (Better indicate | d by lower value          | es)                     |                       | · · · · · · |                      |   |                  |            |
| 2             | randomised<br>trials | serious <sup>1</sup> |                           |                  | no serious<br>imprecision | none                    | 70                    | 74          | -                    | MD 0.06 lower (0.12 lower to 0.01 higher) | ⊕⊕⊕O<br>MODERATE | CRITICAL   |
| Length of     | hospital stay        | - Orthopa            | aedic surgery (Be         | ter indicated by | lower values)             |                         |                       | · · · · · · |                      |   |                  |            |
| 3             | randomised<br>trials | serious <sup>1</sup> |                           |                  | no serious<br>imprecision | none                    | 46                    | 43          | -                    | MD 0.1 higher (0.32 lower to 0.53 higher) | ⊕⊕⊕O<br>MODERATE | CRITICAL   |
| Complica      | tion rate            |                      |                           | I                |                           |                         | L                     | ·ł          |                      |   | ·                |            |

| 8         | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | serious <sup>3</sup>      | none | 71/272<br>(26.1%) | 19.2% | RR 0.92<br>(0.73 to 1.17) | 15 fewer per 1000<br>(from 52 fewer to 33<br>more) | ⊕⊕OO<br>LOW      | IMPORTANT |
|-----------|----------------------|----------------------|-----------------------------|----------------------------|---------------------------|------|-------------------|-------|---------------------------|--|------------------|-----------|
| Fatigue ( | postoperative        | ) (Better in         | ndicated by lower           | values)                    | •                         |      |                   |       |                           |  |                  |           |
| 3         | randomised<br>trials | serious <sup>1</sup> | very serious <sup>2</sup>   | no serious<br>indirectness | no serious<br>imprecision | none | 131               | 137   | -                         | SMD 0.28 higher (0.22<br>lower to 0.78 higher)     | ⊕000<br>VERY LOW | IMPORTANT |
| Well-beir | ng (postoperat       | ive) (Bette          | er indicated by lov         | ver values)                | •                         |      |                   |       |                           |  |                  |           |
| 2         | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none | 99                | 106   | -                         | SMD 0 higher (0.27<br>lower to 0.28 higher)        | ⊕⊕⊕O<br>MODERATE | CRITICAL  |
| Nausea (  | 24 h) (Better in     | ndicated b           | y lower values)             | <u> </u>                   |                           |      |                   |       |                           |  |                  |           |
| 2         | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | no serious<br>imprecision | none | 112               | 122   | -                         | MD 1.71 lower (4.06<br>lower to 0.64 higher)       | ⊕⊕⊕O<br>MODERATE | IMPORTANT |
| Vomiting  | (postoperativ        | e)                   | I                           | ł                          |                           |      |                   |       |                           |  |                  |           |
| 3         | randomised<br>trials |                      | no serious<br>inconsistency | no serious<br>indirectness | very serious <sup>3</sup> | none | 19/122<br>(15.6%) | 8.5%  | RR 1.18<br>(0.65 to 2.12) | 15 more per 1000<br>(from 30 fewer to 95<br>more)  | ⊕000<br>VERY LOW | IMPORTANT |

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, unexplained by subgroup analysis Heterogeneity, I2=50%, p=0.04, unexplained by subgroup analysis.

<sup>3</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

#### Table 16: Clinical evidence profile: Clear fluids (water) versus fasting


| Quality assessment | No of patients | Effect | Quality | Importance |  |
|--------------------|----------------|--------|---------|------------|--|
|--------------------|----------------|--------|---------|------------|--|

| No of<br>studies | Design               | Risk of<br>bias | Inconsistency | Indirectness               | Imprecision                  | Other<br>considerations | Clear fluids<br>(Water) | Fasting | Relative<br>(95% Cl)      | Absolute   |                     |           |
|------------------|----------------------|-----------------|---------------|----------------------------|------------------------------|-------------------------|-------------------------|---------|---------------------------|--|---------------------|-----------|
| Nausea (P        | OD1)                 |                 |               |                            |                              |                         |                         |         |                           |  |                     |           |
|                  | randomised<br>trials |                 |               | no serious<br>indirectness | serious <sup>2</sup>         | none                    | 5/25<br>(20%)           | 51.7%   | RR 0.39 (0.16<br>to 0.91) | 315 fewer per 1000 (from<br>47 fewer to 434 fewer) | ⊕⊕OO<br>LOW         | IMPORTANT |
| Vomiting (       | POD1)                |                 |               |                            |                              |                         |                         |         |                           |  |                     |           |
|                  | randomised<br>trials |                 |               | no serious<br>indirectness | serious <sup>2</sup>         | none                    | 3/25<br>(12%)           | 34.5%   | RR 0.35 (0.11<br>to 1.13) | 224 fewer per 1000 (from<br>307 fewer to 45 more)  | ⊕⊕OO<br>LOW         | IMPORTANT |
| Headache         | (POD1)               |                 |               |                            |                              |                         |                         |         |                           |  |                     |           |
|                  | randomised<br>trials |                 |               |                            | very<br>serious <sup>2</sup> | none                    | 6/25<br>(24%)           | 41.4%   | RR 0.58 (0.26<br>to 1.32) | 174 fewer per 1000 (from<br>306 fewer to 132 more) | ⊕OOO<br>VERY<br>LOW | IMPORTANT |

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

# Appendix G: Health economic evidence selection

Figure 26: Flow chart of health economic study selection for the guideline



\* Non-relevant population, intervention, comparison, design or setting; non-English language

# Appendix H: Health economic evidence tables

None.

# **Appendix I: Excluded studies**

## I.1 Excluded clinical studies

#### Table 17: Studies excluded from the clinical review

| Reference   | Reason for exclusion   |
|---|--|
| Adamova 2017 <sup>1</sup>                                   | Incorrect study design   |
| Agarwal 1989 <sup>2</sup>                                   | Unclear outcomes – how outcomes measured unclear and not specified |
| Aguilar-Nascimento 2009 <sup>26</sup>                       | Not in English   |
| Amer 2017 <sup>4</sup>                                      | Systematic Review : references screened                            |
| American Society of<br>Anesthesiologists 2011 <sup>94</sup> | Incorrect study design   |
| Anonymous 2018 <sup>5</sup>                                 | Not available  |
| Anonymous 2017 <sup>29</sup>                                | Incorrect comparison   |
| Aronsson 2009 <sup>6</sup>                                  | Incorrect comparison   |
| Awad 2013 <sup>8</sup>                                      | Systematic Review : references screened                            |
| Azagury 2015 <sup>9</sup>                                   | Not available  |
| Bhaskaran 2018 <sup>10</sup>                                | Incorrect comparison   |
| Bilku 2014 <sup>11</sup>                                    | Systematic Review : references screened                            |
| Bisgaard 2004 <sup>12</sup>                                 | Incorrect comparison   |
| Bopp 2011 <sup>13</sup>                                     | No relevant outcomes   |
| Borges Dock-Nascimento 2011 <sup>14</sup>                   | No relevant outcomes   |
| Brady 2003 <sup>15</sup>                                    | Systematic Review : references screened                            |
| Breuer 2006 <sup>16</sup>                                   | Incorrect population   |
| Campos 2018 <sup>18</sup>                                   | Incorrect study design   |
| Chen 2014 <sup>21</sup>                                     | Not in English   |
| Chen 2015 <sup>22</sup>                                     | Not in English   |
| ChiCtr 2018 <sup>23</sup>                                   | Citation only  |
| de Aguilar-Nascimento 2010 <sup>25</sup>                    | Incorrect study design   |
| de Aguilar-Nascimento<br>2014 <sup>24</sup>                 | No relevant outcomes   |
| Dilmen 2017 <sup>27</sup>                                   | No relevant outcomes   |
| Dock-Nascimento 2012 <sup>28</sup>                          | No relevant outcomes   |
| Feguri 2017 <sup>32</sup>                                   | Incorrect population   |
| Feng 1995 <sup>33</sup>                                     | Not in English   |
| Gava 2016 <sup>34</sup>                                     | No relevant outcomes   |
| Ghorashi 201435   | Incorrect population   |
| Gianotti 2018 <sup>36</sup>                                 | Incorrect comparison   |
| Gonik 2016 <sup>38</sup>                                    | Incorrect population   |
| Goodwin 1991 <sup>39</sup>                                  | Incorrect population   |
| Harsten 2012 <sup>40</sup>                                  | Data included within Systematic review included                    |
| Hausel 2005 <sup>42</sup>                                   | Data included within Systematic review included                    |
| Henriksen 200345  | Data included within Systematic review included                    |
|   |  |

| Reference                       | Reason for exclusion                            |
|---------------------------------|---|
| Hosny 2018 <sup>46</sup>        | Incorrect population                            |
| Hutchinson 1988 <sup>47</sup>   | Incorrect comparison                            |
| Itou 2012 <sup>48</sup>         | Incorrect comparison                            |
| Jones 2011 <sup>49</sup>        | Incorrect study design                          |
| Karlsson 2016 <sup>50</sup>     | No relevant outcomes                            |
| Kaska 2006 <sup>51</sup>        |   |
| Kaska 2000 <sup>52</sup>        | Not in English                                  |
|                                 | Data included within Systematic review included |
| Kwon 1994 <sup>53</sup>         | Not in English                                  |
| Lagerkranser 1997 <sup>54</sup> | Abstract only                                   |
| Lam 1993 <sup>55</sup>          | Incorrect study design – non randomized         |
| Lambert 2016 <sup>56</sup>      | Systematic Review : references screened         |
| Lauwick 2009 <sup>57</sup>      | Incorrect comparison                            |
| Li 2012 <sup>59</sup>           | Systematic Review : references screened         |
| Li 2015 <sup>60</sup>           | Not in English                                  |
| Lidder 2013 <sup>61</sup>       | Data included within Systematic review included |
| Liu 2018 <sup>62</sup>          | Incorrect population                            |
| Ljunggren 2014 <sup>63</sup>    | No relevant outcomes                            |
| Ljungqvist 1998 <sup>64</sup>   | Abstract only                                   |
| Ljungqvist 2001 <sup>65</sup>   | Incorrect study design                          |
| Ludwig 2013 <sup>66</sup>       | Incorrect study design                          |
| Maltby 1986 <sup>68</sup>       | Incorrect population                            |
| Maltby 2006 <sup>67</sup>       | Incorrect study design                          |
| Manchikanti 201169              | Incorrect study design                          |
| Mathur 2010 <sup>70</sup>       | Data included within Systematic review included |
| McKenna 2008 <sup>71</sup>      | Incorrect study design                          |
| Meisner 2008 <sup>72</sup>      | Not in English                                  |
| Miller 1983 <sup>74</sup>       | No relevant outcomes                            |
| Morimoto 201975                 | No relevant outcomes                            |
| Noba 2019 <sup>78</sup>         | Incorrect comparisons                           |
| Noblett 2006 <sup>79</sup>      | Incorrect comparison                            |
| Nygren 1996 <sup>81</sup>       | Abstract only                                   |
| Nygren 1999 <sup>80</sup>       | No relevant outcomes                            |
| Nygren 2007 <sup>82</sup>       | Incorrect study design                          |
| Nygren 2015 <sup>83</sup>       | Incorrect study design                          |
| Orbey 2009 <sup>85</sup>        | Incorrect comparison                            |
| Ozdemir 2011 <sup>86</sup>      | Not in English                                  |
| Ozkan 2000 <sup>87</sup>        | Not in English                                  |
| Perrone 2011 <sup>88</sup>      | Incorrect comparison                            |
| Pexe-Machado 2013 <sup>89</sup> | Data included within Systematic review included |
| Pimenta 2014 <sup>90</sup>      | Incorrect study design                          |
| Popovic 2019 <sup>91</sup>      | Systematic Review : references screened         |
| Pousman 2009 <sup>92</sup>      | Incorrect study design & population             |
| Power 2012 <sup>93</sup>        | Incorrect study design                          |
| Pu 2005 <sup>95</sup>           | Not in English                                  |
| Savluk 2017 <sup>99</sup>       | -   |
| Saviuk 2017                     | Incorrect population                            |

 $\ensuremath{\textcircled{\sc online \sc on$ 

| Reference                        | Reason for exclusion                    |
|----------------------------------|---|
| Singh 2015 <sup>100</sup>        | No relevant outcomes                    |
| Smith 2012 <sup>101</sup>        | Systematic review: incorrect population |
| Soop 1998 <sup>103</sup>         | Not in English                          |
| Soreide 1996 <sup>104</sup>      | Incorrect study design                  |
| Tran 2013 <sup>105</sup>         | Incorrect population                    |
| van Ginhoven 2011 <sup>106</sup> | Incorrect intervention                  |
| Xu 2017 <sup>108</sup>           | Systematic Review : references screened |
| Yagci 2008 <sup>109</sup>        | No relevant outcomes                    |
| Yildiz 2013 <sup>111</sup>       | Systematic Review : references screened |
| Yilmaz 2013 <sup>112</sup>       | No relevant outcomes                    |
| Zhan 2018 <sup>114</sup>         | Incorrect population                    |

## I.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details

#### Table 18: Studies excluded from the health economic review

| Reference | Reason for exclusion |
|-----------|----------------------|
| None.     |                      |

# **Appendix J:Research recommendation**

#### **Research question**

What is the optimal timing of administration of carbohydrate drinks as part of a preoperative fasting strategy?

#### Why this is important

Patients are expect to be 'nil by mouth', or have a period of starvation, prior to undergoing a surgical procedure that requires a general anaesthetic. While some may not fully understand the mechanism of risk (aspiration of stomach contents), all are aware that eating and drinking prior to your operation can be very bad for you.

While we have consensus guidance from the royal colleges of Anaesthetists and Nursing promoting the liberal, or relaxed, fasting guidance we still see variance in our local practice. Unsurprisingly this causes confusion, not only for the patient, but also the clinical staff, who often opt for a 'better safe than sorry' strategy. This in turn leads to prolonged periods of starvation and the negative consequences being without fluid and sustenance.

Over the past 10 years we have seen perioperative care evolve. One such advancement is the use of high energy, carbohydrate rich, drinks to aid recovery. These are given before and after surgery with the assumption that they provide the patient with a metabolic boost to overcome the negative effects, and reduce the complications, of surgery. Again, as with fasting, the timing and impact of these drinks appears varied, with no clear guide on appropriate timing or dosing of these drinks.

This research question will explore the optimal timing of carbohydrate drunks to hopefully clarify these issues and provide clinicians the detail needed to develop standardised and safe fasting protocols.

| PICO question | <ul> <li>Population: Adults 18 years and over who require major surgery</li> <li>Intervention(s) and comparison: <ul> <li>no food for &lt;4 hours</li> <li>no food for 4-6 hours</li> </ul> </li> <li>no food for &gt;6 hours</li> <li>Outcome(s): Health-related quality of life, mortality, patient, family and carer experience of care, adverse events and complications (Clavien-Dindo, postoperative morbidity score (POMS), aspiration – pulmonary complications, acute kidney injury), length of hospital stay, unplanned ICU</li> </ul> |
|---------------|--|
|               | admission, thirst, headache and cancellation of surgery  |